{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/json": {
       "ascii": false,
       "bar_format": null,
       "colour": null,
       "elapsed": 0.012079954147338867,
       "initial": 0,
       "n": 0,
       "ncols": null,
       "nrows": 29,
       "postfix": null,
       "prefix": "Downloading tokenizer.model",
       "rate": null,
       "total": 534194,
       "unit": "B",
       "unit_divisor": 1000,
       "unit_scale": true
      },
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "3430a5777b3a4239b607b043a3eab4ea",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading tokenizer.model:   0%|          | 0.00/534k [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\nirc\\AppData\\Local\\Programs\\Python\\Python310\\lib\\site-packages\\huggingface_hub\\file_download.py:133: UserWarning: `huggingface_hub` cache-system uses symlinks by default to efficiently store duplicated files but your machine does not support them in C:\\Users\\nirc\\.cache\\huggingface\\hub. Caching files will still work but in a degraded version that might require more space on your disk. This warning can be disabled by setting the `HF_HUB_DISABLE_SYMLINKS_WARNING` environment variable. For more details, see https://huggingface.co/docs/huggingface_hub/how-to-cache#limitations.\n",
      "To support symlinks on Windows, you either need to activate Developer Mode or to run Python as an administrator. In order to see activate developer mode, see this article: https://docs.microsoft.com/en-us/windows/apps/get-started/enable-your-device-for-development\n",
      "  warnings.warn(message)\n"
     ]
    },
    {
     "data": {
      "application/json": {
       "ascii": false,
       "bar_format": null,
       "colour": null,
       "elapsed": 0.010114669799804688,
       "initial": 0,
       "n": 0,
       "ncols": null,
       "nrows": 29,
       "postfix": null,
       "prefix": "Downloading (…)cial_tokens_map.json",
       "rate": null,
       "total": 208,
       "unit": "B",
       "unit_divisor": 1000,
       "unit_scale": true
      },
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "1572270980ae4afeb867a9cd0a196cdf",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading (…)cial_tokens_map.json:   0%|          | 0.00/208 [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/json": {
       "ascii": false,
       "bar_format": null,
       "colour": null,
       "elapsed": 0.01597905158996582,
       "initial": 0,
       "n": 0,
       "ncols": null,
       "nrows": 29,
       "postfix": null,
       "prefix": "Downloading (…)okenizer_config.json",
       "rate": null,
       "total": 700,
       "unit": "B",
       "unit_divisor": 1000,
       "unit_scale": true
      },
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "632c55edef534d0a95249557c7ec78e1",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading (…)okenizer_config.json:   0%|          | 0.00/700 [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/json": {
       "ascii": false,
       "bar_format": null,
       "colour": null,
       "elapsed": 0.015963315963745117,
       "initial": 0,
       "n": 0,
       "ncols": null,
       "nrows": 29,
       "postfix": null,
       "prefix": "Downloading (…)lve/main/config.json",
       "rate": null,
       "total": 555,
       "unit": "B",
       "unit_divisor": 1000,
       "unit_scale": true
      },
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "28d1a67e14854e6c997da385d57fd607",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading (…)lve/main/config.json:   0%|          | 0.00/555 [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/json": {
       "ascii": false,
       "bar_format": null,
       "colour": null,
       "elapsed": 0.009010791778564453,
       "initial": 0,
       "n": 0,
       "ncols": null,
       "nrows": 29,
       "postfix": null,
       "prefix": "Downloading (…)model.bin.index.json",
       "rate": null,
       "total": 33444,
       "unit": "B",
       "unit_divisor": 1000,
       "unit_scale": true
      },
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "d23171af430c451b9cb6d0304edee084",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading (…)model.bin.index.json:   0%|          | 0.00/33.4k [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/json": {
       "ascii": false,
       "bar_format": null,
       "colour": null,
       "elapsed": 0.008976459503173828,
       "initial": 0,
       "n": 0,
       "ncols": null,
       "nrows": 29,
       "postfix": null,
       "prefix": "Downloading shards",
       "rate": null,
       "total": 11,
       "unit": "it",
       "unit_divisor": 1000,
       "unit_scale": false
      },
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "74008a2605034070a851d4be5dea519d",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading shards:   0%|          | 0/11 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/json": {
       "ascii": false,
       "bar_format": null,
       "colour": null,
       "elapsed": 0.014020681381225586,
       "initial": 0,
       "n": 0,
       "ncols": null,
       "nrows": 29,
       "postfix": null,
       "prefix": "Downloading (…)l-00001-of-00011.bin",
       "rate": null,
       "total": 4881257231,
       "unit": "B",
       "unit_divisor": 1000,
       "unit_scale": true
      },
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "be0ae0dd1ad0435aa93c4299c4306dce",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading (…)l-00001-of-00011.bin:   0%|          | 0.00/4.88G [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/json": {
       "ascii": false,
       "bar_format": null,
       "colour": null,
       "elapsed": 0.016030550003051758,
       "initial": 0,
       "n": 0,
       "ncols": null,
       "nrows": 29,
       "postfix": null,
       "prefix": "Downloading (…)l-00002-of-00011.bin",
       "rate": null,
       "total": 4970427631,
       "unit": "B",
       "unit_divisor": 1000,
       "unit_scale": true
      },
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "37d71e87d79046429a42c81b2a314215",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading (…)l-00002-of-00011.bin:   0%|          | 0.00/4.97G [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/json": {
       "ascii": false,
       "bar_format": null,
       "colour": null,
       "elapsed": 0.008004426956176758,
       "initial": 0,
       "n": 0,
       "ncols": null,
       "nrows": 29,
       "postfix": null,
       "prefix": "Downloading (…)l-00003-of-00011.bin",
       "rate": null,
       "total": 4970428201,
       "unit": "B",
       "unit_divisor": 1000,
       "unit_scale": true
      },
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "93a6668ce587468cac359125a2687b7e",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading (…)l-00003-of-00011.bin:   0%|          | 0.00/4.97G [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/json": {
       "ascii": false,
       "bar_format": null,
       "colour": null,
       "elapsed": 0.015981435775756836,
       "initial": 0,
       "n": 0,
       "ncols": null,
       "nrows": 29,
       "postfix": null,
       "prefix": "Downloading (…)l-00004-of-00011.bin",
       "rate": null,
       "total": 4970428189,
       "unit": "B",
       "unit_divisor": 1000,
       "unit_scale": true
      },
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "9d45cf362abc4acbb845fb606bf429ee",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading (…)l-00004-of-00011.bin:   0%|          | 0.00/4.97G [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/json": {
       "ascii": false,
       "bar_format": null,
       "colour": null,
       "elapsed": 0.007979154586791992,
       "initial": 0,
       "n": 0,
       "ncols": null,
       "nrows": 29,
       "postfix": null,
       "prefix": "Downloading (…)l-00005-of-00011.bin",
       "rate": null,
       "total": 4970428189,
       "unit": "B",
       "unit_divisor": 1000,
       "unit_scale": true
      },
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "16aed334016143f890f4104ef1ba7f58",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading (…)l-00005-of-00011.bin:   0%|          | 0.00/4.97G [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/json": {
       "ascii": false,
       "bar_format": null,
       "colour": null,
       "elapsed": 0.008986949920654297,
       "initial": 0,
       "n": 0,
       "ncols": null,
       "nrows": 29,
       "postfix": null,
       "prefix": "Downloading (…)l-00006-of-00011.bin",
       "rate": null,
       "total": 4792128609,
       "unit": "B",
       "unit_divisor": 1000,
       "unit_scale": true
      },
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "f7cf2ed3af9d4acfabc625e78866e31f",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading (…)l-00006-of-00011.bin:   0%|          | 0.00/4.79G [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/json": {
       "ascii": false,
       "bar_format": null,
       "colour": null,
       "elapsed": 0.010421276092529297,
       "initial": 0,
       "n": 0,
       "ncols": null,
       "nrows": 29,
       "postfix": null,
       "prefix": "Downloading (…)l-00007-of-00011.bin",
       "rate": null,
       "total": 4792170221,
       "unit": "B",
       "unit_divisor": 1000,
       "unit_scale": true
      },
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "1925f28bba1546bd862c178b86d8e5a2",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading (…)l-00007-of-00011.bin:   0%|          | 0.00/4.79G [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/json": {
       "ascii": false,
       "bar_format": null,
       "colour": null,
       "elapsed": 0.016134977340698242,
       "initial": 0,
       "n": 0,
       "ncols": null,
       "nrows": 29,
       "postfix": null,
       "prefix": "Downloading (…)l-00008-of-00011.bin",
       "rate": null,
       "total": 4792170257,
       "unit": "B",
       "unit_divisor": 1000,
       "unit_scale": true
      },
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "58e0c145867141d682c7c1bdd3a3a1bb",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading (…)l-00008-of-00011.bin:   0%|          | 0.00/4.79G [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/json": {
       "ascii": false,
       "bar_format": null,
       "colour": null,
       "elapsed": 0.007997989654541016,
       "initial": 0,
       "n": 0,
       "ncols": null,
       "nrows": 29,
       "postfix": null,
       "prefix": "Downloading (…)l-00009-of-00011.bin",
       "rate": null,
       "total": 4970427631,
       "unit": "B",
       "unit_divisor": 1000,
       "unit_scale": true
      },
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "55155a8e2f6040509d682b334836a2d8",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading (…)l-00009-of-00011.bin:   0%|          | 0.00/4.97G [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/json": {
       "ascii": false,
       "bar_format": null,
       "colour": null,
       "elapsed": 0.015977859497070312,
       "initial": 0,
       "n": 0,
       "ncols": null,
       "nrows": 29,
       "postfix": null,
       "prefix": "Downloading (…)l-00010-of-00011.bin",
       "rate": null,
       "total": 4970428201,
       "unit": "B",
       "unit_divisor": 1000,
       "unit_scale": true
      },
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "7e80633c77754c5cb95533b6f43a8977",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading (…)l-00010-of-00011.bin:   0%|          | 0.00/4.97G [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/json": {
       "ascii": false,
       "bar_format": null,
       "colour": null,
       "elapsed": 0.015980005264282227,
       "initial": 0,
       "n": 0,
       "ncols": null,
       "nrows": 29,
       "postfix": null,
       "prefix": "Downloading (…)l-00011-of-00011.bin",
       "rate": null,
       "total": 2983308471,
       "unit": "B",
       "unit_divisor": 1000,
       "unit_scale": true
      },
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "35b089477adb4c369d05ac428d4b0f81",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading (…)l-00011-of-00011.bin:   0%|          | 0.00/2.98G [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "The model weights are not tied. Please use the `tie_weights` method before using the `infer_auto_device` function.\n"
     ]
    },
    {
     "data": {
      "application/json": {
       "ascii": false,
       "bar_format": null,
       "colour": null,
       "elapsed": 0.008006095886230469,
       "initial": 0,
       "n": 0,
       "ncols": null,
       "nrows": 29,
       "postfix": null,
       "prefix": "Loading checkpoint shards",
       "rate": null,
       "total": 11,
       "unit": "it",
       "unit_divisor": 1000,
       "unit_scale": false
      },
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "8ff482be92ab480892b55504fa850b52",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Loading checkpoint shards:   0%|          | 0/11 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/json": {
       "ascii": false,
       "bar_format": null,
       "colour": null,
       "elapsed": 0.007990837097167969,
       "initial": 0,
       "n": 0,
       "ncols": null,
       "nrows": 29,
       "postfix": null,
       "prefix": "Downloading (…)neration_config.json",
       "rate": null,
       "total": 132,
       "unit": "B",
       "unit_divisor": 1000,
       "unit_scale": true
      },
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "a6a50d048a84403fb54b384aa0e74d29",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading (…)neration_config.json:   0%|          | 0.00/132 [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import torch\n",
    "from transformers import LlamaForCausalLM, LlamaTokenizer\n",
    "\n",
    "# Hugging Face model_path\n",
    "model_path = 'psmathur/orca_mini_13b'\n",
    "tokenizer = LlamaTokenizer.from_pretrained(model_path)\n",
    "model = LlamaForCausalLM.from_pretrained(\n",
    "    model_path, torch_dtype=torch.float16, device_map='auto',\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "#generate text function\n",
    "def generate_text(prompt, input=None):\n",
    "    tokens = tokenizer.encode(prompt)\n",
    "    tokens = torch.LongTensor(tokens).unsqueeze(0)\n",
    "    tokens = tokens.to('cuda')\n",
    "\n",
    "    instance = {'input_ids': tokens,'top_p': 1.0, 'temperature':0.7, 'generate_len': 1024, 'top_k': 50}\n",
    "\n",
    "    length = len(tokens[0])\n",
    "    with torch.no_grad():\n",
    "        rest = model.generate(\n",
    "            input_ids=tokens, \n",
    "            max_length=length+instance['generate_len'], \n",
    "            use_cache=True, \n",
    "            do_sample=True, \n",
    "            top_p=instance['top_p'],\n",
    "            temperature=instance['temperature'],\n",
    "            top_k=instance['top_k']\n",
    "        )    \n",
    "    output = rest[0][length:]\n",
    "    string = tokenizer.decode(output, skip_special_tokens=True)\n",
    "    return string\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 2463 is (A) You should reassure him that his elevated diastolic BP does not have adverse prognostic implications because his systolic BP is normal.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2464 is \n",
      "\n",
      "A) A < 50% of hypertensive adults are aware that they have hypertension. \n",
      "B) About 50% of people with hypertension are receiving treatment.\n",
      "C) About 75% of people with hypertension are controlled and this rate is steadily improving.\n",
      "D) About 50% of people with hypertension are controlled.\n",
      "E) The prevalence of hypertension has steadily increased over the past decade.\n",
      "\n",
      "Answer: C) About 75% of people with hypertension are controlled and this rate is steadily improving. \n",
      "\n",
      "Explanation: The statement is the correct answer because it is supported by the epidemiology of hypertension. According to the American Heart Association, the following is a summary of the current state of hypertension in the United States: \n",
      "- Hypertension is defined as a blood pressure reading of 120/80 or lower. \n",
      "- Hypertension is a common and widespread condition, affecting millions of people in the United States. \n",
      "- The prevalence of hypertension has steadily increased over the past decade, with about 36% of adults in the US having high blood pressure. \n",
      "- Hypertension is associated with a higher risk for cardiovascular disease and other health problems. \n",
      "- Many people with hypertension are not receiving the appropriate treatment. \n",
      "- The rate of people with hypertension who are receiving treatment is improving but is still lower than the rate of people with high blood pressure. \n",
      "- It is important to increase awareness and understanding of hypertension, improve access to care, and promote healthy lifestyle changes to reduce the prevalence of hypertension.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2465 is C\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2466 is \n",
      "\n",
      "A. High potassium intake results in lower BP levels exclusively in individuals with low sodium intake. \n",
      "\n",
      "Answer: A. This statement is correct. High potassium intake can lower blood pressure (BP) levels exclusively in individuals with low sodium intake. This is because potassium helps to regulate the balance of water and electrolytes in the body, which in turn affects blood pressure. In individuals with low sodium intake, the body needs more potassium to maintain this balance, and higher potassium intake can help to lower blood pressure.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2467 is A. Add atenolol, B. Add minoxidil, C. Add clonidine, D. Add amiloride.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2468 is A. In 6 months, B. In 1 year, C. In 3-5 years, or D. As needed, according to her symptoms.\n",
      "\n",
      "Answer: The most appropriate time for the 32-year-old black woman to have her blood pressure rechecked according to the recommendations of the U.S. Preventive Services Task Force is A. In 6 months. This is because the Task Force recommends that adults age 18-39 with a healthy weight and no history of high blood pressure or other relevant medical conditions have their blood pressure checked every 6 months. This is to detect and manage any early signs of high blood pressure before it becomes more serious and difficult to control.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2469 is A. No change in management, B. Obtain 24-hour ambulatory BP monitoring, C. Obtain an echocardiogram, or D. Start drug treatment.\n",
      "The most appropriate next step in management would be to obtain a 24-hour ambulatory BP monitoring. This would help to determine whether the patient's blood pressure is consistently stable or if there are any patterns that may indicate a need for further management.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2470 is \n",
      "\n",
      "Answer: The most appropriate management based on the 24-hour ambulatory BP monitoring study is to increase the dose of metoprolol. The study shows a significant difference in the average BPs between the day and night times. The average BPs during the daytime and nighttime periods are 140/87 mmHg and 122/78 mmHg, respectively. This suggests that the patient may be experiencing treatment resistance. Increasing the dose of metoprolol can help to lower the BPs, especially during the nighttime period when the patient is sleeping. Therefore, the appropriate management would be to increase the dose of metoprolol.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2471 is A, B, C, D, or E.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2472 is A. 140/80 mmHg, B. 130/80 mmHg, C. 120/75 mmHg, D. 110/75 mmHg\n",
      "Answer: A. 140/80 mmHg is the most appropriate target blood pressure (BP) to attenuate increases in total kidney volume in this patient. The patient is experiencing no known extrarenal manifestations of autosomal dominant polycystic kidney disease and has a liver cyst. Her eGFR (CKD-EPI) is 82 ml/min per 1.73 m2 and her potassium level is 4.1 mEq/L. The patient is on no medications and has a home blood pressure monitoring system that shows an average of 130/82 mmHg. Based on these factors, a target BP of 140/80 mmHg is appropriate to help attenuate increases in total kidney volume.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2473 is A. Droxidopa.\n",
      "\n",
      "Answer: A. Droxidopa is the most appropriate treatment recommendation to improve the patient's orthostatic hypotension. It is a safe and effective medication that has been shown to improve orthostatic hypotension in multiple studies. Additionally, it is not associated with side effects such as edema or supine hypertension. Therefore, droxidopa is a good option for the patient.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2474 is A, B, C, or D.\n",
      "A. Discontinue lisinopril and HCTZ. This is because the new guidelines recommend a lower target blood pressure (120/80 mmHg) and a higher threshold for treatment (150/90 mmHg) than the previous guidelines. As her current BP is 132/74 mmHg, she is likely to fall below the new guidelines.\n",
      "B. Discontinue lisinopril. This is because the new guidelines recommend a lower target blood pressure (120/80 mmHg) than the previous guidelines. As her current BP is 132/74 mmHg, she may still be treated with lisinopril, but the new guidelines suggest that she may not be able to achieve the desired blood pressure goals.\n",
      "C. Discontinue HCTZ. This is because the new guidelines recommend a lower threshold for treatment (150/90 mmHg) than the previous guidelines. As her current BP is 132/74 mmHg, she may still be treated with HCTZ, but the new guidelines suggest that she may not be able to achieve the desired blood pressure goals.\n",
      "D. Make no changes to the current regimen. This is the least appropriate management option as the new guidelines suggest that she may not be able to achieve the desired blood pressure goals with the current medications.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2475 is A. Female sex. (Note: The patient is already taking enalapril, which is a medication used to treat high blood pressure. Therefore, the patient is already at higher risk for hypotension and volume depletion, and may be more susceptible to the hypotensive effects of thiazides. Use of chlorthalidone over HCTZ at equipotent dosing is a risk factor for thiazide-associated hyponatremia, so the patient's current medication use would heighten the risk. Her age and gender are not factors associated with the risk of thiazide-associated hyponatremia, as they do not contribute to decreased sodium levels. Her BMI is a factor that can increase the risk of hypotension and volume depletion, but it is unlikely to cause thiazide-associated hyponatremia specifically.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 2476 is A, B, C, or D.\n",
      "\n",
      "Answer: A. Decreased expression of angiotensin 1 receptors in the proximal tubule.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2477 is \n",
      "A. Nocturnal oxygen supplementation\n",
      "B. Psychotherapy\n",
      "C. Device-guided breathing\n",
      "D. Regular use of continuous positive airway pressure for at least 4 hours per night\n",
      "\n",
      "Answer: A. Nocturnal oxygen supplementation is the most effective nonpharmacologic intervention to lower BP further and improve the nocturnal BP pattern. Nocturnal oxygen supplementation is a safe and effective way to improve oxygenation during sleep, which can help to reduceBP and improve nocturnal blood pressure. It is also noninvasive and can be easily titrated to the patient's needs. The other options are not as effective as nocturnal oxygen supplementation in improving BP and are not as safe.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2478 is A. Measure plasma metanephrines.\n",
      "\n",
      "Answer: A. Measure plasma metanephrines.\n",
      "\n",
      "Explanation: Plasma metanephrins are neurohormones that are produced by the Pineal Gland and are included in the group of Constitutionally Identified Determinants of Ancient Descendents (CIDAs). Plasma metanephrins can be measured using a sensitive immunoassay and are useful in identifying individuals with primary aldosteronism, which is a group of hypertension disorders characterized by excessive production of aldosterone by the adrenal glands. In this patient, the Supine Plasma Aldosterone level is increased, which suggests that she may have primary aldosteronism. Measurement of plasma metanephrins can provide further information on the likelihood of this diagnosis. Therefore, the most appropriate next step in the diagnostic evaluation of this patient is to measure plasma metanephrins.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2479 is \n",
      "A. Add spironolactone 50 mg daily\n",
      "B. Add amiloride 5 mg twice daily\n",
      "C. Refer for adrenal vein sampling\n",
      "D. Keep the existing regimen (BP monitoring and lifestyle changes)\n",
      "\n",
      "Answer: D. Keep the existing regimen (BP monitoring and lifestyle changes)\n",
      "\n",
      "Explanation: The patient has severe resistant hypertension and a right adrenal adenoma shown on abdominal CT scan. However, there are no other medical problems and no evidence of end-organ damage. Therefore, the most appropriate next step in the management of this patient is to continue with the existing regimen of monitoring blood pressure and making lifestyle changes. Adding medications such as spironolactone or amiloride may help to lower blood pressure, but it is not necessary in this case. Adrenal vein sampling may be appropriate if there is a concern about the cause of the adrenaline excess, but this is a complex and potentially dangerous procedure that should only be performed by a specialized adrenal surgeon.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2480 is A. An aldosterone/renin ratio of 40\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2481 is A. Aldosterone/renin ratio. \n",
      "\n",
      "Answer: A. Aldosterone/renin ratio. \n",
      "\n",
      "Explanation: The Aldosterone/renin ratio is a measure of the ratio of the levels of aldosterone and renin in the blood. High levels of aldosterone and/or low levels of renin indicate that the body is producing too much aldosterone and/or not enough renin, respectively. In the given scenario, the patient had an elevation in blood pressure, which is a characteristic of hypertension. Additionally, the patient has a family history of hypertension, which further supports the diagnosis of hypertension. Therefore, the most appropriate diagnostic test to order next is a Aldosterone/renin ratio test to determine if the patient's high blood pressure is caused by primary hyperaldosteronism or secondary hyperaldosteronism.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2482 is A. 123-I-metaiodobenzylguanidine scintigraphy.\n",
      "Answer: A. 123-I-metaiodobenzylguanidine scintigraphy is the next most appropriate step in management as it can provide useful information about the nature and size of the tumor, its location, and any potential complications. It can also help identify any functional abnormalities or abnormalities that may be associated with the tumor.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2483 is \n",
      "\n",
      "Answer: The one associated with the highest 5-year risk of stroke, acute myocardial infarction, and death for this patient is C. Maintenance of his systolic BP <130 mmHg. The American Heart Association recommends that adults without high blood pressure goal a systolic blood pressure of less than 120 mmHg. Therefore, the patient should aim to maintain his systolic blood pressure below 130 mmHg to reduce his risk of future stroke, acute myocardial infarction, and death.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2484 is A. Reversal of INR to 2.0 < 4 hours\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2485 is A, B, C, or D\n",
      "\n",
      "Answer: A is the most predictive of cognitive decline in this woman. High blood pressure is a major risk factor for cognitive decline and can cause damage to the blood vessels and brain. It is possible that the woman's daughter is concerned about her memory decline due to the high blood pressure. The other options are not as predictive of cognitive decline. A diastolic blood pressure is a measure of the pressure in the eye of the blood, and a systolic blood pressure is a measure of the pressure in the arteries. A dietary sodium intake is not a direct cause of cognitive decline, but it can contribute to high blood pressure. The absence of nocturnal dipping may indicate the presence of another condition, but it is not directly related to cognitive decline.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2486 is C. His age is MOST likely to be associated with resistant hypertension in this man.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2488 is \n",
      "\n",
      "A. Continue the same treatment\n",
      "B. Decrease the dose of lisinopril to allow her systolic BP to increase above 140 mmHg\n",
      "C. Add amlodipine, targeting a systolic BP of < 140 mmHg\n",
      "D. Add amlodipine, targeting a systolic BP of < 120 mmHg\n",
      "E. Stop lisinopril and substitute amlodipine.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2489 is (A) The study results were difficult to interpret because the separation of systolic BP between the two groups was only 4 mmHg (130 mmHg versus 126 mmHg).\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2490 is A. Start losartan, aspirin, and atorvastatin.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2491 is A. 25OHD deficiency is associated with higher rates of hypertension in individuals below age 50 but not among older patients.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2492 is \n",
      "\n",
      "Answer: The correct option is D. Beetroot juice increases pulse wave reflection. Beetroot juice is a well-known cause of hypertension and should be avoided.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2493 is A. Make no changes to the current regimen.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 2494 is A. Low hemoglobin.\n",
      "\n",
      "The answer is A. Low hemoglobin. The laboratory results suggest that the woman is experiencing a syndrome of hemolysis, elevated liver enzymes, and low platelets, rather than worsening lupus nephritis. The increased proteinuria is a characteristic of the syndrome. The woman's medications may also contribute to her symptoms. However, a comprehensive evaluation by her healthcare provider is necessary to determine the exact cause of her symptoms and determine the appropriate treatment plan.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2495 is A. Implement a 2-g sodium-restricted diet. \n",
      "\n",
      "Answer: A. Implement a 2-g sodium-restricted diet. \n",
      "\n",
      "Explanation: The woman is both pregnant and has chronic hypertension, which increases the risk of adverse pregnancy outcomes. Although her current medications are appropriate, it is possible that her sodium intake is contributing to the development of fetally harmful edema. Implementing a 2-g sodium-restricted diet can help to reduce her risk of developing fetally harmful edema and other adverse pregnancy outcomes.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2496 is A, B, C, or D.\n",
      "Answer: A. Induction of labor and delivery.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2497 is A, B, C, or D.\n",
      "Answer: A. Discontinue intravenous magnesium, intravenous labetalol, and oral nifedipine.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2498 is A. Labetalol. \n",
      "\n",
      "Letalol is the most appropriate management option based on the patient's history and current medical status. It is a suitable antihypertensive medication that can help to control blood pressure and reduce the risk of complications during pregnancy. The patient's past medical history of well-controlled blood pressure on losartan suggests that she is likely to respond positively to another antihypertensive medication. The remainder of the physical examination and laboratory tests are normal, which makes it difficult to determine the cause of the current hypertension. Therefore, the best approach is to use a trial of the selected medication and adjust the dosage as needed to achieve the desired blood pressure goal.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2499 is A or B. The most appropriate intervention for a woman with a history of preeclampsia and a current BMI of 32 kg/m2 is likely to be weight loss targeting a BMI of < 30 kg/m2. While there is no direct relationship between calcium carbonate and preeclampsia, it is important to note that women with preeclampsia often have changes in their mineral metabolism, including calcium, so it may be necessary to supplement with calcium carbonate if the woman is not able to maintain her current intake through diet alone. However, it is not recommended to use calcium carbonate as a means of weight loss. Aspirin is typically recommended for the prevention of preeclampsia, but it may not be appropriate for the woman in this situation as it may cause side effects or interact with her current medications. It is important for the woman to consult with her healthcare provider for personalized advice on how to reduce her risk of preeclampsia.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2500 is A, B, C, D, E.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2501 is A. She is at increased risk for preeclampsia.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2502 is A, B, C, or D.\n",
      "\n",
      "Answer: The most likely diagnosis is A, B, C, or D, as the patient presented with symptoms suggestive of AKI, which is difficult to differentiate from other liver diseases. However, further tests and observations are necessary to make a definitive diagnosis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2503 is \n",
      "Answer: The most appropriate management would be \"B. Provide plasma exchange.\".\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2504 is A or C.\n",
      "A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 activity is MOST likely to predict her risk for recurrent AFLP.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2505 is A. Kidney biopsyB. Immediate delivery (within 24 hours)C. Observation with expectant medical managementD. Intravenous magnesium\n",
      "\n",
      "Answer: A. Kidney biopsy. \n",
      "\n",
      "Justification: A kidney biopsy is the most appropriate management as it allows for an accurate diagnosis and targeted treatment of the underlying cause of the hypertension. Delivery should be avoided in this situation as it is not an emergency and may put the baby at risk. Observation with expectant medical management is not recommended as it may lead to complications such as proteinuria and other complications. Intravenous magnesium is not appropriate as it is not a treatment for hypertension and may cause side effects. A kidney biopsy allows for a specific diagnosis and targeted treatment, which is the best management option in this situation.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2506 is A. GFR is decreased by 10% compared to pre-pregnancy levels.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2507 is A. Gestational hypertension\n",
      "\n",
      "Answer: A. Gestational hypertension is the most likely diagnosis based on the information provided. The patient is evaluated for new-onset hypertension confirmed on repeat testing, which is a characteristic of gestational hypertension. The physical examination shows a normalBP, which is also consistent with gestational hypertension. The complete blood count, renal function, liver chemistries, and urinalysis are all normal, which further supports the diagnosis of gestational hypertension.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2508 is A, B, C, or D.\n",
      "Answer: A. Intravenous normal saline plus furosemide is the most appropriate next step in management. The patient's creatinine level has risen, and the urinalysis shows 1+ protein and occasional fine granular casts, indicating that the patient may have acute kidney injury. held for 1 hour, and a 250-ml bolus of normal saline and 100 ml of furosemide are given.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2509 is A. Continue current dialysis regimen.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2510 is \n",
      "A. The absence of edema\n",
      "B. The absence of preeclampsia in her first pregnancy\n",
      "C. A low soluble fms-like tyrosine kinase-1 to placental growth factor ratio\n",
      "D. A normal serum uric acid\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2511 is A. Hydrochlorothiazide, B. Atenolol, C. Enalapril, or D. Metoprolol\n",
      "\n",
      "Answer: A. Hydrochlorothiazide is the most appropriate treatment based on the information provided. The patient's blood pressure is rising to pre-pregnancy levels, which indicates that the baby has already passed through the placenta. The physical examination shows pretibial edema, which suggests that the baby may be large. In addition, a urine albumin-to-creatinine ratio of 800 mg/g is greater than normal, which may indicate protein loss. \n",
      "\n",
      "Atenolol and Metoprolol are both beta-blockers used to treat high blood pressure. They are not appropriate choices in this situation because they may not be effective in reducing blood pressure or may cause side effects such as fatigue, dizziness, and nausea.\n",
      "\n",
      "Enalapril is also a medication used to lower blood pressure, but it is not appropriate in this situation because it is not effective in reducing blood pressure.\n",
      "\n",
      "Therefore, Hydrochlorothiazide is the most appropriate treatment as it is effective in reducing blood pressure and has been shown to be safe and effective in treating hypertension during pregnancy.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 2512 is A, B, C, or D.\n",
      "Answer: A. She should have a cesarean section to avoid trauma to the graft during labor.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2513 is \n",
      "A, B, C, or D.\n",
      "\n",
      "Answer: A. The probability of achieving pregnancy is reduced compared with spontaneous conception. PGT is associated with an increased risk of fetal anomalies compared with routine assisted reproductive technology. Therefore, the probability of achieving a successful pregnancy is reduced with PGT.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2514 is \n",
      "\n",
      "Answer: The most appropriate management would be to continue the current immunosuppression regimen, which includes mycophenolate mofetil and tacrolimus. There is no need to stop mycophenolate mofetil or change the immunosuppression regimen as the fetus is viable and the current regimen is already ensuring the safety of the fetus.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2515 is A. Fetal cardiac monitoring.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2516 is A. Begin Intravenous Insulin.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2517 is A. Nephrostomy tube placement.\n",
      "Answer: A. Nephrostomy tube placement.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2518 is A. No additional managementB. Enzyme replacement therapyC. GabapentinD. Diltiazem\n",
      "Answer: B. Enzyme replacement therapy is the most appropriate management. It is important to start enzyme replacement therapy as soon as possible as it can help prevent further damage to the brain and other organs. There is no need to wait for the baby's birth to start the treatment. A. No additional management is not recommended as it may lead to further complications during pregnancy. C. Gabapentin and Diltiazem are not recommended as they do not have any benefit in treating Fabry disease and may even cause adverse effects.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2519 is A and C. (A) It increases her risk for gestational hypertension and (C) It places her at increased risk for preterm labor.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2520 is C\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2521 is A, B, C, or D.\n",
      "Answer: The most appropriate initial management strategy is A. Referral to urology for bilateral ureteral stent placement. This is because the presence of proteinuria and hematuria indicates a possible urinary tract infection or other kidney disorder, and a ureteral stent placement can help to exclude or diagnose these conditions. It is important to establish an accurate diagnosis as soon as possible because it could have implications for the fetus and the mother. If a urinary tract infection is confirmed, betamethasone can be used to promote fetal maturation, and induction of labor can be considered. If a kidney disorder is identified, appropriate treatment can be implemented.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2522 is A.\n",
      "Answer: A is the correct statement regarding her risk of CKD progression and preterm delivery. The woman has significant renal insufficiency and her risk of progressing to ESRD during or shortly postpartum is about 20%. Her risk of preterm delivery (< 37-weeks gestation) is also about 20%, which is a common complication in women with severe renal disease. However, her risk of extreme preterm delivery (< 34-weeks gestation) is not increased, as she is not experiencing any symptoms of preterm labor at this time.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2523 is A. FSGS.\n",
      "\n",
      "Answer: A. FSGS. \n",
      "\n",
      "Explanation: FSGS is a condition in which the glomerular tuft bulges are >10 microns in size, which is suggestive of a primary or secondary glomerular disorder. In this case, the patient's age, gender, weight, and height, as well as the remainder of the history and physical examination, are normal. However, the presence of erythrocytes in the urine sediment and the albumin-to-creatinine ratio of 39 mg/g suggest that there may be an underlying issue with the patient's renal function. Therefore, a renal biopsy is recommended to determine the specific cause of the patient's symptoms.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2524 is A or B.\n",
      "Answer: A. Start low-dose ramipril.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2525 is A. Repeat kidney biopsy.\n",
      "Answer: A repeat kidney biopsy is the next most appropriate step in this patient's management. The initial kidney biopsy revealed minimal-change disease, which is a chronic condition that typically requires lifelong therapy. The patient's history and the results of the kidney biopsy suggest that repeat biopsies may be necessary to determine the appropriate management plan for the patient. The other options are not as appropriate as a repeat kidney biopsy as they do not provide any additional information that may help in managing the patient.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2526 is (A) Repeat kidney biopsy with electron microscopy.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2527 is [A. Serum soluble urokinase–type plasminogen activator receptor level]\n",
      "\n",
      "Answer: A. Serum soluble urokinase–type plasminogen activator receptor level is the most appropriate next step in this patient's diagnostic evaluation at this time. This test can help to determine if the patient has a primary or secondary cause of nephrotic syndrome. A primary cause of nephrotic syndrome is a genetic disorder, such as FSGS, while a secondary cause is a medication or a viral infection. A soluble urokinase–type plasminogen activator receptor level can help to differentiate between these two causes. A positive result would suggest a primary cause, while a negative result would suggest a secondary cause.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2528 is A.Oral angiotensin receptor blockers (ARBs) or B.Oral high–dose steroids are the most appropriate treatments for this patient based on the information provided. The patient's proteinuria is a feature of glomerulonephritis, which can be caused by an underlying autoimmune disorder. In such cases, the patient requires a medication that can help reduce proteinuria and protect the kidneys. ARBs are commonly used in this setting to help block the effects of the angiotensin-II hormone, which can cause increased proteinuria. High-dose steroids are also commonly used to help manage the symptoms of glomerulonephritis and to reduce proteinuria. However, the use of high-dose steroids should be carefully monitored and may need to be tapered off over time.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2529 is \n",
      "A. Oral glucocorticoids\n",
      "B. Mycophenolate mofetil\n",
      "C. Omega-3 fatty acids\n",
      "D. Cyclophosphamide\n",
      "E. Azathioprine\n",
      "\n",
      "Answer: D. Cyclophosphamide. \n",
      "\n",
      "Reasoning: \n",
      "\n",
      "Cyclophosphamide is a medication that is commonly used to treat autoimmune disorders, including IgA nephropathy. It works by blocking the production of autoantibodies and immune cells that cause the disease. In randomized clinical trials, cyclophosphamide has been shown to reduce protein excretion over the short term (e.g., 2 years) in patients with IgA nephropathy and persistent proteinuria (0.75 g/d) after a 3- to 6-month trial of angiotensin blockade.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 2530 is \n",
      "\n",
      "A. Continue steroids at reduced dosage (0.5 mg/kg per day) for another 3 months. \n",
      "\n",
      "B. Oral cyclosporine and low-dose steroids for greater than or equal to 4 months. \n",
      "\n",
      "C. Rituximab and tapering doses of steroids. \n",
      "\n",
      "D. Corticotropin injection gel and tapering of oral steroids. \n",
      "\n",
      "E. Mycophenolate mofetil and tapering dosage of steroids. \n",
      "\n",
      "Answer: B.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2531 is A, B, C, D, or E.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2532 is A. Extensive deposition of C3 in the capillary loops by immunoﬂuorescence microscopy.\n",
      "Answer: A. Extensive deposition of C3 in the capillary loops by immunoﬂuorescence microscopy is the ﬁnding that would indicate that a primary form of the disorder is MOST likely present. This ﬁnding suggests that the immune system is attacking the capillary loops of the kidney, which is a characteristic feature of membranous nephropathy. The other options do not indicate a primary form of the disorder.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2533 is A, B, C, or E.\n",
      "\n",
      "Answer: Based on the provided information, I would choose option A, which is the combination of an angiotensin-converting enzyme inhibitor (ACEI), an ARB, a statin agent, and a low-sodium diet. This regimen has been shown to improve proteinuria and reduce the risk of kidney damage in patients with membranous nephropathy. Additionally, the use of an ARB has been shown to improve heart failure outcomes in patients with reduced left ventricular function.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2534 is \n",
      "Answer: The next step to identify the cause of the lesion should be answer A, Pronase digestion of parafﬁn-embedded material and staining for PLA2R antigen. This will help to identify the presence of PLA2R antibodies, which are responsible for the membranous nephropathy. The other options are not directly related to the cause of the lesion and can be ruled out as they are not helpful in identifying the cause of the membranous nephropathy.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2535 is A, B, C, D, or E.\n",
      "Answer: A. Sarcoidosis causing secondary membranous nephropathy. This is the most likely diagnosis based on the information provided. The patient has a presenting feature of a chronic cough and mild dyspnea, which could be indicative of lung cancer, but the biopsy of the kidney biopsy showed membranous nephropathy, which is more likely caused by sarcoidosis. Additionally, the finding of bilateral hilar adenopathy and scattered interstitial lesions at the base of both lungs on the computed tomography scan could also be indicative of sarcoidosis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2536 is \n",
      "\n",
      "A. Dietary salt and protein restriction only. \n",
      "\n",
      "The answer is A. Dietary salt and protein restriction only. This is because the patient has IgA nephropathy, which is a type of kidney disease that damage the kidneys, leading to proteinuria. Salt and protein restriction are the most effective initial therapy for this condition. The patient's proteinuria is 1.2 g per day, which is a relatively high amount, and may indicate that the patient is not adhering to a salt and protein restricted diet. Therefore, the answer is to maintain a salt and protein restricted diet as the initial therapy for the patient.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2537 is A. Stain the specimen for serum amyloid P component.\n",
      "Answer: It is not possible to determine which of the most appropriate next steps is based on the information provided. The information only mentions the presence of amyloidosis in the patient's serum protein electrophoresis and the fact that a renal biopsy shows Congo Red positivity. The other options listed are not relevant to this patient's symptoms and have no information to determine their relevance. It is important to perform a detailed and comprehensive diagnostic evaluation of the patient's amyloidosis to determine the most appropriate next step.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2538 is C. C3 nephritic factor. \n",
      "\n",
      "Answer: The next best serologic study to help define the etiology of the woman's disease is a C3 nephritic factor test. \n",
      "\n",
      "Justification: The C3 nephritic factor is a specific serological test for the presence of abnormal complement molecules in human blood. It can be used to identify individuals with complement-related disorders, including chronic hemolytic anemia, lupus nephritis, and other autoimmune diseases. \n",
      "\n",
      "The other options are not as specific for the diagnosis of the woman's disease. Antistreptolysin O titers may be useful in identifying individuals with streptococcal infections, but it is not specific for the woman's disease. Soluble C5b-9 levels may be useful in identifying individuals with complement-related disorders, but it is not specific for the woman's disease. Factor H levels may be useful in identifying individuals with complement-related disorders, but it is not specific for the woman's disease. Serum immunofixation and free light chain assays are not specific for the woman's disease and may be useful in identifying individuals with other types of autoimmune diseases.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2539 is A. Occult hepatitis B. \n",
      "\n",
      "Explanation: The patient's biopsy shows predominantly IgM on immunofluorescence, which suggests that the underlying cause of the membranoproliferative GN may be an autoimmune disorder. The patient has no serologic evidence of hepatitis B or C infection, and coconut abuse is not a common cause of membranoproliferative GN. Therefore, the most likely diagnosis to consider is A. Occult hepatitis B.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2540 is \n",
      "A. Antibody levels to double-stranded DNA\n",
      "B. Staining the kidney biopsy for hepatitis B surface antigen and core antigen\n",
      "C. Measurement of serum anti–PLA2R antibodies\n",
      "D. Stool for occult blood\n",
      "\n",
      "Answer: The test that would be of the most help to confirm this patient's diagnosis is measurement of serum anti-PLA2R antibodies. This test can identify whether the patient's proteinuria is a result of membranous nephropathy or other conditions. The other tests mentioned are not specific for membranous nephropathy. Antibody levels to double-stranded DNA are not informative in this context, as they do not distinguish between different types of kidney diseases. Staining the kidney biopsy for hepatitis B surface antigen and core antigen can provide information about the patient's hepatitis B status, but it is not specific for identifying membranous nephropathy.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2541 is A, B, C, or D.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2542 is A. Collapsing FSGS.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2543 is A. Begin an ACEI. \n",
      "\n",
      "Explanation: Based on the information provided, the patient has microscopic hematuria on kidney biopsy, which is a suggestsive finding for glomerular basement membrane disease. However, other glomerular basement membrane abnormalities were not noted on electron microscopy. The patient's eGFR and BP are normal, and he does not have evidence of hearing impairment. Therefore, the best advice for this patient would be to begin an ACEI. While the patient's kidney prognosis is likely to be good long term, there is uncertainty in the diagnosis, and therefore, yearly follow-up is advisable. In addition, given the patient's family history, genetic testing would be beneficial to achieve a molecular diagnosis.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 2544 is A. A calcineurin inhibitor.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2545 is A, B, or C.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2546 is A, B, C, or D.\n",
      "\n",
      "Answer: Based on the given information, the most appropriate induction therapy for the patient is either option A or B. Intravenous methylprednisolone and oral prednisone are both effective options for reducing inflammation and immune complex-related kidney injury. Intravenous cyclophosphamide or rituximab may be options for patients with more advanced disease or refractory necrotizing GN. Mycophenolate mofetil is generally not recommended as it has been shown to cause lung damage in some patients with GN. Plasmapheresis may be a consideration in selected patients with severe refractory GN, but it is generally not appropriate for all patients.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2547 is \n",
      "A) Rituximab > azathioprine > mycophenolate > extended cyclophosphamide (PREFERRED order of use)\n",
      "B) Extended cyclophosphamide > mycophenolate > azathioprine (PREFERRED order of use)\n",
      "C) Azathioprine = mycophenolate > extended cyclophosphamide (PREFERRED order of use)\n",
      "D) Azathioprine > mycophenolate > extended cyclophosphamide (PREFERRED order of use)\n",
      "\n",
      "Answer: The preferred order of use of maintenance drugs is A) Rituximab > azathioprine > mycophenolate > extended cyclophosphamide.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2548 is \n",
      "\n",
      "The most appropriate treatment for the patient is not listed as an option, as the choices listed are not specific to the given patient's condition. The patient's medical history and current symptoms do not indicate which treatment option would be most effective. It is important to consult with a healthcare provider for the best course of treatment based on the patient's individual medical history and symptoms.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2549 is A. Provide supportive care and management for ESRD.\n",
      "Answer: A. Provide supportive care and management for ESRD. The patient requires initiation of dialysis on the third hospital day for progressive pulmonary congestion and hyperkalemia. It is not appropriate to use high-dose corticosteroids, plasmapheresis, and cyclophosphamide, as they may cause further harm to the patient's kidneys. Intravenous rituximab at 1000 mg two times 2 weeks apart may be appropriate, but it is not necessary for the management of the patient's current condition. High-dose corticosteroids should be avoided in the patient's current state. Therefore, the most appropriate management for the patient is A. Provide supportive care and management for ESRD.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2550 is A, B, C, or D.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2551 is A. Add an exchange of a part of the answer choices to create a new answer choice. (Note: This is a multiple-choice question and there are no right or wrong answers.)\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2552 is A, B, C, or D.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2553 is A. Increase sevelamer to 3200 mg three times daily\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2554 is \n",
      "A. Hip fracture\n",
      "B. Mortality\n",
      "C. Coronary calcification\n",
      "D. Osteitis fibrosa\n",
      "E. Adynamic bone\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2555 is \n",
      "Answer: A. Outpatient minimally invasive parathyroidectomy can achieve excellent control of secondary hyperparathyroidism.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2556 is A. No additional intervention ( choice A is the most appropriate answer because it means that the patient's current treatment is already appropriate and there is no need for further intervention. The patient's laboratory values are within the reference range for calcium, phosphorus, and intact PTH, and the patients's alkaline phosphatase is slightly elevated but within the reference range. The patient is also taking calcium acetate at 2001 mg three times daily with each meal, which is appropriate for his condition. Therefore, the patient does not require any additional intervention.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2557 is \n",
      "\n",
      "Answer: The most appropriate management for this patient would be Cinacalcet. It is a calcimimetic agent that binds to the calcium channel in the kidneys and helps to lower the amount of calcium in the blood. It has been shown to improve the quality of life of patients with end-stage renal disease. The other options are not recommended as they do not address the patient's underlying conditions and may not be effective in reducing the symptoms of frequent pain.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2558 is A. Add calcitriol. (Alternative answer: B. Add denosumab)\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2559 is A or C.\n",
      "\n",
      "Answer: A. The effect of phosphate binders does not increase linearly with dose. \n",
      "\n",
      "Explanation: The statement A is correct because studies have shown that the effect of phosphate binders on linearity is not consistent, and the relationship between the amount of phosphate and the effect is not directly proportional. The statement B is incorrect because several studies have shown an increased mortality associated with noncalcium-containing phosphate binders. The statement C is incorrect because randomized trials have shown that phos-phate binders lead to decreased mortality.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2560 is A, B, C, or D.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2561 is A. Tumor lysis syndrome.\n",
      "Explanation: Based on the information provided, it is most likely that the cause of this man's hyperphosphatemia is tumor lysis syndrome. This is because the elevate levels of sodium, chloride, and total CO2 suggest that the patient may have developed a state of dehydration due to the release of end-organ damage. Additionally, the elevated levels of IgG, IgM, and IgA suggest that the patient may have developed an immune complex disorder. These factors are more indicative of a immune disorder than of a renal disorder.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2564 is A management strategy is to add cinacalcet.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2566 is A. Start bisphosphonate therapy. \n",
      "\n",
      "Answer: A. Start bisphosphonate therapy. \n",
      "\n",
      "Explanation: The patient's hypercalcemia and hyperphosphatemia are suggestive of a parathyroid adenoma, which is a common cause of hyperparathyroidism. Bisphosphonate therapy is a standard treatment for hyperparathyroidism. While Sestamibi scan of the parathyroids may be performed to identify the cause of hyperparathyroidism, it is not necessary for the patient. A denosumab scan is not indicated for the patient's condition, and the patient may not have any reason to start denosumab treatment. Therefore, the best step in management for the patient is to start bisphosphonate therapy.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 2567 is A. Measure 24-hour urine phosphate. \n",
      "\n",
      "Answer: A. Measure 24-hour urine phosphate. \n",
      "\n",
      "Explanation: As the patient has advanced alcohol-related cirrhosis, it is possible that his phosphate levels are abnormal. Measurement of 24-hour urine phosphate level is the most appropriate next step in the evaluation of his hyperphosphatemia. This will provide information on the amount of phosphate excreted by the patient in a 24-hour period and can help to determine if his phosphate levels are appropriate or not. Measurement of ionized calcium, tubular reabsorption of phosphate, and creatinine are not directly related to the evaluation of hyperphosphatemia.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2568 is A. Intact PTH level.\n",
      "\n",
      "Answer: The most likely explanation for this patient's condition is hyperparathyroidism. The patient's history, age, and laboratory tests suggest that his hypercalcemia and hypercalciuria are related to abnormal parathyroid function. The normal angiotensin–converting enzyme level and the absence of abnormal parathyroid tissue on two operations support this diagnosis. The patient's family history and a normal chest radiograph also do not suggest any underlying medical conditions. A DEXA scan may be helpful in further evaluating the patient's bone density.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2569 is A. Standard dose denosumab. \n",
      "\n",
      "Answer: Based on the given information, the standard-dose denosumab is the most appropriate treatment for the man's hypercalcemia. It is a reversible means to lower calcium levels in the blood. The other options may not be effective as well, as they do not lower calcium levels or may be less effective.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2570 is A. Lymphomatous inﬁltration.\n",
      "Answer: A biopsy of the affected area is MOST likely to show A. Lymphomatous inﬁltration. This is because the patient's hobby is weight-lifting, which can cause muscle injury and lead to the development of a neoplastic disease. The use of parafﬁn oil for bodybuilding can also be a risk factor for the development of certain types of cancer, such as sarcomas. Therefore, the biopsy is most likely to show a lymphomatous inﬁltration.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2571 is A. Prolonged hypocalcemia is the most likely potential complication of denosumab therapy in this woman.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2572 is [A. Hypercalcemia]\n",
      "The most likely cause of the MRI ﬁndings in this woman is hypercalcemia. Hypercalcemia is a condition where the calcium level in the blood is higher than normal, which can cause confusion, seizures, and other symptoms. The woman's lethargy, confusion, and headache are consistent with hypercalcemia. The increased creatinine and calcium levels may be related to the development of the cancer. However, further testing and analysis are needed to determine the exact cause of her symptoms.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2573 is \n",
      "A. Hypermagnesemia but not hypomagnesemia is associated with an increased risk of premature mortality.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2574 is A. Cinacalcet therapy.\n",
      "\n",
      "Answer: A. Cinacalcet therapy is the most appropriate management strategy for this woman. While the patient's age and medical history make her a candidate for parathyroidectomy, her fear of the procedure and the potential risks associated with it make her a good candidate for cinacalcet therapy. The patient's calcium levels are within the normal range, but her PTH levels are high, which suggests that her parathyroid glands are still functioning. Cinacalcet therapy is a safe and effective way to manage hypercalcemia, and it can be easily titrated to achieve the desired calcium level.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2575 is (A) A repeat PTH level.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2576 is \n",
      "\n",
      "A. Oncogenic osteomalacia\n",
      "B. Primary hyperparathyroidism\n",
      "C. Secondary hyperparathyroidism caused by vitamin D deﬁciency\n",
      "D. Acetazolamide\n",
      "E. Acute respiratory alkalosis\n",
      "\n",
      "Answer: A. Oncogenic osteomalacia.\n",
      "\n",
      "Explanation: Oncogenic osteomalacia is a rare bone disease characterized by the presence of excess parathyroid hormone leading to phosphaturia and hypophosphatemia. The most likely cause of the patient's hypophosphatemia is this condition. The patient's history of hip surgery and myocardial infarction may also contribute to her muscle weakness, but a cause-and-effect relationship between these events and her current state is not established. Acetazolamide is a medication used to treat glaucoma, but it does not cause hypophosphatemia. Acute respiratory alkalosis is a possible cause of hypophosphatemia, but the patient's symptoms are not consistent with this diagnosis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2577 is A. The release of a phosphaturic factor from the liver.\n",
      "Answer: A. The release of a phosphaturic factor from the liver is the most likely cause of this man's hypophosphatemia. This is because the patient's pre-operative laboratory studies showed a serum calcium of 9.6 mg/dl and a serum phosphorus of 4.1 mg/dl, and the patient had no symptoms of hyperparathyroidism. The only possible cause of hypophosphatemia is a phosphaturic factor released from the liver, which can cause a decrease in the levels of phosphorus in the blood. Therefore, a release of a phosphaturic factor from the liver is the most likely cause of this man's hypophosphatemia.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2578 is C\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2579 is A. Calcitonin, B. Zoledronic acid, C. Ketoconazole, D. Prednisone, E. Parathyroidectomy.\n",
      "Answer: A. Calcitonin.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2580 is A, B, C, D, or E.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2581 is A. Follow-up ultrasonography imaging in 10 days, B. Repeat evaluation of urinary parameters in 2 weeks, or C. The stone should be sent for chemical analysis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2582 is A. Infusion of 0.9% saline.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2583 is A. PD is unlikely to be successful because of adhesions and inadequate peritoneal mem-brane transport.\n",
      "Answer: A. PD is unlikely to be successful because of adhesions and inadequate peritoneal mem-brane transport.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2584 is (A) A peritoneal dialysate leak, (B) Increased lymphatic absorption, (C) Encapsulating peritoneal sclerosis, or (D) A high transport membrane.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2585 is A. She can expect an increased risk of all-cause mortality with HHD. (Note: This is a complex question and the answer may vary depending on the specific patient's medical history and other factors. However, the statement is generally accurate as HHD patients are at higher risk for mortality due to a variety of factors such as an increased risk of infections, cardiovascular disease, and other life-threatening complications. It is important to discuss these risks and benefits with the patient and provide personalized recommendations based on their individual needs and circumstances.)\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 2586 is A. Repeat the cell count after infusing 1 L of dialysate that dwells for 1–2 hours.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2587 is A, B, or C.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2588 is \n",
      "Answer: A. An increased risk of infectious complications.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2589 is C. An increase in dialysate sodium to 140 mEq/L.\n",
      "Explanation: The man's dialysate composition is already at a high level of sodium, which is known to cause residents in his body and reduce the duration of the recovery time after dialysis. Increasing the sodium in the dialysate to 140 mEq/L would further increase the residents in his body, leading to a longer duration of the recovery time. The other interventions, such as increasing the blood flow rate, reducing the dialysate flow rate, and decreasing the frequency of dialysis, are not likely to have a significant impact on the duration of the recovery time for this man.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2590 is A decline in dialysis adequacy.\n",
      "Explanation: The literature suggests that regular exercise during dialysis can improve dialysis outcomes, including blood flow, patency, and overall survival. Moderate exercise with weights and elastic bands during the ﬁrst 2 hours of dialysis can help to maintain or increase blood flow and oxygen consumption, which can improve dialysis quality and patient outcomes. Therefore, the most appropriate answer is A. A decline in dialysis adequacy.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2591 is A, B, C, or D.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2592 is \n",
      "Answer: C. He is unlikely to develop hypocalcemia.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2593 is A. An increase in left ventricular mass. The median follow-up of the FHN Daily Trial was 3.6 years, and the finding of an increase in left ventricular mass is a long-term outcome that was not found in the intervention group.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2594 is A. Increased 6-month mortality. \n",
      "\n",
      "Answer: A. Increased 6-month mortality. \n",
      "\n",
      "Explanation: The 6-month mortality rate was found to be higher in patients receiving dialyzable β-blockers compared with those receiving nondialyzable β-blockers in older patients undergoing intermittent hemodialysis. Therefore, the most appropriate answer is A. Increased 6-month mortality.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2595 is A, B, C, or D.\n",
      "Answer: A. 6%–7% Weight gain is the most appropriate ultrafiltration goal target to decrease the risk of intradialytic hypotension.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2596 is \n",
      "\n",
      "A. Pravastatin plus ezetimibe\n",
      "B. Pravastatin\n",
      "C. Fenoﬁbrate\n",
      "D. No additional management \n",
      "\n",
      "Answer: A. Pravastatin plus ezetimibe is the most appropriate management for the given patient. The patient has hyperlipidemia which is causing a significant risk of cardiovascular disease. Pravastatin and ezetimibe work well together to lower LDL cholesterol levels in the blood. Pravastatin is a widely used medication for the treatment of hyperlipidemia, while ezetimibe is a more recent medication that works by blocking the reuptake of cholesterol in the bloodstream. By combining these two medications, the patient can achieve a lower total cholesterol and LDL cholesterol level, which is necessary to reduce the risk of cardiovascular disease. Therefore, the most appropriate management for the given patient is A. Pravastatin plus ezetimibe.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2597 is A. They lower systolic BP.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2598 is A. Decrease the dialysate sodium to 136 mEq/L.\n",
      "Answer: A. Decrease the dialysate sodium to 136 mEq/L. The man's blood pressure is influenced by his age, diabetes, and the presence of apnea during sleep, which can be exacerbated by the high sodium content of the dialysate. By decreasing the sodium in the dialysate, the man's blood pressure can be better controlled, and he may also experience improved sleep quality. Decreasing epoetin may also be appropriate, but this should be done after consulting with the dialysis team and in combination with the other management options. Gradual lowering of the target weight may be helpful, but the man's interdialytic weight gains are already within the recommended range. Increasing carvedilol may also be appropriate, but this should be done in combination with the other management options and after consulting with the dialysis team.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2599 is A. Isolation of patients who test positive for hepatitis C antibody should be included in the policies of your outpatient dialysis center.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2600 is A. Increase organ procurement by instituting opt–out donation policies. \n",
      "\n",
      "Answer: A. Increase organ procurement by instituting opt-out donation policies. This is the best strategy to reduce the overall cost of care for patients with ESRD. Increasing organ procurement through opt-out donation policies would not only help to reduce the cost of care for patients with ESRD but also improve the quality of care as patients who receive organs from living donors are more likely to have better outcomes.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2601 is A. His ability to ambulate.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2602 is A.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2603 is A. A reduction in his left ventricular mass\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2604 is A. A dialysate calcium level of 2.0 mEq/L.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2605 is \n",
      "A. Discontinue pravastatin now\n",
      "B. Discontinue pravastatin at the time of transplantation\n",
      "C. Increase pravastatin to 80 mg daily\n",
      "D. Continue pravastatin at the current dose\n",
      "\n",
      "Answer: The most appropriate management of this patient's statin therapy is to continue pravastatin at the current dose. Therefore, the answer is \"D. Continue pravastatin at the current dose.\"\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2606 is A. or B. or C. or D.\n",
      "\n",
      "Answer: A. or B. or C. or D. It is difficult to determine which of the choices is the most likely contributing factor to her sexual inactivity without further evaluation and testing. However, it is possible that a combination of factors may be contributing to her sexual inactivity. It is important to consider the possibility of other medical conditions or lifestyle factors that may be contributing to her symptoms.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2607 is A, B, C, D, or E.\n",
      "Answer: The next best step in management would be to arrange for placement of a tunneled dialysis catheter. This is because the patient's condition requires the use of a tunneled dialysis catheter, which is necessary for the management of ESRD. Therefore, it is important to arrange for placement of a tunneled dialysis catheter.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 2608 is A. Hypertension\n",
      "Answer: A. Hypertension is the most likely increased risk for calciﬁc uremic arteriolpathy. Hypertension can cause damage to the blood vessels that supply the kidneys with blood, leading to the development of calciﬁc uremic arteriolpathy. The high blood pressure can also cause damage to the kidneys themselves, increasing the risk of developing the disorder. The other factors listed, such as diabetes, obesity, and dialysate composition, are not as directly related to the development of calciﬁc uremic arteriolopathy as hypertension is.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2609 is A. Decreased dietary ﬁber.\n",
      "\n",
      "A. Decreased dietary ﬁber is the most likely intervention to lower the woman's serum levels of indoxyl sulfate. This is because dietary ﬁiber helps to prevent the absorption of indoxyl sulfate into the bloodstream, and as the woman is on hemodialysis, she may not be able to absorb enough ﬁiber from her diet to maintain healthy levels of indoxyl sulfate. Therefore, increasing the amount of ﬁiber in her diet may help to lower her indoxyl sulfate levels.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2610 is A. Metoprolol, B. Enalapril, C. Bisoprolol, or D. Digoxin.\n",
      "The best initial pharmacologic intervention for maintaining rate control in this woman with atrial ﬁbrillation during dialysis is the use of an antiarrhythmic medication that is used to treat atrial ﬁbrillation. Therefore, the best answer is A. Metoprolol, B. Enalapril, C. Bisoprolol, or D. Digoxin.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2611 is A, C, or D.\n",
      "Answer: A) The absence of pre-ESRD nephrology care is the most likely factor to be associated with an increased rate of referral for transplantation within 1 year of starting dialysis for this woman. Pre-ESRD nephrology care can help identify patients who are at risk of developing ESRD and provide early intervention to prevent or delay the need for dialysis. Without this care, patients may be more vulnerable to complications of ESRD, such as cardiovascular disease and infections, which can further impact their health and increase the risk of referral for transplantation.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2612 is \n",
      "The most appropriate treatment strategy to reduce the subsequent risk of stroke for this woman is: C. Warfarin with time in the therapeutic range > 70%. \n",
      "\n",
      "Explanation: The woman has a risk of stroke due to her age and underlying medical conditions. Anticoagulation can help to reduce this risk. The choice of anticoagulation agent depends on the woman's preference, her medical history, and the results of her laboratory tests. In this case, the woman is in favor of anticoagulation to reduce her risk of stroke. Warfarin is the most appropriate treatment option as it is effective and has a lower risk of serious complications compared to other anticoagulants. The woman's age, medical history, and laboratory tests are consistent with the general population that is appropriate for warfarin therapy. Warfarin is a cost-effective and well-tolerated medication that can be used for the woman.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2613 is A. Discontinue furosemide. \n",
      "\n",
      "Answer: A. Discontinue furosemide. Furosemide is a loop diuretic that helps to increase the urinary excretion of water. In this patient, the weight has remained stable, and there is no evidence of dehydration, so furosemide is not necessary. The patient's symptoms have persisted, so she should continue to receive the other medications, lisinopril and spironolactone. It is possible that the patient's increased creatinine levels may indicate a need for more aggressive management, but further testing and evaluation by her doctor is appropriate.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2614 is \n",
      "Answer: As the patient's sodium level is not consistent with the 139 mEq/L level on laboratory studies obtained 1 year ago, a more detailed evaluation of the patient's fluid status and possible causes of hyponatremia are necessary. It is possible that the patient may have a secondary cause of hyponatremia, such as a brain injury, or an underlying medical condition. It is recommended that the patient be referred to a nephrologist for further evaluation and management. \n",
      "\n",
      "The best initial treatment for this patient is not clear based on the given information, as the patient's sodium level is not consistent with the previous laboratory studies. It is possible that the patient may require more aggressive management, such as a decrease in water intake or diuretic therapy, but further evaluation by a nephrologist is necessary.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2615 is A, B, C, or D.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2616 is \n",
      "A. Urine sodium plus urine potassium equal to 36 mEq/L\n",
      "B. Urine osmolality of 200 mOsm/kg after exercise\n",
      "C. Weight gain .3 kg after exercise\n",
      "D. An increase in urinary osmolality during exercise\n",
      "\n",
      "Answer: A. Urine sodium plus urine potassium equal to 36 mEq/L is the most likely to be associated with the development of hyponatremia in individuals involved in heavy exercise. This is because exercise can cause increases in body water balance, which can lead to an increase in sodium and potassium levels in the urine. As a result, the combination of high levels of sodium and potassium in the urine can lead to hyponatremia. An increase in weight gain after exercise may also be a contributing factor, but it is less directly linked to the development of hyponatremia. An increase in urinary osmolality during exercise is a less common cause of hyponatremia, but it can occur in some individuals.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2617 is \n",
      "A. Discontinue desmopressin. The man's enuresis is controlled by the desmopressin medication, but the heart failure is still a concern. It is possible that the enuresis may be a contributing factor to the heart failure, although it is not clear to what extent. Therefore, it is best to avoid any further medication and seek medical advice on how to manage the heart failure.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2618 is \n",
      "\n",
      "Answer: The most appropriate treatment for the patient is: A. Restart intranasal desmopressin at 10 mg twice daily. \n",
      "\n",
      "While the patient's initial symptoms were mild, the increased fluid intake caused by the upper respiratory tract infection may have led to dehydration and an imbalance in electrolytes. The patient's current symptoms, such as fatigue and difficulty concentrating, may be related to this imbalance. Restarting intranasal desmopressin at 10 mg twice daily can help to restore the patient's sodium balance, which may improve his overall symptoms. The other options may also help to restore the patient's sodium balance to some extent, but they may cause more side effects and may not be as effective as intranasal desmopressin.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2619 is A. Discontinue metformin 2-3 days before CA.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2620 is \n",
      "\n",
      "A. Discontinue furosemide and begin intravenous 0.9% saline at 125 ml/h.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2621 is A or B. (Note: A is not a valid answer as it does not address the question and is not a management option.)\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 2622 is A, B, C, or D.\n",
      "Answer: A. 4.0 L. \n",
      "\n",
      "Explanation: Even though the patient is receiving a large amount of water, it is unlikely that all of it is being absorbed by the body. Insensible water losses of 0.8 L/d will depend on factors such as age, sex, and physical activity. Therefore, it is reasonable to assume that the patient can absorb some water, but not all of it. To decrease the serum sodium to 145 mEq/L over the next 24 hours, it is recommended to administer enough water to maintain the patient's weight, while still keeping the sodium concentration appropriate. A volume of 4 liters (4.0 L) is appropriate for this purpose.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2623 is A. Excessive water intake and retention (A) and B. Sequestration of water in the gastrointestinal tract (B) are the two most important factors in the development of hyponatremia. Excessive water intake and retention can cause an imbalance in the body's water balance, leading to a decrease in sodium levels in the blood. On the other hand, sequestration of water in the gastrointestinal tract can also cause hyponatremia by preventing the absorption of water in the body. The remaining options are not as important in the pathogenesis of hyponatremia.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2624 is (A or B)\n",
      "\n",
      "Answer: Continuous RRT at 25 ml/kg per hour is the next best step in management. It is important to correct the hypovolemia as soon as possible to prevent further complications. Continuous RRT can help to restore the patient's intravascular volume and remove waste products from the body.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2625 is \n",
      "\n",
      "A. Torsemide has increased bioavailability and a longer half-life.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2626 is \n",
      "A. 0 L\n",
      "B. 1.8 L\n",
      "C. 2.3 L\n",
      "D. 2.8 L\n",
      "\n",
      "Answer: D. 2.8 L. \n",
      "\n",
      "This answer is based on the given information, which demonstrates that the patient has a normal physical examination, a normal laboratory profile, and a normal urine profile. It also shows that the patient is drinking 0.8 L of water per day, and has a daily urine volume of 2 L. \n",
      "\n",
      "Fluid restriction is recommended, as the patient has a condition that is associated with dehydration, and the daily urine volume suggests that the patient may be losing some amount of water insensibly. \n",
      "\n",
      "Without a further decrease in the serum sodium, it is recommended to drink a maximum amount of solute-free water to maintain a healthy fluid balance. The amount of water needed may depend on the patient's age, physical activity, and other factors. However, based on the given information, the maximum amount of solute-free water that the patient can drink without a further decrease in the serum sodium is 2.3 L. \n",
      "\n",
      "Therefore, the answer is D. 2.8 L.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2627 is A, B, C, or D.\n",
      "\n",
      "Answer: The woman's acid-base status is A. Simple metabolic alkalosis. This is because she has a pH of 7.45, which is greater than 7.0, indicating an alkaline pH. Additionally, her PaCO2 is 54 mmHg, which is less than 40 mmHg, indicating a lowly bicarbonate concentration. Therefore, she is experiencing a simple metabolic alkalosis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2628 is A. Primary hyperaldosteronism.\n",
      "\n",
      "Answer: A. Primary hyperaldosteronism.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2629 is \n",
      "\n",
      "A. Reduce tacrolimus to achieve trough levels of 4–5 ng/ml.\n",
      "\n",
      "B. Start chlorthalidone.\n",
      "\n",
      "C. Start ﬂudrocortisone.\n",
      "\n",
      "D. Start sodium bicarbonate.\n",
      "\n",
      "Answer: A. Reduce tacrolimus to achieve trough levels of 4–5 ng/ml. Hyperkalemia is a serious condition that can lead to muscle weakness, heart palpitations, and even cardiac arrest. In this patient, the high levels of potassium are causing hyperkalemia. Tacrolimus can be reduced to achieve trough levels of 4–5ng/ml. Chlorthalidone, ﬂudrocortisone, and sodium bicarbonate are not the best management options for this patient's hyperkalemia.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2630 is A. Hypomagnesemia. \n",
      "\n",
      "Answer: A. Hypomagnesemia. The patient is at risk for hypomagnesemia as a result of the use of patiromer calcium, which is known to cause changes in magnesium levels. Calcium can interfere with the absorption of magnesium, leading to elevations in magnesium levels or magnesium-related disorders such as hypomagnesemia.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2631 is \n",
      "A. Decreased activity of 11β-hydroxysteroid dehydrogenase and C. Cushing syndrome are the MOST likely causes of hypokalemia.A. Decreased activity of 11β-hydroxysteroid dehydrogenase is a possible cause of hypokalemia, but the patient's history and abnormal biochemical values do not suggest this as a primary cause of the condition.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2632 is A. The frequency of colonic necrosis is approximately 0.1%'.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2633 is A, B, C, or D.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2634 is A. 24-hour urine collection for potassium.\n",
      "\n",
      "Answer: A 24-hour urine collection for potassium is the most appropriate diagnostic test to perform next. The patient's history and symptoms point to an underproduction of alkaline by- products of the kidneys, which can be confirmed by a urine potassium measurement. A 24-hour urine collection for potassium will help determine the exact amount of potassium excreted by the patient in a given day, which can provide valuable information on the patient's hypokalmic state. The other options are not as relevant to the patient's symptoms and do not add much to the diagnosis. A genetic test for mutations in the CLCNKB gene is not indicated in this case, as the symptoms are not related to genetic factors. A urine calcium-to-creatinine ratio and a fractional chloride clearance in response to hydrochlorothiazide are not relevant to the patient's symptoms and are therefore not appropriate diagnostic tests.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2635 is A. The thick ascending limb of the loop of Henle is contributing the MOST to this woman's hypomagnesemia.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2636 is A. Hypokalemic distal renal tubule acidosis (type 1) is the most likely diagnosis. The patient has symptoms of weakness and hypokalemic metabolic acidosis, which are consistent with the diagnosis of a distal renal tubule acidosis (type 1). The patient's laboratory studies also support this diagnosis, with normal blood pressure and pulse, and a creatinine of 1.3 mg/dl, which is consistent with the patient's age and gender. While the other options may also be possible diagnoses, they are less likely given the patient's symptoms and laboratory results.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2637 is A. Type 4 renal tubular acidosis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2638 is A. A 20-year-old man with glucocorticoid-remediable aldosteronism (GRA) and B. A 23-year-old man with Liddle syndrome are at an increased risk for profound metabolic alkalosis and hypovolemia in response to hydrochlorothiazide.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 2639 is A. Nasogastric suction, B. Gentamicin, C. Posthypercapnic alkalosis, D. Sodium chloride loss in sweat, E. Ceftazidime.\n",
      "Answer: The most likely cause of the acid-base abnormality in this woman is C. Posthypercapnic alkalosis. The woman is receiving high-dose ceftazidime, which is an aminoglycoside that can cause acid-base disturbances, especially when used in high doses. In addition, the woman's physical examination shows Inspiratory crackles at the right base, which is a feature of a respiratory infection. The laboratory studies also show abnormalities in sodium, potassium, and chloride, which are consistent with a respiratory infection. It is possible that the pseudomonas pneumonia and the high-dose ceftazidime may together contribute to the acid-base abnormality. However, further studies are needed to determine the exact cause of the acid-base abnormality.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2640 is A. Ammonium chloride challenge test\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2641 is A. Fludrocortisone, B. Patiromer, C. Isotonic sodium bicarbonate infusion, or D. Hemodialysis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2642 is (A) Begin isolated ultraﬁltration. The MOST appropriate management is to begin isolated ultraﬁltration. This is because the patient's creatinine has increased, which is a sign of kidney damage. Isolated ultraﬁltration, which is the process of removing excess water from the patient's blood, can help to improve creatinine levels and other kidney functions.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5444 is \n",
      "\n",
      "Answer: Based on the given information, the most likely diagnosis is acute tubular necrosis. The patient's symptoms and laboratory studies suggest a sudden injury or insult to the kidney, which is consistent with the diagnosis of acute tubular necrosis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5445 is \n",
      "\n",
      "A) Increased risk of gastrointestinal bleeding \n",
      "B) Decreased inpatient mortality risk \n",
      "C) Improved mental status \n",
      "D) Lower serum ammonia level\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5446 is [A] Norepinephrine, [B] Midodrine plus octreotide or terlipressin alone, [C] Dopamine, or [D] Transjugular intrahepatic portosystemic shunt.\n",
      "\n",
      "The next most appropriate step in management of the given patient is to continue with the current management plan, which includes octreotide and midodrine. Norepinephrine is a pressor agent and may increase blood pressure, which is not desired in a patient with ascites and encephalopathy. Dopamine is a neurotransmitter that is not specific to the Renin-angiotensin system and may not be effective in managing ascites. The transjugular intrahepatic portosystemic shunt may be an option in selected cases, but it is not a first-line treatment for ascites and encephalopathy. It is also a complex and potentially dangerous procedure that requires specialized expertise and equipment. Therefore, the best option is to continue with the current management plan.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5447 is A, B, or C.\n",
      "Answer: A, B, or C. It takes into account the complexity of the issue and suggests several possible interventions to decrease the risk of progression to severe AKI in patients receiving aminoglycosides.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5448 is (A) A fractional excretion of urea > 50%\n",
      "\n",
      "Answer: A fractional excretion of urea > 50% is MOST likely to predict the development of stage 3 AKI and the impending need for renal replacement therapy in this man. A spot urine albumin-to-creatinine ratio > 30 mg/g, urine volume < 200 ml over 2 hours after 1.5 mg/kg of intravenous furosemide, and a urine neutrophil gelatinase–associated lipocalin level > 150 ng/ml may also be useful in predicting AKI. However, a fractional excretion of urea > 50% is the most specific and sensitive measure to diagnose AKI and predict its progression.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5450 is \n",
      "\n",
      "As an AI language model, I cannot provide a single answer to this question as it requires a more detailed analysis of the patient's medical history, current status, and other factors that may affect the choice of anticoagulation strategy. However, I can provide some general information on the topic.\n",
      "\n",
      "Continuous renal replacement therapy (CRRT) is a rescue therapy for severe kidney injury or failure, and it is commonly used in patients with AKI or other forms of kidney disease. It involves continuous delivery of a solution of hypotonic, hypertonic, or isotonic composition to the patient's bloodstream, which helps to replace lost Glomerular filtration capacity (Gf) and restore the body's ability to excrete water and electrolytes.\n",
      "\n",
      "The choice of anticoagulation strategy depends on various factors, such as the patient's age, medical history, comorbidities, and the intended duration of CRRT. In general, it is recommended to use heparin-based anticoagulation strategies, such as unfractionated heparin (UFH) or low-molecular-weight heparins (Lmwhs), for CRRT due to their safety and effectiveness. However, the choice of anticoagulation strategy should be made on a case-by-case basis, taking into account the specific patient's characteristics and the goals of therapy. \n",
      "\n",
      "To determine which anticoagulation strategy is most likely to yield the longest filter life and the lowest risk of bleeding complications, it is important to consider the patient's medical history, including their age, medical condition, and prior reactions to anticoagulants, as well as the specific characteristics of the CRRT system and the patient's response to it. It may also be helpful to consult with a nephrologist or other healthcare provider who has experience with CRRT and anticoagulation.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5451 is \n",
      "A) Intravenous isotonic crystalloid solution and/or albumin tailored to her hemodynamic status with addition of vasopressors if unresponsive to ﬂuids/albumin. \n",
      "\n",
      "A) is the most appropriate initial management strategy for this patient.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5452 is \n",
      "\n",
      "A. Increased risk for acute lung injury\n",
      "B. Decreased requirement for vasoactive drugs\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5453 is \n",
      "A. 1. 0.9% Saline \n",
      "B. Isotonic balanced electrolyte solution \n",
      "C. 5% dextrose in water (D5W) with sodium bicarbonate at 100 mEq/L \n",
      "D. Hydroxyethyl starch. \n",
      "\n",
      "Answer: A 72-year-old woman is hospitalized for treatment of urosepsis and requires resuscitation with 6 L of ﬂuids over the initial 48 hours of hospitalization. According to published retrospective cohort studies, resuscitation with 0.9% saline is least likely to be associated with the development of severe AKI in this patient. Therefore, the best answer is A. 1. 0.9% Saline.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5454 is (A) Increased risk of AKI, (B) Decreased number of AKI-free days, (C) Increased risk of RRT, (D) Decreased mortality risk.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5455 is \n",
      "\n",
      "A) Coronary artery bypass surgery \n",
      "B) Open abdominal aortic aneurysm repair \n",
      "C) Radiocontrast exposure \n",
      "D) Aortic valve replacement surgery \n",
      "\n",
      "Answer: A) Coronary artery bypass surgery. \n",
      "\n",
      "Remote ischemic preconditioning has been shown to be useful in preventing the development of AKI in clinical scenarios such as coronary artery bypass surgery. The process of remote ischemic preconditioning involves the use of a non-invasive device to create a mild, but effective, ischemic condition in the patient's native heart. This is achieved by delivering controlled, rhythmic electrical impulses to the heart, which cause it to enter a state of \"maple syrup\" heart block. This state of ischemia-reperfusion is thought to be protective and can help prevent the development of AKI during and after cardiothoracic surgeries.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5456 is \n",
      "\n",
      "Answer: Based on currently available published literature, the most likely outcome that would be associated with treatment with intrvenous alkaline phosphatase in this patient is \"1. Decreased rate of progression to stage 2 AKI\".\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5457 is \n",
      "A) Give a ﬂuid bolus and reassess in 1 hour\n",
      "B) Give dopamine 1 µg/kg per minute\n",
      "C) Give intravenous furosemide 20 mg and reassess in 4 hours\n",
      "D) No intervention and reassess in 4 hours\n",
      "\n",
      "Answer: The most appropriate next step in management based on the Fluid and Catheter Treatment Trial Lite Fluid Management Protocol would be to give a ﬂuid bolus and reassess in 1 hour. This is because the decrease in urine output is a common symptom of respiratory failure, and a ﬂuid bolus can help to increase blood pressure and improve lung function. The reassessment after 1 hour will help to determine if the ﬂuid bolus has had a positive effect on the patient's condition.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5458 is \n",
      "\n",
      "A. Her age\n",
      "B. Her bilirubinuria\n",
      "C. Her critical illness status\n",
      "D. Her albuminuria\n",
      "\n",
      "Answer: D. Her albuminuria. \n",
      "\n",
      "Explanation: The answer is D because albuminuria is an important feature of AKI. It is a measure of the amount of albumin in the urine, which is an index of kidney function. In this woman, the urine albumin-to-creatinine ratio is 43mg/g, which suggests that she has albuminuria. Therefore, measuring urine tissue inhibitor of metalloproteinase-2 X IGF binding protein-7 product in this woman is not useful in predicting the development of AKI.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5459 is \n",
      "\n",
      "A) Her baseline SCr level\n",
      "\n",
      "B) Her Urine output on postoperative day 1\n",
      "\n",
      "C) Her SCr level on postoperative day 2\n",
      "\n",
      "D) A combination of all 3 parameters\n",
      "\n",
      "Answer: D) A combination of all 3 parameters. The patient's baseline SCr level, her urine output on postoperative day 1, and her SCr level on postoperative day 2 are all important parameters to consider in determining the risk for mortality. The patient's baseline SCr level may indicate her overall health status, while her urine output on postoperative day 1 may indicate the extent of kidney injury caused by the surgery. Her SCr level on postoperative day 2 may indicate her response to the injury and the need for further intervention. Therefore, a combination of all three parameters is most highly associated with an increased risk for mortality.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5460 is \n",
      "\n",
      "A) Black race\n",
      "B) Diabetes mellitus\n",
      "C) History of congestive heart failure\n",
      "D) Baseline CKD\n",
      "\n",
      "Answer: A) Black race. \n",
      "\n",
      "Explanation: The strongest predictor of AKI in nontraumatic hip arthroplasty is a history of congestive heart failure. Congestive heart failure is a condition in which the heart is unable to pump blood effectively, leading to fluid retention, which can cause AKI. In this man, the cardiac examination shows an S4 gallop, which is a sign of congestion in the heart. The rest of the physical examination is normal, which suggests that the man has a significant amount of time to rest before the surgery. The laboratory studies show that the creatinine is 1.8 mg/dl, which is stable, and the eGFR is 43ml/min per 1.73m2, which is below the normal range. Therefore, the man is at higher risk for AKI due to his age, stage of CKD, and the presence of diabetes mellitus. However, given the normal remainder of the physical examination, it is less likely that he will develop AKI during the surgery.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5461 is \n",
      "\n",
      "A) Amlodipine and azithromycin\n",
      "B) Amlodipine and clarithromycin\n",
      "C) Nifedipine and azithromycin\n",
      "D) Nifedipine and clarithromycin\n",
      "\n",
      "Answer: The combination of amlodipine and azithromycin is associated with the greatest risk for hospitalization with AKI over the next month. This is because amlodipine and azithromycin are both renin-angiotensin system blockers that can cause a decrease in blood pressure, which can lead to AKI. In contrast, the other combinations do not have this risk.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5462 is A) Vancomycin-associated AKI only occurs when co-administered with piperacillin-tazobactamB) The risk of AKI is not increased unless vancomycin levels exceed the therapeutic range for > 3 daysC) She is not at risk for vancomycin-associated AKI, because her baseline renal function is normalD) Her risk of AKI is twofold higher than if she were not treated with vancomycin.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5463 is \n",
      "\n",
      "A) Gunshot injury\n",
      "B) Explosive mechanism injury\n",
      "C) Chest injury\n",
      "D) Head injury\n",
      "\n",
      "Answer: A) Gunshot injury. The trauma victim was sustaining multiple gunshot wounds to the head, chest, and abdomen, which increase the risk of rhabdomyolysis. Gunshot injuries can cause rapid Hemorrhage, shock, and other life-threatening injuries. Therefore, the trauma victim is at increased risk for rhabdomyolysis due to the severity of the gunshot injuries.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5464 is \n",
      "\n",
      "A) Lisinopril and Pravastatin should not be coprescribed with clarithromycin to avoid an increased risk of AKI.\n",
      "\n",
      "B) Carvedilol and Metformin should not be coprescribed with clarithromycin to avoid an increased risk of AKI.\n",
      "\n",
      "C) Pravastatin and Amoxicillin should not be coprescribed with clarithromycin to avoid an increased risk of AKI.\n",
      "\n",
      "D) Carvedilol and Amoxicillin should not be coprescribed with clarithromycin to avoid an increased risk of AKI. \n",
      "\n",
      "The answer is A) Lisinopril and Pravastatin should not be coprescribed with clarithromycin to avoid an increased risk of AKI.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5465 is \n",
      "A 76-year-old man with a history of heart failure is given furosemide by continuous infusion at a rate of 10 mg/h, and he is continued on his home regimen of lisinopril and metoprolol. On day 3 of treatment, his net negative output has increased to 12 L, but his BUN and creatinine have risen from 20 mg/dl and 1.4 mg/dl to 65mg/dl and 3.0 mg/dl, respectively. Based on this information, which ONE of the following statements best describes his renal status?\n",
      "\n",
      "A 76-year-old man with a history of heart failure is given furosemide by continuous infusion at a rate of 10 mg/h, and he is continued on his home regimen of lisinopril and metoprolol. On day 3 of treatment, his net negative output has increased to 12 L, but his BUN and creatinine have risen from 20 mg/dl and 1.4 mg/dl to 65mg/dl and 3.0 mg/dl, respectively. Based on this information, which statement best describes his renal status?\n",
      "\n",
      "A 76-year-old man with a history of heart failure is given furosemide by continuous infusion at a rate of 10 mg/h, and he is continued on his home regimen of lisinopril and metoprolol. On day 3 of treatment, his net negative output has increased to 12 L, but his BUN and creatinine have risen from 20 mg/dl and 1.4 mg/dl to 65mg/dl and 3.0 mg/dl, respectively. Based on this information, which statement best describes his renal status? \n",
      "\n",
      "The statement that best describes his renal status is \"Stage 2 AKI\". \n",
      "\n",
      "Net negative output increased to 12 L, but BUN and creatinine rose from 20 mg/dl and 1.4 mg/dl to 65mg/dl and 3.0 mg/dl, respectively. \n",
      "\n",
      "Stage 2 AKI is a condition where the kidney is still working but has difficulty removing waste products from the body. The increase in net negative output suggests that the man's kidneys are still functioning but are not able to keep up with the load of waste products in his body. The rise in BUN and creatinine levels indicates that the man's kidneys are not able to filter excess proteins and other waste products from the blood, leading to a condition of AKI.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5466 is A) Continuous RRT (24 h/day), B) Intermittent hemodiaﬁltration (4 hours 3 d/week), C) Intermittent hemodialysis (4 hours 3 d/week), or D) Prolonged intermittent RRT (8 h/day)\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5467 is \n",
      "\n",
      "I would choose 2. If her eGFR increases to > 60 ml/min per 1.73 m2, her 1-year survival following transplant is likely to be worse than that in those with normal pre-VAD eGFR.\n",
      "\n",
      "This is because VAD placement can improve heart function, but it may also cause AKI and worsen kidney function in some patients. Therefore, it's possible that her eGFR may temporarily improve, but it's unlikely to be sustained and may even worsen if she requires another round of VAD placement or other procedures.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5468 is \n",
      "\n",
      "I'm sorry, but I cannot answer this question without more information. It seems that the question is asking for the best characterization of the relationship between AKI and long-term risk of CKD. However, the question only provides a list of options, and I would need more information to choose the most appropriate answer.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5469 is A) Norfloxacin or rifaximin.\n",
      "Answer: A) Norfloxacin or rifaximin.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5470 is \n",
      "\n",
      "A. No further treatment\n",
      "B. Prednisone 0.5–1 mg/kg per day\n",
      "C. Plasma exchange\n",
      "D. Rituximab\n",
      "\n",
      "Answer: The most appropriate initial treatment for the patient is \"No further treatment\" as the patient is currently receiving nivolumab therapy and has not developed any symptoms or complications from the AKI.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5471 is \n",
      "A) Serum creatine kinase \n",
      "B) Urine eosinophils \n",
      "C) Kidney ultrasound \n",
      "D) Serum antineutrophil cytoplasmic antibody \n",
      "\n",
      "Answer: As the information provided in the question suggests, the most likely diagnostic test to influence management in this man is a kidney ultrasound. This is because the physical examination and laboratory results point towards an acute kidney injury, which is a common cause of confusion and altered mental status. A kidney ultrasound can provide further information on the severity of the injury and help determine appropriate management.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5472 is \n",
      "\n",
      "Answer: The most likely cause of the AKI in this patient is Heroin. The patient's smoking of illicit \"cigarettes\" and the presence of Heroin in his system are two strong indicators of Heroin abuse. The fact that the patient developed AKI after smoking these drugs is itself a strong indication of Heroin addiction. Additionally, the presence of Heroin in the patient's system is a confirmatory diagnosis of Heroin addiction.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5473 is A) Lenalidomide\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2981 is \n",
      "A. A very low–carbohydrate diet (< 30 g of carbohydrates per day) is associated with the lowest risk of CKD progression. This diet restricts high-calorie foods such as fruits, vegetables, and whole grains, and includes only low-calorie, nutrient-dense foods like lean proteins, healthy fats, and low-sugar foods. This diet may help the man maintain his current weight and also reduce his blood pressure.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2982 is \n",
      "\n",
      "A) Excess adverse events have led to early termination of clinical trials. \n",
      "B) Five-year follow-up data on renal outcomes is available. \n",
      "C) ESRD has been examined as a primary outcome. \n",
      "D) Short-term data indicate a slower decline in eGFR compared with placebo.\n",
      "\n",
      "Answer: D) Short-term data indicate a slower decline in eGFR compared with placebo.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5416 is \n",
      "A reduced risk of death from renal disease.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5417 is \n",
      "A) A faster rate of GFR decline\n",
      "B) A lower mean GFR at baseline\n",
      "C) A lower competing risk of mortality\n",
      "D) A higher prevalence of albuminuria\n",
      "\n",
      "Answer: A lower mean GFR at baseline is not the factor that does not explain the higher incidence rate of ESRD among blacks compared with whites in the United States. A faster rate of GFR decline, a lower competing risk of mortality, and a higher prevalence of albuminuria are all potential explanations for the higher incidence of ESRD among blacks. However, a lower mean GFR at baseline is not a factor that has been consistently linked to a higher incidence of ESRD.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5418 is C\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5419 is \n",
      "The best answer is: \n",
      "\n",
      "The best answer is: \n",
      "\n",
      "The increased intracellular potassium efﬂux that initiates programmed podocyte death. \n",
      "\n",
      "This is because APOL1 high-risk variants can cause increased intracellular potassium levels, which can lead to programmed podocytes death. This may be the primary mechanism by which APOL1 high-risk variants lead to kidney disease.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5420 is \n",
      "\n",
      "A) Add glipizide, targeting a hemoglobin A1c of < 7%\n",
      "B) Discontinue empagliﬂozin\n",
      "C) No change in management\n",
      "D) Discontinue neutral protamine Hagedorn insulin\n",
      "\n",
      "Answer: A) Add glipizide, targeting a hemoglobin A1c of < 7% is the most appropriate management. This is because adding glipizide is a sulfonylurea medication that can help improve blood sugar control and lower hemoglobin A1c levels. It is also a relatively safe medication with a low risk of hypoglycemia. Therefore, adding glipizide would be an appropriate treatment option for the given patient.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5421 is \n",
      "\n",
      "Answer: \n",
      "It will not impact the rate of CKD progression.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5422 is \n",
      "\n",
      "A. There is no indication to begin urate-lowering therapy, because it only slows GFR decline when started in individuals with an eGFR > 45 ml/min per 1.73 m2.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5423 is A) Low potassium intake is associated with faster annual eGFR decline.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5424 is \n",
      "\n",
      "A) Atrasentan\n",
      "B) Finerenone\n",
      "C) Linagliptin\n",
      "D) Furosemide\n",
      "\n",
      "Answer: C) Linagliptin. \n",
      "\n",
      "Justification: \n",
      "\n",
      "Given the patient's stage 4 CKD and the declining eGFR, it is appropriate to choose a medication that is focused on blood pressure reduction. Atrasentan is a medication that can help with blood pressure reduction, but it is not specifically indicated for use in patients with kidney disease. Finerenone is a medication that is used to manage blood pressure in patients with kidney disease, but it is not specifically indicated for use in patients with type 2 diabetes. Linagliptin is a medication that is used to treat type 2 diabetes, but it does not have a direct effect on blood pressure. Therefore, the most appropriate medication for the patient is Linagliptin.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5425 is A) 1. Oral adsorbents delay need for RRT, B) 2. Existing studies show no beneﬁt, C) 3. Poor adherence limits the use of oral adsorbents, or D) 4. Oral adsorbents reduce serum indoxyl sulfate levels more than placebo.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5426 is (A) Increased urinary excretion signiﬁes glomerular injury (B) It is freely ﬁltered and then metabolized by the proximal tubule (C) Increased urinary levels do not predict tenofovir nephrotoxicity (D) Increased urinary levels do not correlation with diabetes duration. \n",
      "\n",
      "Answer: (B) It is freely ﬁltered and then metabolized by the proximal tubule.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5427 is \n",
      "\n",
      "A) No change in management \n",
      "B) Discontinue metformin \n",
      "C) Discontinue empagliﬂozin \n",
      "D) Discontinue esomeprazole and start ranitidine \n",
      "\n",
      "Answer: A) No change in management. The patient's symptoms do not suggest any dehydration or need for urgent medical attention. Continuation of the current medications is appropriate.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5428 is \n",
      "\n",
      "A) His systolic hypertension \n",
      "B) His obesity \n",
      "C) His low potassium intake \n",
      "D) His HIV status \n",
      "\n",
      "Answer: A) His systolic hypertension \n",
      "\n",
      "Explanation: The patient's systolic hypertension is likely the primary modifier of his increased risk of CKD. High blood pressure is known to damage the kidneys and increase the risk of kidney disease. The patient's obesity and low potassium intake may also contribute to his increased risk of CKD, but high blood pressure is the most likely primary modifier. The patient's HIV status may also contribute to his increased risk of CKD, but it is less likely to be the primary modifier.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5429 is \n",
      "\n",
      "Answer: The one that best fits the patient's situation is \"Individuals carrying two APOL1 high-risk variants will always develop CKD.\" This answer is the most accurate because it emphasizes that individuals with two high-risk APOL1 variants are at a higher risk of developing CKD, which is the most important point to convey to the patient. The other answer choices are less accurate because they do not accurately reflect the impact of APOL1 risk variants on CKD progression.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5430 is \n",
      "A) Her low health-related quality of life\n",
      "B) Her parental history of cardiovascular disease\n",
      "C) Her dietary sodium intake\n",
      "D) Her retinopathy\n",
      "\n",
      "Answer: C) Her dietary sodium intake is associated with an increased risk of progressive CKD in this woman. The woman completed the Kidney Disease Quality of Life-36 survey and scored 1.2 SDs below the mean, indicating that she has poor health-related quality of life. Her father died at age 51 years old after a myocardial infarction, which is associated with cardiovascular disease. Her dietary sodium intake may also contribute to her poor health-related quality of life and an increased risk of progressive CKD.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5431 is \n",
      "\n",
      "A) The elevated PASP is uncommon in stages 3 and 4 CKD, with a frequency of < 5%. \n",
      "\n",
      "B) The elevated PASP is associated with an increased risk of progression to ESRD. \n",
      "\n",
      "C) His LVH is not associated with an increased risk of cardiovascular events because it is eccentric. \n",
      "\n",
      "D) His LVH is associated with an increased risk of renal death. \n",
      "\n",
      "Answer: C (His LVH is not associated with an increased risk of cardiovascular events because it is eccentric). \n",
      "\n",
      "Explanation: The man's echocardiogram showed a left ventricular ejection fraction of 55%, mild eccentric left ventricular hypertrophy (LVH), and an elevated pulmonary artery systolic pressure (PASP) of 48 mmHg. According to the American Heart Association, a PASP of 48 mmHg is uncommon in stages 3 and 4 CKD, with a frequency of < 5%. Therefore, option A is incorrect. \n",
      "\n",
      "Option B is partially correct because an elevated PASP is associated with an increased risk of progression to ESRD. However, it is not the only correct answer as the man's LVH is also an important factor to consider. \n",
      "\n",
      "Option C is the correct answer because the man's LVH is not associated with an increased risk of cardiovascular events because it is eccentric. An eccentric LVH is typically found in patients with non-cardiovascular diseases, such as chronic obstructive pulmonary disease (COPD) or lung cancer. \n",
      "\n",
      "Option D is incorrect because an increased risk of renal death is more likely associated with an increased left ventricular mass, which is a feature of stage 5 CKD. The man's LVH is not associated with an increased risk of renal death.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5432 is A) Cardiac resynchronization therapy, B) Implantable cardioverter defibrillator, C) Spironolactone, or D) Darbepoetin.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5433 is \n",
      "A) Warfarin\n",
      "B) Edoxaban\n",
      "C) Dabigatran\n",
      "D) Rivaroxaban\n",
      "E) Apixaban\n",
      "\n",
      "Answer: A) Warfarin\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5434 is \n",
      "\n",
      "A) The choices are not listed. Please provide the options.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5435 is (A) His elevated high-sensitivity C-reactive protein (B) His serum calcium (C) His use of alcohol (D) His education status (E) His race/ethnicity\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5436 is \n",
      "A) Addition of niacin\n",
      "B) Smoking cessation\n",
      "C) Addition of sodium bicarbonate\n",
      "D) Increase atorvastatin\n",
      "\n",
      "Answer: A) Addition of niacin. \n",
      "\n",
      "Niacin has been shown to improve cardiovascular outcomes in dialysis patients. It can also be used as a cholesterol-lowering medication. Smoking cessation is an important intervention, but it may not be the only or primary intervention needed for this man's cardiovascular health. Addition of sodium bicarbonate may cause further complications for the patient, and increasing atorvastatin may contribute to weight loss and improved cholesterol levels but may not have a significant impact on his cardiovascular outcomes.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5437 is A) An improvement in the serum creatinine level after surgery always reﬂects an improvement in kidney function. \n",
      "\n",
      "Explanation: The answer is A) An improvement in the serum creatinine level after surgery always reﬂects an improvement in kidney function. Renal function decline is a common complication of obesity and type 2 diabetes, and bariatric surgery can improve kidney function. By reducing body fat and blood sugar levels, bariatric surgery can help improve kidney function and reduce the risk of kidney stones and ESRD. Therefore, the statement is accurate.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5438 is A) Continue lisinopril. B) Stop lisinopril at least 6 weeks before conception. C) There is no increased risk of GFR decline during pregnancy. D) Increased risk of preterm labor. E) No increased risk of GFR decline during pregnancy.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5439 is \n",
      "\n",
      "A 65-year-old man with stage 3b CKD and type 2 diabetes mellitus is admitted for further management of unstable angina. His functional status has been excellent, and he has been walking about 2 miles several times per week before admission. Coronary angiography shows signiﬁcant three-vessel disease (90% stenoses in the left circumﬂex artery, left anterior descending artery, and right coronary artery). His ejection fraction is 48%. \n",
      "\n",
      "Question: Which intervention has the greatest potential to reduce his risk of repeat percutaneous intervention or myocardial infarction over the next 3 years?\n",
      "\n",
      "A) Coronary angioplasty with placement of a bare-metal stent\n",
      "B) Coronary artery bypass surgery\n",
      "C) Coronary angioplasty with placement of an everolimus-eluting stent\n",
      "D) Optimal medical therapy without intervention\n",
      "\n",
      "Answer: The intervention with the greatest potential to reduce the risk of repeat percutaneous intervention or myocardial infarction over the next 3 years is C) Coronary angioplasty with placement of an everolimus-eluting stent. This is because the stent is designed to help reduce the risk of restenosis after a heart attack or other procedures. It works by releasing medication that helps prevent the buildup of plaque in the arteries. Therefore, this intervention is the best option for the patient as it can help reduce the risk of a heart attack or other cardiovascular events.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5440 is A, B, C, or D. (Note: A is the correct answer)\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5441 is \n",
      "\n",
      "A) Simeprevir and sofosbuvir\n",
      "B) Ledipasivir and sofosbuvir\n",
      "C) Paritaprevir and ritonavir\n",
      "D) Grazoprevir and elbasivir\n",
      "\n",
      "Answer: The most appropriate combination for treating the patient's hepatitis C infection is Simeprevir and sofosbuvir. This combination has been shown to be effective in treating both genotype 1a and 1b hepatitis C virus infections in clinical trials. Additionally, Simeprevir has a higher barrier to resistance compared to other hepatitis C drugs, making it a good choice for the patient. Therefore, the best option is to initiate treatment with Simeprevir and sofosbuvir.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5442 is \n",
      "A) They are present in 10% of the CKD population.\n",
      "B) They are associated with a higher risk of CKD progression.\n",
      "C) They do not portend a higher risk of adverse cardiovascular outcomes.\n",
      "D) They only predict adverse cardiovascular outcomes in diabetes.\n",
      "\n",
      "Answer: A) They are present in 10% of the CKD population.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5443 is \n",
      "(A) Add empagliﬂozin (B) Discontinue metformin (C) Change hydrochlorothiazide to furosemide (D) Discontinue enalapril.\n",
      "\n",
      "Answer: (D) Discontinue enalapril. \n",
      "\n",
      "Explanation: \n",
      "Based on the current information, it is not appropriate to add empagliﬂozin, as it is a sodium-wasting medication and can contribute to the development of ascending nephropathy. Discontinuation of metformin is not recommended as it is a life-sparing medication for type 2 diabetes. Changing hydrochlorothiazide to furosemide may not be the best option as the patient already takes a medication that can cause diuretic resistance. Therefore, the best management option is to discontinue enalapril as it is a relatively safe medication to use in a patient with type 2 diabetes and can help to maintain BP within a safe range.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2643 is \n",
      "A. His race\n",
      "B. His cPRA\n",
      "C. His age\n",
      "D. His blood type\n",
      "\n",
      "Answer: A. His race. \n",
      "\n",
      "The new KAS system prioritizes candidates based on their cPRA level, age, and blood type. In this case, the patient has a high cPRA level of 80%, which gives him an advantage in receiving a deceased donor kidney. Additionally, his age of 68 years old and his blood type of A are also factors that may increase his chances of receiving a kidney from a deceased donor. However, race is not a factor that associates with an increased likelihood of receiving a deceased donor kidney under the new KAS system.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2644 is \n",
      "A. It will not affect his graft survival after kidney transplantation.\n",
      "\n",
      "Answer: A. It will not affect his graft survival after kidney transplantation. \n",
      "\n",
      "Explanation: The patient's age, stage 5 CKD, and the fact that he has been maintained on hemodialysis for 3 months indicate that he is an elderly patient with a poor functional status. However, his physical function is not expected to have a significant impact on his graft survival after kidney transplantation. While physical therapy can help mitigate the effects of frailty on his transplant outcomes, it is unlikely that it would significantly improve his graft survival. Therefore, the best answer is A. It will not affect his graft survival after kidney transplantation.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2645 is \n",
      "A. The PHS-IRD kidney option is associated with an increased waiting time.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2646 is A, B, C, D.\n",
      "Answer: A. The quality of decreased donor kidneys has deteriorated since implementation of Kidney Allocation System (KAS), with a median kidney donor risk index of > 80%. This means that the wait time for a deceased donor kidney is likely to be longer than before implementation of KAS. Therefore, it is important to inform the patient that she may have to wait longer for a transplant.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2647 is \n",
      "A. Consent to receive an HCV-positive kidney may dramatically reduce his waiting time. \n",
      "\n",
      "Answer: A. Consent to receive an HCV-positive kidney may dramatically reduce his waiting time. This is because an HCV-positive kidney is associated with a lower risk of wait-list mortality and a higher likelihood of receiving a living kidney from a donor who is HCV-positive. Additionally, an HCV-positive kidney can be cryopreserved and stored for a longer period of time, reducing the risk of organ discard. However, it is important to note that the decision to receive an HCV-positive kidney should be made in conjunction with a HCV-negative kidney.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2648 is A. The risk of delayed graft function (DGF) is equivalent to receiving a deceased donor kidney without AKI.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2649 is SELECT (A, B, C, or D) that is most likely to be true based on the information provided.\n",
      "Answer: The most likely statement that is true based on the information provided is \"A. The presence of the donor-speciﬁc antibody increases her risk of DGF.\"\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2650 is A. Pregnancy after kidney donation is more likely to be complicated by low-birth weight infants.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2651 is A. It is higher compared with black donors.\n",
      "Answer: A. It is higher compared with black donors. \n",
      "\n",
      "Explanation: It is important to inform the patient that his risk of developing kidney failure after kidney donation is higher compared to non-donors in the general population. This is because kidney donation can put a strain on the kidney and increase the risk of developing kidney damage or failure. Donors are more likely to develop chronic kidney disease than the general population. Therefore, it is appropriate to inform the patient that his risk of developing kidney failure is higher than that of non-donors.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2652 is \n",
      "\n",
      "Answer: A. It is associated with an increased risk of mortality.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2653 is A. Basiliximab therapy associ-ates with marked reduction in rejection risk in tacrolimus/mycophenolate/steroid-treated nonsensi-tized patients.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2654 is (A) Dose reductions stemming from adverse effects are associated with an increased risk of rejection and graft failure. (B) The risk of cytomegalovirus (CMV) viremia is greater with azathioprine compared with mycophenolate. (C) Mycophenolate is associated with a reduced risk of mortality compared with azathioprine. (D) Physical frailty does not affect the frequency of mycophenolate adverse events. (E) Dose-limiting adverse effects are more commonly seen in living compared with de-ceased donor allograft recipients.\n",
      "\n",
      "Answer: (A) Dose reductions stemming from adverse effects are associated with an increased risk of rejection and graft failure.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 2655 is \n",
      "Answer: The statement that best addresses the question is: \"Blood transfusion may induce donor-speciﬁc antibody and an increased risk of rejection.\" This statement accurately describes the risks associated with blood transfusion, which is that it may cause allosensitization and increase the risk of rejection. The other options are not accurate in this context. statement.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2656 is C\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2657 is A. Kidney injury marker-1, B. Neutrophil gelatinase–associated lipocalin, C. Perforin, D. Granzyme B, E. Urine protein-to-creatinine ratio and/or urine albumin-to-creatinine ratio.\n",
      "Answer: A. Kidney injury marker-1, B. Neutrophil gelatinase–associated lipocalin, C. Perforin, D. Granzyme B, and E. Urine protein-to-creatinine ratio and/or urine albumin-to-creatinine ratio are all useful biomarkers in monitoring allograft stability. The choice of which biomarker(s) to use will depend on the specific patient's medical history, lifestyle, and other factors. It is important to carefully consider the patient's unique characteristics and the purpose of monitoring before selecting the appropriate biomarker(s).\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2658 is A. No further treatment, B. Denosumab, C. A bisphosphonate, or D. Teriparatide.\n",
      "A. No further treatment is the most appropriate management strategy for this woman. She has prompt function of the allograft, and her serum creatinine level has been stable at 1.2 mg/dl for the last six weeks. She is also at a low risk for hip fracture based on the Fracture Risk Assessment Tool (FRAX). Her current medications are tacrolimus, mycophenolate mofetil, and prednisone, which are generally well-tolerated. However, it is possible that she may have a risk of fractures due to her age and medical conditions, and further evaluation by her healthcare provider may be necessary. Therefore, the best management strategy would be to monitor her condition closely and consider any additional interventions as needed.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2659 is \n",
      "Answer: The most appropriate next step in treatment is A. Subtotal parathyroidectomy. The patient's condition is severe and requires immediate medical intervention. While cinacalcet and paricalcitol are also appropriate options, the patient's condition is too severe for denosumab to be given. Subtotal parathyroidectomy is the only option that can provide the patient with a prompt and effective treatment.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2660 is A, B, C, or D. \n",
      "\n",
      "Answer: A. Transition MMF to azathioprine > 6 weeks prior to attempts to conceive and plan to increase tacrolimus about 20%–25% during the second trimester to maintain therapeutic levels.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2661 is (A or B) The patient's medical history and current medication regimen do not suggest the need for a diuretic. The patient's current medications are already effective in controlling their blood pressure. Therefore, adding a diuretic medication would not be necessary. The available options are furosemide, hydralazine, labetalol, and lisinopril. The use of hydralazine may be appropriate for a patient with high blood pressure, but the patient's current medication regimen is already effective and they do not have any prior cardiovascular history. Furosemide and lisinopril are also not appropriate options as the patient does not have any prior cardiovascular history and their current medication regimen is already effective. Labetalol may be the most appropriate agent to add for BP control, but it should be used with caution in patients with diabetes mellitus, especially those with a history of narrow angle glaucoma.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2662 is A, B, C, or D.\n",
      "\n",
      "Answer: A. His risk of graft loss (death censored) is similar to that of nonobese transplant recipients.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2663 is A. Midodrine use. \n",
      "\n",
      "Answer: A. Midodrine use. \n",
      "\n",
      "Midodrine is a medication used to treat hypotension during dialysis. It is a powerful vasodilator that can cause hypotension by constricting blood vessels in the splanchnic and mesenteric circulations. Therefore, it is likely that midodrine use is a contributing factor to the patient's hypotension during dialysis. The other options are not directly associated with graft loss after transplant.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2664 is \n",
      "\n",
      "A. Use of cyclosporine rather than tacrolimus for maintenance immunosuppression\n",
      "B. Use of thymoglobulin induction therapy\n",
      "C. Referral to a transplant center with extensive prior experience in HIV-positive transplantation\n",
      "D. Avoidance of HIV-positive deceased donors\n",
      "\n",
      "Answer: The most appropriate management for a 44-year-old man with HIV-associated nephropathy on dialysis for 4 years who wishes to pursue kidney transplantation is C. Referral to a transplant center with extensive prior experience in HIV-positive transplantation. This is because the patient's HIV viral load is undetectable on highly active antiretroviral therapy, and he has no opportunistic infections. The use of cyclosporine rather than tacrolimus for maintenance immunosuppression is not an appropriate management choice for this patient, as it is more nephrotoxic and may lead to an increased risk of rejection. Thymoglobulin induction therapy may also be less effective in HIV-positive patients, and may be more complicated to manage. Avoidance of HIV-positive deceased donors is not a management option for this patient, as it is not possible to predict the safety and effectiveness of a transplant from a deceased donor.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2665 is C. Development of a second viral infection.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2666 is \n",
      "\n",
      "A. An additional 1-year waiting time (total waiting time was 52 years) on the basis of prior skin cancer history.\n",
      "\n",
      "B. Repeat colonoscopy now before proceeding with a living donor transplant.\n",
      "\n",
      "C. Check a screening serum prostate-speciﬁc antigen level.\n",
      "\n",
      "D. Refer him for screening cystoscopy.\n",
      "\n",
      "Explanation: Based on the given information, the most appropriate management recommendation is to perform a repeat colonoscopy before proceeding with a living donor transplant. This is because the patient has a history of a polyp removed during screening colonoscopy 2 years ago, and it is possible that there may be a risk of colon cancer or other colorectal diseases. However, it is important to note that a thorough evaluation with a living donor transplant may still be possible after performing the colonoscopy and depending on the findings, and the patient's suitability for the transplant may also be evaluated.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2667 is A, B, C, or D.\n",
      "\n",
      "Answer: A. The absence of anti-phospholipase A2 receptor (anti-PLA2R) antibody indicates a low risk (< 20%) of recurrent MN. The presence of anti-PLA2R antibodies in the blood can indicate the presence of an autoimmune response against phospholipases, which can lead to recurrent MN. Therefore, the absence of anti-PLA2R antibodies in the blood is a positive sign for the patient's candidacy for kidney transplantation.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 2668 is A. She is an eligible candidate for SPK transplantation.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2669 is A. She is not a candidate for SPK transplantation.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2670 is A. A 64-year-old man with stage 3 CKD (eGFR of 54.5–50 ml/min per 1.73 m2) documented for 4 months and a recent fall in eGFR during a period of hypovolemia to 25 ml/min per 1.73 m2 is the answer. The patient is not eligible for simultaneous liver-kidney transplantation because they have a stage 3 CKD, which is a condition that requires kidney replacement therapy. Simultaneous liver-kidney transplantation is not recommended for patients with stage 3 CKD as it may increase the risk of complications such as liver cirrhosis, liver failure, and even death.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2671 is \n",
      "A. Lower incidence of CMV viremia\n",
      "B. Lower incidence of acute rejection\n",
      "C. Lower incidence of mortality\n",
      "D. Lower incidence of nonskin malignancy\n",
      "\n",
      "Answer: C. Lower incidence of mortality. Tacrolimus/everolimus/prednisone is a combination of rapamycin and tacrolimus, which have been shown to lower the incidence of acute rejection and CMV viremia. However, there is no clear answer to this question as the choice of the most likely clinical outcome depends on the specific patient's medical history and characteristics.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2672 is A. A lower incidence of acute rejection.\n",
      "Answer: A. A lower incidence of acute rejection.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2673 is A, B, C, D, or E.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2674 is C. An improvement in serum albumin.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2675 is A. Preexisting neointimal hyperplasia in the ﬁstula vein biopsy Specimen taken at the time of surgery.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2676 is A. His survival with a catheter is likely to be similar to that achieved with a ﬁstula or a graft.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2677 is A. Placement of a hybrid graft–catheter device or B. Placement of a graft with a venous stent or C. Placement of an early cannulation arterio-venous graft or D. Placement of an arteriovenous ﬁstula with sirolimus wrap around an arterial anastomosis.\n",
      "Answer: The strategy that is most likely to provide the quickest transition away from catheter-based HD is placement of a hybrid graft-catheter device. This strategy combines the benefits of a graft with the patency of a catheter, which may allow for earlier ambulation and better outcomes. Placement of a graft with a venous stent or early cannulation arterio-venous graft may also be a good option, but it may require additional imaging and procedures. Placement of an arteriovenous ﬁstula with sirolimus wrap around an arterial anastomosis may not be suitable for all patients and may require additional therapy and monitoring.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2678 is A. Adjustment of erythropoiesis-stimulating therapy, targeting a hemoglobin of 12 g/dl.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2679 is A, B, or C (One of the most appropriate next steps in management)\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2680 is A, B, C, D, E. The physical examination is remarkable only for mild pedal edema, and there are no uremic symptoms. The laboratory studies show normal values for hemoglobin, potassium, total CO2, and creatinine level. A left forearm brachiocephalic arteriovenous graft has not functioned for over 19 years. Vein mapping shows a patent left upper arm outﬂow cephalic vein from a previous arteriovenous graft. The veins in her right upper extremity are also suitable for placement of an arteriovenous ﬁstula. Therefore, all options are appropriate to initiate dialysis in this patient.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2681 is (A) Vascular ultrasonographic mapping of peripheral and central veins.\n",
      "Explanation: The best preoperative imaging study to plan this patient's access surgery is A. Vascular ultrasonographic mapping of peripheral and central veins. This study will provide detailed information about the patient's venous system, including the number and location of suitable veins for catheter placement. maps out the peripheral and central veins, allowing for a more accurate planning of the access surgery.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2682 is A, B, or C.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2683 is A. No beneﬁt of stent graft placement com-pared with angioplasty alone.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2684 is (A,B,C,D) - the next best step in management.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2685 is A. It is associated with an increased risk of unassisted ﬁstula maturation failure in comparison with no stenosis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2686 is A. The available surveillance methods are equally sensitive in identifying both inﬂow and outﬂow stenosis in both ﬁstula and graft.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2687 is A. A signiﬁcantly reduced risk of permanent access loss.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2688 is A. Immediate procedural success is more likely when thrombectomy is performed within 24 hours of the time of thrombosis diagnosis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2689 is C. Advanced laparoscopic catheter placement is associated with an increased risk for subsequent need to change her modality to HD.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2690 is A. Patients starting PD one week after catheter placement had signiﬁcantly higher leaks in comparison with patients who started after 2 weeks.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2691 is C\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2692 is \n",
      "A. Ultrasonographic ﬂow measurements and left arm arteriogram\n",
      "B. Recommend hand-grip exercises only\n",
      "C. Start amlodipine and aspirin\n",
      "D. Referral for immediate surgical ligation\n",
      "E. Change his dialysis access to a tunneled central venous catheter and monitor the left hand\n",
      "\n",
      "Answer: A. Ultrasonographic ﬂow measurements and left arm arteriogram. \n",
      "\n",
      "The most appropriate next step in management is to perform an ultrasonographic flow measurement and left arm arteriogram to determine the cause of the hand's ischemia. The left arm arteriogram can help identify whether there is a steal phenomenon, which is a possible cause of the hand's ischemia. If a steal phenomenon is identified, immediate surgical ligation may be necessary.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 2693 is A. Pulmonary embolus.\n",
      "\n",
      "Answer: A. Pulmonary embolus. \n",
      "\n",
      "Explanation: A pulmonary embolus is a blockage in the arteries that supply blood to the lungs, which can cause difficulty breathing, chest pain, coughing, and shortness of breath. The symptoms of perioral numbness, confusion, tachypnea, and hand paresthesias can be indicative of a pulmonary embolus. The other options are not likely causes of the symptoms observed. Use of the citrate lock solution can cause complications but not the symptoms observed. A panic attack, venous air embolism, and a complication from use of the citrate lock solution are not likely causes of the symptoms observed.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2694 is A. Remove the catheter and place a translumbar or transhepatic catheter.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2695 is A\n",
      "The best next step in management would be to avoid cannulation in the areas of breakdown and mark alternative sites for cannulation. The patient's access has increased in size over the years, and there is evidence of breakdown and aneurysm dilation. Therefore, it is important to avoid cannulating this site and find alternative access points that are suitable for the patient's needs. This may involve marks the area on the skin where a potential alternative access point could be located. The patient's access should be monitored closely by the dialysis technician to ensure that it remains functional and safe for use.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2696 is A central venous catheter is the preferred access for frequent HD because it minimizes the risk of needle dislodgement during dialysis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2697 is A. Recommend continuing hand grip exercises to assist in ﬁstula maturation because it has not yet had adequate time to mature. \n",
      "\n",
      "Guidelines:\n",
      "- The patient has stage 5 CKD and a radiocephalic arteriovenous ﬁstula.\n",
      "- The ﬁstula is poorly developed and does not augment well on examination.\n",
      "- An ultrasonographic evaluation shows a superﬁcial ﬁstula, with a diameter of 4 mm and blood ﬂow of 350 ml/min.\n",
      "- The patient has a history of hand grip exercises.\n",
      "- The patient's weight is stable.\n",
      "- The current laboratory studies are acceptable.\n",
      "- The patient has not yet started dialysis.\n",
      "\n",
      "Answer: A. Recommend continuing hand grip exercises to assist in ﬁstula maturation because it has not yet had adequate time to mature. \n",
      "\n",
      "Justification: The patient has stage 5 CKD and a radiocephalic arteriovenous ﬁstula, which is a common indication for creation of a radiocephalic arteriovenous ﬁstula. The ﬁstula is poorly developed and does not augment well on examination, which suggests that it may not be ready for dialysis. The patient has a history of hand grip exercises, which are known to assist in the development of the ﬁstula. The patient's weight is stable, and the current laboratory studies are acceptable. The patient has not yet started dialysis, which suggests that the ﬁstula has not yet been used for dialysis. Therefore, the most appropriate next step in management is to continue hand grip exercises to assist the ﬁstula in maturation and to avoid radiocontrast exposure, given the patient's stage of CKD.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2698 is A. Accessory veins are signiﬁcant contributors to nonmaturity in ﬁstulas and must always be ligated to allow maturation. [This statement is the current recommendation for management of accessory veins in nonmaturing ﬁstulae as of 2021. It is important to emphasize that ligation of the accessory veins is necessary to allow maturation of the ﬁstula and to avoid long-term complications such as late ﬁstula failure and patency loss. If the accessory veins are not ligated, they may continue to divert a portion of the outflow and impede the maturation of the ﬁstula.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2699 is A. Plan right brachiocephalic ﬁstula.\n",
      "\n",
      "Answer: A. Plan right brachiocephalic ﬁstula. \n",
      "\n",
      "Justification: Based on the information provided, the best next step in management would be to plan a right brachiocephalic ﬁstula. This is because the right brachiocephalic ﬁstula is the only option that can provide a blood source for the upper extremity. The plan a right forearm arteriovenous graft to allow veins in the upper extremity to develop for a secondary ﬁstula is not a suitable option because there is no information provided on the presence of any veins in the upper extremity. Similarly, contrast venography of her central veins to evaluate for unsuspected central venous stenosis is not a suitable option because there is no information provided on any central venous stenosis. The plan a right brachiobasilic arteriovenous ﬁstula because the cephalic veins are not visible in the forearm is also not a suitable option because no veins are visible on physical examination, and it is unknown if the cephalic veins are still viable.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2700 is \n",
      "A. A reduction in luminal diameter by 25 percent is consistent with a diagnosis of a stenotic lesion of an arteriovenous ﬁstula as it is a sign of a narrowing of the affected vessel that restricts blood flow to the surrounding tissues. The other options are not directly related to a stenotic lesion of an arteriovenous ﬁstula.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2701 is A or B.\n",
      "A. Renal masses are not seen on bedside kidney ultrasonography.\n",
      "B. Hydronephrosis is seen on bedside kidney ultrasonography.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2702 is A or B.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5535 is \n",
      "\n",
      "Answer: We need more information to determine the most appropriate management.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5536 is C\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5537 is [ ]\n",
      "Answer: The most appropriate management for this patient is to increase paricalcitol. Paricalcitol is a hormone that helps regulate calcium levels in the body. In this patient, the PTH values have been consistently high, which indicates that the calcium levels are not balanced. Increasing the paricalcitol can help bring the calcium levels down to a safe range.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5538 is \n",
      "\n",
      "Answer: \n",
      "Based on the patient's laboratory ﬁndings, the addition of cinacalcet is appropriate. The patient has hyperphosphatemia and low calcium levels, which are both common in patients with ESRD. Cinacalcet is a calcimimetic medication that is used to treat hyperphosphatemia in patients with ESRD. It works by decreasing the tubular reabsorption of phosphorus, which leads to a decrease in PTH levels. Therefore, the statement that \"The addition of cinacalcet is likely to decrease PTH levels by 15% to 20%\" may be accurate in this patient.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5541 is (A) Cinacalcet and parathyroidectomy are associated with a similar decrease in serum calcium.\n",
      "\n",
      "Answer: (A) Cinacalcet and parathyroidectomy are associated with a similar decrease in serum calcium.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5542 is A) Erythropoietin therapy decreases the levels of FGF23 in circulation.\n",
      "\n",
      "Answer: A) Erythropoietin therapy decreases the levels of FGF23 in circulation.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5543 is \n",
      "\n",
      "A) Measurements of DEXA are useful in predicting the underlying bone histologic features in patients with CKD stage G3a–G5D. \n",
      "\n",
      "B) DEXA is predictive of fracture risk in adults with CKD stage G3a–G5D. \n",
      "\n",
      "C) Parathyroidectomy has not been associated with increases in bone density. \n",
      "\n",
      "D) Denosumab may lead to hypercalcemia in patients with CKD.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5544 is \n",
      "A) The majority of such patients are expected to achieve remission of hyperparathyroidism after 1 year of cinacalcet therapy.\n",
      "B) He should be prescribed paricalcitol to decrease PTH.\n",
      "C) The patient has tertiary hyperparathyroidism and needs urgent parathyroidectomy.\n",
      "D) Cinacalcet therapy would be expected to lower serum phosphorus further.\n",
      "\n",
      "Answer: A) The majority of such patients are expected to achieve remission of hyperparathyroidism after 1 year of cinacalcet therapy.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5545 is (A) A gain of function mutation in the calcium sensing receptor gene, (B) A loss of function mutation in the calcium sensitive gene, (C) A mutation in the adaptor-related protein complex 2 sigma subunit 1 (AP2S1) gene, or (D) Loss of function mutation in G-protein α-11. \n",
      "\n",
      "The calcium-sensing receptor (CaR) plays a crucial role in regulating calcium levels in the body. A gain of function mutation in the CaR gene or a loss of function mutation in the CaR gene can result in hypocalcemia. A mutation in the AP2S1 gene or a loss of function mutation in G-protein α-11 can also explain the clinical condition. However, a loss of function mutation in the calcium-sensing gene is the most likely explanation based on the information provided.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5546 is \n",
      "\n",
      "A) Hypertension\n",
      "B) Her ethnicity\n",
      "C) Her use of activated vitamin D\n",
      "D) Her treatment with multiple insulin injections\n",
      "\n",
      "Answer: C) Her use of activated vitamin D is MOST likely associated with an increased risk of the complication of calciphylaxis in this patient. The reference range for PTH levels is suggests that the patient's PTH levels are within the normal range, but the range of 486 to 592 pg/ml is suggestive of hyperparathyroidism. Therefore, it is possible that the patient's use of activated vitamin D may be contributing to her hyperparathyroidism, which could increase her risk for calciphylaxis. Hypertension and her ethnicity are not likely associated with an increased risk of calciphylaxis. Her treatment with multiple insulin injections may also contribute to her risk of calciphylaxis if not managed properly.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5547 is (A) Primary hyperparathyroidism, (B) Familial hypocalciuric hypercalcemia, (C) Thiazide-induced hypocalciuria, (D) Occult malignancy, or (E) Sarcoidosis. \n",
      "\n",
      "Answer: The most likely primary cause of her hypercalcemia is (A) Primary hyperparathyroidism.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5548 is \n",
      "\n",
      "A 67-year-old man with recent onset of ESRD resulting from diabetic kidney disease is evaluated 1 week after starting hemodialysis. He is asymptomatic and is up to date on all age-appropriate cancer screenings. Routine laboratory studies show a hemoglobin of 11.1 gm/dl, albumin of 3.5 g/dl, creatinine of 6.7 mg/dl, calcium of 9.8 mg/dl, phosphorus of 3.7 mg/dl, and PTH of 363 pg/ml (reference range 12–72 pg/ml). \n",
      "\n",
      "Based on these laboratory values, which of the following would you recommend next? \n",
      "\n",
      "A) Calcium carbonate tabs\n",
      "B) Vitamin D\n",
      "C) Phosphate binder therapy\n",
      "D) Ionized calcium testing\n",
      "E) PTH-related protein testing\n",
      "\n",
      "Answer: The routine laboratory values suggest that the patient's phosphorus levels are elevated. Therefore, the next step would be to measure ionized calcium levels to determine if the patient is within the normal range. If the patient is not within the normal range, further evaluation and management may be necessary.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5549 is \n",
      "\n",
      "A) Surreptitious intake of vitamin D\n",
      "B) Sarcoidosis\n",
      "C) Monoclonal protein causing an artefactual increase in 25-hydroxyvitamin D\n",
      "D) Plasma cell-induced stimulation of 25-hydroxyvitamin D synthesis\n",
      "\n",
      "Answer: C) Monoclonal protein causing an artefactual increase in 25-hydroxyvitamin D. \n",
      "\n",
      "Explanation: The patient's laboratory proﬁle is consistent with an increase in 25-hydroxyvitamin D caused by a monoclonal protein. The elevated 25-hydroxyvitamin D level is consistent with the patient's history of taking oral vitamin D supplements. The other options are unlikely to cause the patient's laboratory proﬁle. A) is unlikely because the patient's weight loss and symptoms are not consistent with a vitamin D excess. B) is unlikely because sarcoidosis does not typically cause an increase in 25-hydroxyvitamin D. D) is unlikely because a plasma cell-induced increase in 25-hydroxyvitamin D is not likely in this patient's context.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5550 is \n",
      "\n",
      "A) Hypomagnesemia \n",
      "B) Hyperkalemia \n",
      "C) Hypercalcemia \n",
      "D) Hyperphosphatemia \n",
      "\n",
      "Answer: A) Hypomagnesemia. \n",
      "\n",
      "Explanation: Hypomagnesemia is a factor that can increase the risk of developing diabetes mellitus after transplantation. It can causing changes in calcium and phosphorus levels, leading to hyperphosphatemia and other complications. In the given patient, his laboratory values show normal levels of calcium, magnesium, and phosphorus, but his sodium is high, which could indicate hyponatremia. It is possible that the patient's hyperkalemia and hyperphosphatemia are due to hypomagnesemia. However, the patient's biopsy did not show any evidence of rejection or acute tubular injury, which suggests that other factors may be contributing to his condition.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5551 is \n",
      "A) Zoledronic acid\n",
      "B) Calcitonin\n",
      "C) Denosumab\n",
      "D) Phenytoin\n",
      "E) Cinacalcet\n",
      "\n",
      "Answer: A) Zoledronic acid.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5552 is C\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5553 is \n",
      "a) Increased serum uric acid is a risk factor for stone formation in men without a previous history of stone formation.\n",
      "b) Lowering serum uric acid reduces the risk of calcium stone formation.\n",
      "c) Increased serum uric acid is a risk factor for stone formation in women without a previous history of stone formation.\n",
      "d) Serum uric acid predicts the risk of uric acid stone, but not calcium stone, formation.\n",
      "e) Patients with hyperuricemia usually have hyperuricosuria.\n",
      "Answer: a) Increased serum uric acid is a risk factor for stone formation in men without a previous history of stone formation.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5554 is \n",
      "\n",
      "Answer: The next best step in the evaluation of this patient is 'Chest CT'. The abnormal QaTc intervals as well as the ST segment/T wave abnormalities suggest that the patient may have a diagnosis of aortic artery disease. A chest CT scan would allow for further evaluation of the heart and aorta.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5555 is A or B.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5556 is A) Hypophosphatemia\n",
      "Answer: A) Hypophosphatemia.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5557 is A) Oncogenic osteomalacia, B) Occult hyperparathyroidism, C) Poor phosphate intake, D) Ferric carboxymaltose infusions, E) Autosomal dominant hypophosphatemia. \n",
      "\n",
      "Answer: A) Oncogenic osteomalacia. It is the most likely cause of hypophosphatemia in this patient based on the available information. Oncogenic osteomalacia is a rare and acquired disorder of bone formation that causes osteomalacia, a condition characterized by poor bone development and growth. The patient's symptoms, including fatigue, diffuse muscle pain, and weakness, are consistent with the signs of osteomalacia. The fact that she has received 2 doses of parenteral ferric carboxymaltose 500 mg before presentation is suggestive of a diagnosis of iron deﬁciency anemia, which can be a presenting feature of oncogenic osteomalacia. However, furthermore testing and evaluation by a bone density scan and other imaging tests may be necessary to confirm the diagnosis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5558 is \n",
      "A) Ankylosing spondylitis\n",
      "B) Adynamic bone disease\n",
      "C) Tumor-induced osteomalacia\n",
      "D) Osteitis ﬁbrosa cystica\n",
      "\n",
      "Answer: The most likely cause of this patient's clinical problem is A) Ankylosing spondylitis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5559 is A) PTH level, B) Serum calcium, C) Serum phosphorus, D) Serum calcitonin, or E) Serum 1,25-dihydroxyvitamin D.\n",
      "\n",
      "The PTH level is a factor that is significantly associated with an increased risk of new-onset nephrolithiasis in an otherwise healthy male population with otherwise normal serum chemistry values. The PTH level is directly related to the stone-forming propensity of the kidneys and is a risk factor for the development of nephrolithiasis. Therefore, the PTH level should be monitored and managed to prevent the occurrence of nephrolithiasis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5560 is a) Hypercalciuria b) Renal tubular acidosis c) Hypocitraturia d) Increased 2,8-dihydroxyadenine excretion e) Increased uric acid excretion\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5561 is \n",
      "\n",
      "Answer: The most likely explanation of her hypomagnesemia is a question mark. It is possible that she has a combination of factors contributing to her symptoms, including decreased gastrointestinal absorption, which is supported by the presence of a positive Chvostek sign. However, further testing and evaluation by her healthcare provider is necessary to determine the exact cause of her symptoms.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5562 is [A. Her vitamin C use places her at increased risk for recurrent stones. (This statement is only partially correct. While vitamin C can cause an increase in oxalate levels, it does not necessarily increase the risk of kidney stones.)]\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5563 is \n",
      "\n",
      "A. Parathyroidectomy \n",
      "B. Observation on a twice-a-year schedule \n",
      "C. Cinacalcet \n",
      "D. Estrogen therapy \n",
      "E. Denosumab\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2733 is A, B, C, or D.?\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2734 is \n",
      "The most helpful management option for the patient is C. Bariatric surgery because the FSGS is likely secondary to her obesity. \n",
      "\n",
      "Explanation: \n",
      "The patient's obesity is likely the primary cause of her FSGS. Obesity can lead to increased pressure on the kidneys, which can cause glomerular damage and injury. The proteinuric response to the high-dose prednisone may have further damaged the kidneys, leading to the current state of progressive CKD. Bariatric surgery can help the patient lose weight and reduce the risk of recurrence of FSGS. While genetic analysis and repeat kidney biopsy may provide further information about the patient's condition, they may not necessarily be the best course of action for her management. Forgo kidney transplantation is not recommended as the patient's condition is likely to recur in the allograft.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2735 is A, B, C, or D.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2736 is A. The worsening kidney function is most likely due to progression of diabetic nephropathy, and the patient needs better control of his BP.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2737 is A. Supportive care because the patient most likely has postinfectious GN, and this will resolve with treatment of the infection. The patient's creatinine concentration on admission was 1.4 mg/dl, which is higher than the reference range of 0.8095–0.9239 mg/dl. Her systolic BP on admission was 100 mmHg, and she received iv saline with stabilization of the systolic BP at 115 mmHg. However, over the next few days her creatinine slowly increased to 2.3 mg/dl. The urine output over the preceding 24 hours was about 800 ml, indicating a high urinary output, suggestive of AKI. The patient has been receiving vancomycin, and the vancomycin trough on the day of the consultation was 24 µg/ml, which is higher than the reference range of 10–20 µg/ml. The patient has a low C3 level at 62 mg/dl and a positive MPO-ANCA at 49 U/ml, which is consistent with the diagnosis of ANCA-asso-liated nephritis. Based on the patient's symptoms and sera, the most appropriate treatment is a course of corticosteroids and cyclophosphamide. However, a kidney biopsy is necessary to verify the diagnosis and guide the appropriate treatment plan.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2738 is (A) or (B) or (C) or (D)The correct answer is (A) interferon-based antiviral therapies do not decrease the chances of developing cryoglobulinemia and GN in patients infected with hepatitis C, genotype 1.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2739 is A. How much interstitial ﬁbrosis and tubular atrophy were present on the kidney biopsy specimen taken before treatment was started. It is important to know the amount of interstitial ﬁbrosis and tubular atrophy present on the kidney biopsy to determine the likelihood of the need for permanent renal replacement therapy.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2740 is A.Urine protein electrophoresisB. Serum immunoﬁxation plus serum free light chainsC. Serum complement levelsD. Laser dissection/mass spectrometry analysis of the kidney biopsy.\n",
      "Explanation: To determine the best next test(s) to help decide on therapy for a patient with proliferative GN with monoclonal immuno-globulin deposits, the nephropathologist may choose one or more of the following options: Urine protein electrophoresis, Serum immunoﬁxation plus serum free light chains, Serum complement levels, or Laser dissection/mass spectrometry analysis of the kidney biopsy. Each of these options can provide valuable information about the patient's condition and guide the decision on therapy. For example, urine protein electrophoresis can help determine the amount of protein in the urine, which may indicate the stage of disease and the need for therapy. Similarly, serum immunoﬁxation plus serum free light chains can help identify the presence of monoclonal immuno-globulin deposits, which is a key feature of the patient's condition. Serum complement levels may also be useful in determining the patient's risk of developing kidney damage. Finally, laser dissection/mass spectrometry analysis of the kidney biopsy can provide a detailed analysis of the patient's kidney damage, which can help guide the decision on therapy. Therefore, the best next test(s) to help decide on therapy for a patient with proliferative GN with monoclonal immuno-globulin deposits may depend on the specific patient's condition and the goals of therapy.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 2741 is (A) Serologic testing for lupus\n",
      "\n",
      "Answer: I would recommend that the patient should begin a low-dose angiotensin converting enzyme inhibitor (AECI) as a preventative measure for kidney injury while taking pembrolizumab. AECI has been shown to improve kidney function in several mouse models of kidney injury and can also be used to manage blood pressure in patients with established kidney disease. However, it is important to note that the decision to start AECI should be made in collaboration with the patient's oncologist and should be based on a thorough understanding of the patient's medical history and current condition.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2742 is None of the above. \n",
      "\n",
      "Answer: The most appropriate management for the patient is a combination of plasmapheresis, high-dose corticosteroids, and cyclophosphamide. The patient should also be monitored closely for any signs of respiratory or kidney deterioration.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2743 is A. A combination of low-dose tacrolimus and low-dose mycophenolate mofetil (MMF) with prednisone.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2744 is A.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2745 is A. Add a calcineurin inhibitor to the regimen.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2746 is \n",
      "\n",
      "A. The fact that he is male\n",
      "B. The history of IgM antibodies to cardiolipin and β2-glycoprotein\n",
      "C. Dialysis vintage > 5 years\n",
      "D. Low complement factor C4\n",
      "E. His age\n",
      "\n",
      "Answer: D. Low complement factor C4 makes it LESS likely that he is experiencing a lupus ﬂare.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2747 is A. Treat the patient with rituximab monotherapy for recurrent class V lupus nephritis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2748 is None of the above is appropriate as the patient's symptoms are not severe enough to require immunosuppressive therapy. The patient should be followed up closely for any changes in symptoms and may require additional testing or treatment if necessary.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2749 is A. ANCA titers decreased but were still positive when maintenance therapy was started.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2751 is A or B\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2752 is A, B, C, or D.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2753 is A. The choice is dependent on the patient's symptoms and the stage of the disease. A patient with rapidly progressive GN may develop sings of dehydration and kidney failure, making a serum creatinine level of 6.4 mg/dl a concern. Therefore, a doctor should consider the patient's symptoms and medical history to determine the best course of treatment and care. It is important to keep the patient informed about the potential outcomes of their disease and provide them with the most accurate and up-to-date information available.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2754 is A, B, C, or D.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2755 is A or C.\n",
      "\n",
      "The most likely mutation to be revealed by genetic testing is in the NPHS2 gene, which codes for podocin. Therefore, the correct answer is D. NPHS2.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2756 is A. Antiviral therapy without additional immunosuppression.\n",
      "Answer: A. Antiviral therapy without additional immunosuppression is the most appropriate management for the given patient. It is important to avoid further immune suppression and the associated risks of infections, cancer, and organ damage. Antiviral therapy can help to manage the symptoms of the patient, and the antiviral load of 2,180,385 IU/ml suggests that the patient is infectious and may benefit from antiviral therapy.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2757 is .\n",
      "Answer: Based on the information provided, the most appropriate management for this patient would be Pegylated interferon. This is because Pegylated interferon is a treatment option for hepatitis B, and the patient's biopsy shows membranous nephropathy with positive staining for hepatitis B antigen, which is a characteristic of hepatitis B. Additionally, Pegylated interferon has been shown to be effective in treating hepatitis B.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2758 is \n",
      "A. Supportive care without further antibiotics or immunosuppression.\n",
      "B. Refer for mitral valve replacement.\n",
      "C. Eculizumab.\n",
      "D. Cyclophosphamide plus corticosteroids.\n",
      "\n",
      "Answer: A. Supportive care without further antibiotics or immunosuppression. This patient is already receiving intravenous penicillin G for 6 weeks, and she has not had fever for the past month. Repeated blood cultures have been negative, and a repeated trans-esophageal echocardiogram did not show persistent vegetations or other abnormalities. The serum creatinine level increased from 0.8 mg/dl on admission to 4.5 mg/dl, which suggests that the patient's kidneys are not functioning properly. A kidney biopsy shows 35% cellular crescents without fibrinoid necrosis, and diffuse granular mesangial and segmental granular capillary wall staining for IgG (3+), IgM (2+), C3 (3+), C1q (3+), kappa-light chains (2–3+), and lambda-light chains (1–2+), but no staining for IgA or phospholipase A2 receptor antigen. Electron microscopy shows scattered subepithelial and mesangial deposits. Based on the results of the kidney biopsy, the patient's kidneys are likely damaged, and furthermore, she has mitral vegetation and mild mitral re-gurgitation on an initial transesophageal echocardiogram. Therefore, the most appropriate management is supportive care without further antibiotics or immunosuppression. A kidney biopsy is a relatively safe and informative procedure, and it can be performed on an outpatient basis with local anesthesia.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2759 is A. Begin prednisone 1 mg/kg per day for 6 to 8 weeks, if the patient does not improve after a 2-week course of losartan.\n",
      "Answer: A. Begin prednisone 1 mg/kg per day for 6 to 8 weeks, if the patient does not improve after a 2-week course of losartan. This is because the patient has developed membranoproliferative GN with mesangial and subendothelial deposits, which is an autoimmune disease that can be responsive to glucocorticoids. Prednisone has been shown to be effective in treating membranoproliferative GN, and it is commonly used in combination with other treatments such as cyclophosphamide and rituximab. Therefore, the best course of action is to start a short course of prednisone and monitor the patient's response.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2760 is A. Cyclophosphamide, bortezomib plus dexamethasone.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2761 is A. IgG4-related disease.\n",
      "\n",
      "A. IgG4-related disease is MOST likely overlapping with the diagnosis of ANCA-associated vasculitis in this case. The presence of positive PR3-ANCA at 132 U/ml and the features of pauci-immune crescentic necrotizing GN on the kidney biopsy are suggestive of ANCA-associated vasculitis. However, further testing and evaluation by a rheumatologist or nephrologist is necessary to confirm the diagnosis.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 2762 is (B) > 50% of patients treated with rituximab can expect improvement or stabilization of kidney function.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2763 is The answer is C. A QRS-T angle of greater than or equal to 75 degrees on signal-averaged electrocardiogram has been associated with an increased risk of sudden cardiac arrest in patients with ESRD.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2764 is A) Elevated BMI will predispose him to cardiac complications and increase his mortality risk.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2765 is A. It will be less likely to cause hypocalcemia than cinacalcet.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2766 is A. The risk of SCD is the same in HD and PD patients.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2767 is C\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2768 is A. HDF improves patient-reported posttreatment recovery times.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2769 is A.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2770 is A, B, C, D, E.\n",
      "Answer: A, B, C, D, E.\n",
      "\n",
      "Justification: The patient is an elderly man with obesity and a diagnosis of acute myocardial infarction, which is associated with an increased risk of hospital readmission. The decrease in the number of his pre-scribed medications could also contribute to his increased risk of readmission if he is not adhering to his medication regimen. Therefore, the patient's age, sex, diagnosis, and the number of his medications are all factors that could contribute to his increased risk of hospital readmission.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2771 is A. AF is associated with an increased risk of ischemic stroke.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2772 is \n",
      "(A. Reduce apixiban to 2.5 mg twice daily)\n",
      "(B. Change apixiban to rivaroxaban)\n",
      "(C. No change in management)\n",
      "(D. Recommend adding a supplemental 2.5-mg dose after each HD session)\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2773 is A. Use of IV epoetin. \n",
      "\n",
      "Answer: Use of IV epoetin has been associated with an increased risk of calcic valvular disease in patients with ESRD on HD. The increased risk is due to the hypercoagulable state of these patients, which can cause damage to the valvular endothelial cells and lead to the development of calcic valvular disease.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2774 is A. A signiﬁcant reduction in mortality\n",
      "Explanation: The only option that is likely to result from use of a dialysate calcium level of 2.5 mEq/L compared with 3.5 mEq/L over a period of 2 years is A. A significant reduction in mortality. Use of a lower dialysate calcium level has been shown to result in a reduction in mortality in patients with ESRD. The other options are not likely to result from use of a lower dialysate calcium level.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2775 is A. Higher dialysate sodium concentration.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2776 is A.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2777 is A. The majority of patients on HD experience deterioration of cognitive function.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2778 is C\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2779 is \n",
      "\n",
      "Answer: A. PIH is associated with higher all-cause hospitalization and mortality.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2780 is A. The most effective option is to inform the patient about tenapanor as a novel agent that enhances gastrointesti-nal excretion of phosphate. It is currently under investigation for the treatment of hyperphosphatemia in ESRD.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2781 is A. Preoperative prophylactic antibiotics reduce the risk of early peritonitis.\n",
      "Explanation: The answer is A because it directly addresses the question asked by the patient about the risk of developing peritonitis soon after having the catheter placed. Preoperative prophylactic antibiotics can reduce the risk of early peritonitis in patients with an embedded catheter. The other options do not directly address the question asked by the patient or are not related to the development of early peritonitis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2782 is A. PD vintage for < 5 years.\n",
      "Answer: A. PD vintage for < 5 years. The patient's medical history shows that she has had four episodes of PD-related peritonitis over the past 2 years. This history places her at increased risk for encapsulating peritoneal ﬁbrosis, which is a rare but serious condition that can occur in patients with previous peritonitis or other factors. The peritoneal ﬂuid analysis shows 10 total nucleated cells/mm3 with 40% neutrophils, which suggests that the patient has an active infection. The computed tomographic scan also shows thickened peritoneum, bowel wall thickening, and dilatated loops of bowel, which are further evidence of an active infection. The patient's medications include vancomycin and warfarin, which are both used to treat infections. Overall, the patient's medical history and peritoneal ﬂuid analysis suggest that she is at increased risk for encapsulating peritoneal ﬁbrosis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2783 is A. Centers with <10 incident PD patients per year.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2784 is \n",
      "A. Abdominal wall complications can be reduced to < 10% by initiating PD with low dwell volumes with gradual titration over the ﬁrst month of therapy.\n",
      "B. Pericatheter leak and subcutaneous leak are the most common mechanical complications of urgent-start PD.\n",
      "C. Urgent-start PD should always be initiated as intermittent peritoneal dialysis rather than automated peritoneal dialysis to avoid catheter dysfunction.\n",
      "D. Transfer to HD within 1 year occurs in over 30% of patients treated with urgent-start PD.\n",
      "\n",
      "Answer: A. Abdominal wall complications can be reduced to < 10% by initiating PD with low dwell volumes with gradual titration over the ﬁrst month of therapy.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2785 is \n",
      "A. Patients who have cirrhosis and ESRD who are treated with PD have a signiﬁcantly lower mortality in comparison with HD patients who have cirrhosis and ESRD.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2786 is A. His age. \n",
      "\n",
      "Answer: A. His age is associated with an increased risk of transition from home HD to in-center dialysis in this patient. The patient's age can be a significant factor in determining the success of home HD and the need for in-center dialysis. Younger patients may require more frequent and/or longer sessions, while older patients may have more difficulty with the logistics of home HD, including transportation, medical appointments, and personal responsibilities.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 2787 is A or B.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2788 is (A)\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2789 is A or B\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2790 is A, B, or D.\n",
      "Answer: A. Incremental HD is associated with a significantly slower decline in residual kidney function compared with conventional dialysis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2791 is A. Avoid skin trauma and subcutaneous injections\n",
      "Answer: A. Avoid skin trauma and subcutaneous injections\n",
      "Explanation: The patient has tender necrotic lesions on her medial thighs without evidence of secondary infection, and an aggressive regimen of wound management, analgesics, and sodium thiosulfate is given. Therefore, the most appropriate next step in managing this patient's CUA is to avoid skin trauma and subcutaneous injections. Transfer to PD may be a good option if the patient's condition improves.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2792 is A.\n",
      "A previous study found that patients receiving HD with an ESA and iron therapy had lower rates of anemia-related hospitalizations compared to those receiving HD without an ESA. However, it is not clear whether this relationship is due to the iron therapy or other factors, including patient-specific factors such as age, gender, and comorbidities. Therefore, the advanced practice provider should be cautious in interpreting this relationship and consider other factors that may influence the relationship between iron therapy and anemia-related outcomes in patients with ESRD.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2793 is (A,B,C,D)\n",
      "\n",
      "C. Serum C3, C4, and an anti-nuclear antibody may be performed to rule out a primary immunodeficiency as a cause of the hematuria. However, it is not necessary to perform a kidney ultrasound.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2794 is A. Increased glomerular density (number of glomeruli per cubic millimeter)\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2795 is A, B, C, or D.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2796 is (A) Perform genetic testing for a podocytopathy, (B) Determine the APOL1 risk allele status, (C) Search for an underlying lymphoma, or (D) Request B7-1 (CD80) stain of the kidney biopsy specimen.\n",
      "Answer: The most appropriate next step in this patient's evaluation is to determine the APOL1 risk allele status.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2797 is A. Serum C3 and C4.\n",
      "\n",
      "Answer: A. Serum C3 and C4 are the most appropriate tests to order next in this scenario. The biopsy specimen showed characteristic diffuse thickening of the glomerular basement membrane with no associated endocapillary hypercellularity, which suggests a primary immune complex disease. The presence of numerous subepithelial immune complex–type deposits on electron microscopy also supports this diagnosis. The ELISA for serum anti–PLA2R antibodies was negative, which further supports the primary immune complex disease. Therefore, a thorough evaluation of the patient's immune system should be performed through the measurement of serum C3 and C4 levels.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2798 is A. Evaluate for an underlying malignancy.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2799 is A, B, C, or D.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2800 is A. Aggressive use of renin-angiotensin inhibition, or B. A 6-month course of low-dose corticosteroids, or C. A 6-month course of combined mycophenolate mofetil (MMF) plus low-dose steroids, or D. Treatment with high-dose steroids, cyclo-phosphamide, and plasmapheresis, or E. Treatment with high-dose steroids only.\n",
      "Answer: A. Aggressive use of renin-angiotensin inhibition is the treatment regimen that is most likely to reduce the rate of progression to ESRD.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2801 is A. Extensive C4d deposition in the mesangium.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2802 is A. A posttransplantation regimen consisting of tacrolimus, MMF, and low-dose corticosteroids\n",
      "\n",
      "Answer: A. A posttransplantation regimen consisting of tacrolimus, MMF, and low-dose corticosteroids is MOST likely to unfavorably affect the risk of recurrence of the disease in a renal allograft for patients with IgA Nephropathy. Tacrolimus, MMF, and low-dose corticosteroids are all recommended as an immune-suppressive regimen for patients with ESRD due to IgA Nephropathy. Tacrolimus and MMF can help to reduce the risk of rejection and improve the overall outcomes of the transplantation. Low-dose corticosteroids can provide additional benefits, such as reducing the risk of GvHD and improving the graft function. Therefore, a posttransplantation regimen consisting of tacrolimus, MMF, and low-dose corticosteroids is a good choice for patients with IgA Nephropathy.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2803 is A. Genetic analysis for pathogenic mutations of complement factor H, I, and membrane cofactor protein.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2804 is \n",
      "\n",
      "Answer: The most useful study to clarify the nature of the disease present in this patient is a study of the kidney biopsy which shows a membranoproliferative pattern of injury with 10% glomerular involvement with crescents on light microscopy. This study provides conclusive evidence that the patient has a glomerular disease and the specific nature of the disease can be determined by further testing. The other studies listed are not directly related to the patient's condition.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2805 is A. Presence of two APOL1 high-risk alleles.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2806 is A, B, C, D, E\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2807 is A, B, C, either D or E.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2808 is A, B, C, or D.\n",
      "Answer: A. The genetic studies strongly indicate that he will be unresponsive to treatment.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2809 is [A. Serum anti–PLA2R antibody negative and PLA2R1 anthemia positive in glomeruli] or [B. Serum anti–PLA2R antibody negative and PLA2R1 anthemia negative in glomeruli].\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2810 is A relapse is not likely when the MMF is discontinued. (D is the correct answer and A, B, and C are incorrect).\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2811 is \n",
      "A. Duration of diagnosed diabetes mellitus\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 2812 is A. C3 glomerulopathy.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2813 is A. Lower mesangial proliferation grade.\n",
      "Answer: A lower mesangial proliferation grade would suggest a high risk for relapse following a remission after an adequate course of steroid therapy. This is because mesangial proliferation grade is a feature of minimal change disease, which is a common entity that can relapse after a remission. Therefore, a lower mesangial proliferation grade in a kidney biopsy Specimen would indicate a higher risk for relapse.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2814 is A. Absence of IgM or C3 deposition.\n",
      "Answer: A. Absence of IgM or C3 deposition. This ﬁnding would indicate a poor response to cortico-steroids and a poor long-term prognosis because a absence of IgM or C3 deposition would indicate that the patient's immune system is not responding to the corticosteroids and that the patient is at risk for developing further complications. Therefore, the most appropriate answer is A. Absence of IgM or C3 deposition.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2815 is A. Serum anti–PLA2R antibody.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2816 is A, B, C, or D.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2817 is \n",
      "\n",
      "A. Increased C4d mesangial deposition is generally regarded as indicating a poor prognosis in IgA nephropathy, in addition to ﬁndings that are incorporated into the OX-FORD-MEST-C scores.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2818 is A. Serum anti-nuclear antibody and anti-dsDNA antibody.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2819 is A. Serum anti–DNA antibody.\n",
      "Answer: A. Serum anti–DNA antibodieshould be performed as it is a more specific and sensitive test for identifying the presence of anti-glomerular basement membrane (GBM) antibodies in the blood. The other options are not recommended as they are not specific for GBM antibodies and may give false positive or false negative results. A repeat kidney biopsy for electron microscopy is not recommended as it is an invasive procedure and may cause unnecessary complications.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2820 is \n",
      "I would choose answer A. Urine protein < 6 g per day at the time of diagnosis prior to transplant as the most likely indicates a high probability of recurrence of a primary form of an FSGS lesion in an adult patient receiving a living donor transplant.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2821 is (A, B, C, or D)\n",
      "\n",
      "Answer: Based on the given information, the best treatment regimen for this patient would be option B, which is the use of MMF 2 g per day for 1 year. The patient has a significant amount of Cushing syndrome due to the repeated treatment courses of oral corticosteroids. The use of MMF, a calcineurin inhibitor, can help to reduce the frequency of relapses and improve the patient's nephrotic syndrome. The daily maintenance dosage of MMF is 2 g per day, which is appropriate for the patient's weight. The treatment duration of 1 year is also appropriate, as the patient's symptoms are chronic and may require long-term treatment.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2822 is A. IgA nephropathy. The most likely cause of the woman's hematuria is IgA nephropathy. This is based on the fact that the woman has a persistent asymptomatic microscopic hematuria that is 5-25 erythrocytes per high power field on urinalysis on three occasions over the past 6 months, which is a common finding in IgA nephropathy. Her age and family history are also important factors to consider. Additionally, the elevated urine albumin-to-creatinine ratio and increased erythrocyte casts are other common characteristics of IgA nephropathy. Therefore, she is likely to receive inpatient palliative care services based on data from the United States National Inpatient Sample Data.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2824 is (B) No difference in mortality at 90 days.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2825 is A, B, D, or E.\n",
      "Answer: A. Decreased incidence of systemic bacteremia. The NUTRIREA-2 study found that enteral feeding was associated with a decreased incidence of systemic bacteremia, which is a serious and potentially life-threatening infection. Systemic bacteremia can be caused by bacteria that are inhaled or ingested, and it can lead to sepsis, shock, and death if not treated promptly. Therefore, enteral feeding may be a more effective way to prevent or manage sepsis in patients with stage G4 CKD and colon cancer.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2826 is A. The angiotensin II infusion may cause the patient's condition to worsen and increase the risk of mortality.B. The angiotensin II infusion can improve the patient's condition and reduce the need for follow-up dialysis.C. The angiotensin II infusion may increase the patient's Sequence Organ Failure Assessment (SOFA) score.D. The angiotensin II infusion can shorten the patient's duration of mechanical ventilation.This statement is not correct as adding angiotensin II infusion may increase the patient's condition and risk of mortality in this setting.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2827 is A decreased risk of surgical site infections.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2828 is (A) Increased risk of mortality, (B) Increased risk of hypercalcemia, (C) Decreased risk of progressive AKI requiring dialysis, (D) Decreased risk of intensive care unit-associated delirium, or (E) Fewer vasopressor-free days.\n",
      "Answer: The answer is (A) Increased risk of mortality.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2829 is A, B, C, or D.\n",
      "Answer: A, B, and C are all important steps in mitigating the patient's morbidity and mortality in the setting of impending septic shock. \n",
      "\n",
      "A. administration of a bolus of 30 ml/kg 0.9% normal saline solution is an important step in providing volume to the patient and replenishing lost fluids due to hypotension and dehydration. \n",
      "\n",
      "B. administration of vasopressors to achieve a mean arterial pressure of 70 mmHg is an important step in managing the patient's blood pressure and preventing further organ damage. \n",
      "\n",
      "C. administration of a combination of fluids and vasopressors to achieve a target central venous saturation of 70% is an important step in improving the patient's oxygenation and overall health. \n",
      "\n",
      "D. early administration of appropriate antibiotics is important in preventing and managing septicemia.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2830 is SELECT A. The 35-year-old woman with a creatinine increase of 1.0 mg/dl over 1 day.\n",
      "Answer: SELECT A. The 35-year-old woman with a creatinine increase of 1.0 mg/dl over 1 day is MOST likely to beneﬁt from electronic alerts in the medical record that identify AKI.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 2831 is A. A reduction in nephrotoxin exposure and events requiring renal replacement therapy (RRT), but no change in hospital mortality.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2832 is A.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2833 is A. Shorter length of mechanical ventilation\n",
      "\n",
      "Explanation: \n",
      "\n",
      "The question is asking which patient outcome is consistent with the implementation of a kidney disease improving global outcomes (KDIGO) based care bundle for post-operative patients with urinary tissue inhibitor of metalloproteinase 2*IGF binding protein factor 7 levels > 0.3 [(ng/ml)2/1000] MOST. The answer is A. Shorter length of mechanical ventilation. \n",
      "\n",
      "This is because mechanical ventilation is a common complication in post-operative patients and can lead to longer lengths of stay in the hospital. By implementing a KDIGO-based care bundle, which includes protocols for maintaining proper fluid balance, managing pain, and monitoring urine output, mechanical ventilation can be reduced, leading to a shorter length of stay in the hospital and improved patient outcomes. \n",
      "\n",
      "Therefore, the answer is A. Shorter length of mechanical ventilation.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2834 is A. Acute renal allograft rejection, B. 1-year mortality, C. Delayed graft function after renal transplantation, or D. 1-year graft survival after renal transplantation.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2835 is A. 56-year-old man with fulminant hepatic failure due to acetaminophen toxicity re-quiring emergent liver transplantation and a high modiﬁed Model for End-stage Liver Disease score of 32. The patient has the lowest risk of AKI as they have a high score of 32, which indicates a low risk of AKI.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2836 is \n",
      "\n",
      "A. Urine kidney injury molecule-1\n",
      "B. Urine neutrophil gelatinase-associated lipocalcin\n",
      "C. Urine liver–fatty acid binding protein\n",
      "D. Urine interleukin-18\n",
      "\n",
      "Answer: Based on the available information, it is likely that urine kidney injury molecule-1 is the most likely biomarker to predict renal tubular injury on biopsy beyond that predicted by the serum creatinine level. Urine kidney injury molecule-1 is a specific biomarker for kidney injury, and it has been shown to be sensitive and specific in detecting kidney damage. A rise in urine kidney injury molecule-1 levels is a reliable indicator of tubular damage, and can be used to identify patients who are at risk of developing kidney injury. Therefore, the most appropriate answer is A. Urine kidney injury molecule-1.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2837 is A. Her baseline serum creatinine is not a risk factor for postoperative AKI.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2838 is A. N-acetylcysteine should be administered 2 days before radiocontrast exposure to reduce the risk of dialysis-requiring AKI in this high-risk patient.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2839 is A. Continuous venovenous hemodiaﬁltration is superior to other modalities of solute removal in gram-negative sepsis.\n",
      "Answer: A. Continuous venovenous hemodiaﬁltration is superior to other modalities of solute removal in gram-negative sepsis. This is supported by the available studies, which have shown that continuous venovenous hemodiaﬁltration achieved better outcomes than other modalities of solute removal in gram-negative sepsis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2840 is A. It has no impact on his subsequent risk of cardiovascular events.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2841 is A or C. (A) The patient is receiving high-dose continuous renal replacement therapy (RRT) with efﬂuent ﬂow rate of at least 35 ml/kg per h. (A) The patient is receiving high-dose continuous renal replacement therapy (RRT) with efﬂuent ﬂow rate of at least 20 ml/kg per h. (C) The patient should be receiving continuous venovenous hemoﬁltration because it offers a survival advantage in this patient. (D) Randomized trials support high-volume efﬂuent ﬂow of 70 ml/kg per h in this clinical setting.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2842 is (A) Isolated severe right ventricular systolic dysfunction (right ventricular ejection frac-tion of 25%) is associated with the HIGHEST risk of mortality in this patient with AKI.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2843 is A, B, or C.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2844 is (A) Vancomycin nephrotoxicity is unlikely because trough levels are not greater than 25 mg/L. (B) Vancomycin/piperacillin-tazobactam nephrotoxicity is unlikely in the absence of leukocytes casts. (C) The combination of vancomycin and piperacillin-tazobactam is associated with a higher risk of AKI than either antibiotic alone. (D) Urgent dialysis is indicated to reduce vancomycin levels and prevent further toxicity.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2845 is A, B, or C. (Note: The answer cannot be determined by the information provided)\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2846 is A, B, C, or D.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2847 is A, B, C, or D.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2848 is A. Off-pump surgery in eligible patients is associated with a reduced risk of AKI during the ﬁrst postoperative month.\n",
      "Answer: A. Off-pump surgery in eligible patients is associated with a reduced risk of AKI during the ﬁrst postoperative month.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2849 is \n",
      "\n",
      "Answer: The most likely lesion to be found on kidney biopsy is \"A. Acute tubulointerstitial nephritis with podocyte injury\". This is because the patient's symptoms and laboratory abnormalities suggest that the kidney biopsy will likely reveal an immune-related reaction, such as acute tubulointerstitial nephritis. This condition is characterized by inflammation and damage to the kidneys, which can lead to proteinuria, hematuria, and other symptoms. While the other options are also possible findings on kidney biopsy, they are less likely to explain the patient's symptoms and laboratory abnormalities. Therefore, the most likely answer is \"A. Acute tubulointerstitial nephritis with podocyte injury\".\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2850 is A. Intermittent hemodiaﬁltration. The patient's condition is complicated by AKI and sepsis, which makes the choice of renal replacement therapy more complex. The patient is also receiving a ventriculostomy drain to reduce intracranial pressure. The physical examination shows 2+ leg edema and a blood pressure of 110/50 mmHg. The chest examination shows crackles and decreased breath sounds in the right midlung zone. The laboratory studies show increased sodium, potassium, chloride, total CO2, BUN, and creatinine. The leukocyte count is 14,700/µl, the hemoglobin is 9.2 g/dl, and the platelet count is 203,000/µl. Intermittent hemodiaﬁltration (A) is the best choice for this patient. It is a safe and effective way to treat AKI and sepsis, and it is not associated with increased risk of mortality or hypotension. Continuous renal replacement therapy (RRT) (B) may increase the risk of hypotension and other complications, especially in patients with sepsis. Sustained low-efﬁciency dialysis (D) is not appropriate for this patient's condition.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 2851 is \n",
      "\n",
      "A. Ipilimumab-related hypophysitis with secondary adrenal insufﬁciency. \n",
      "\n",
      "Explanation: The patient's symptoms, physical examination, and laboratory results suggest that the most likely cause of the hyponatremia is a hypophysitis, which is a rare but known side effect of ipilimumab. The patient's age and medical history also suggest that the hypophysitis is related to secondary adrenal insufﬁciency. The patient's symptoms, such as bifrontal headache with progressive confusion, are consistent with those of primary adrenal insufﬁciency, which is a rare but known side effect of ipilimumab. Therefore, the most likely cause of the hyponatremia is A. Ipilimumab-related hypophysitis with secondary adrenal insufﬁciency.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2852 is A. Focal and segmental glomerulosclerosis plus thrombotic microangiopathy.\n",
      "Overall, the most likely diagnosis is A. Focal and segmental glomerulosclerosis plus thrombotic microangiopathy. This is supported by the presence of ﬁne granular casts and oval fat bodies in the urinalysis, which are characteristic of this diagnosis. The increased proteinuria and edema may also be indicative of this diagnosis. However, further workup and diagnosis by a nephrologist is necessary to confirm the diagnosis and determine the appropriate treatment plan.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2853 is A. The patient does not need to be isolated because he likely has chronic hepatitis B infection.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2854 is The correct answer is A. The patient has both active hepatitis B and hepatitis C infection.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2855 is \n",
      "Answer: D. The patient's age and medical history suggest that the 15-mm induration observed on the PPD tuberculin skin test is likely a false positive due to prior BCG vaccination. Therefore, the best step in this patient's management would be to inform the patient of this possibility and to await further evaluation by a healthcare provider.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2856 is A, B, C, or D.\n",
      "Answer: The most appropriate management would be to cover the lesions and administer dialysis at the outpatient facility in an isolation room under contact precautions. This will help prevent the transmission of infections to the patient and other patients. Transferring the patient to a tertiary care hospital or immediately transferring the patient to a hospital for both airborne and contact isolation may increase the risk of transmission and may not be necessary if the patient's condition is stable.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2857 is A, B, C, D, E.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2858 is A, C, or D.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2859 is A. dialyzing hepatitis C-positive patients in the main area of the unit instead of dialyzing the patient using a dedicated room, machine, and equipment. This is the most frequently associated infection control gap with outbreaks of hepatitis C virus infection in hemodialysis units. It is important to maintain dedicated rooms, machines, and equipment for each patient to avoid cross-contamination and to minimize the risk of transmission of the virus.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2860 is A) Use a mobile cart to transport injectable medications to multiple patients.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2861 is The component that is responsible for removing the majority of endotoxins during water puriﬁcation is A. Water softener resin.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2862 is A. An air leak.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2863 is A. Acquired immunity from vaccination against hepatitis B virus.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2864 is C\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2865 is (A. Change sterile gauze to a transparent semi-permeable dressing after each treatment) (B. Use an alcohol-based chlorhexidine (.0.5%) solution for cleansing the exit site skin, and scrub the hub with 70% alcohol) (C. Use needle-free connectors for all CVC hubs) (D. Use gentamicin-citrate lock solution in all patients) (E. Use an alteplase lock solution in all patients)\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2866 is \n",
      "\n",
      "Answer: The most appropriate method for removing blood on the floor is \"A. Single application of soap and water\". Soap and water can effectively remove the blood from the floor, but it is not necessary to use tuberculocidal disinfectant. Therefore, the correct answer is \"A. Single application of soap and water\".\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2867 is (A) Develop action plans to improve infection control practices, explaining the rationale of each plan with provision of feedback on the plan’s impact.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2868 is \n",
      "A. A medical director is responsible for ensuring that all care-related activities at the facility are performed in accordance with established policies and standards, including the high BSI and CVC rates at that facility.\n",
      "\n",
      "Explanation: The medical director is responsible for ensuring that the facility is providing high-quality care to its patients, and that all care-related activities are performed in accordance with established policies and standards. This includes overseeing the qapi program and ensuring that the facility is taking appropriate steps to address the high infection rate. Therefore, the best characterization of the expected role of medical director with regard to this clinical issue is A.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2869 is A, B, C, or D.\n",
      "\n",
      "Answer: A. The reuse of hemodialyzers can result in gram-negative bloodstream infections. Therefore, it is recommended to avoid reuse of hemodialyzers. The current AAMI guidelines recommend a single-step procedure for hemodialyzer reuse to minimize risks.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2870 is A. Prescribe prophylactic antibiotics for the patients receiving hemodialysis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2871 is A. Obtain two sets of blood cultures from the hemodialysis catheter before administering antibiotics. \n",
      "\n",
      "Answer: A. Obtain two sets of blood cultures from the hemodialysis catheter before administering antibiotics. \n",
      "\n",
      "Justification: The patient has a fever and chills but no additional symptoms, and there are no signs of acute distress. Therefore, it is possible that the patient may have an infection. Obtaining two sets of blood cultures from the hemodialysis catheter and the hemodialysis circuit before administering antibiotics is the best step in this patient's management as it will help to identify any potential infections early and allow for appropriate treatment.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 2872 is \n",
      "Answer: The most appropriate antibiotic regimen for this patient is \"A. Continue vancomycin for at least 4 weeks and monitor trough levels.\" Vancomycin is the standard antibiotic for the treatment of vancomycin-resistant infections caused by methicillin-sensitive Staphylococcus aureus. In this patient, the blood cultures showed the presence of methicillin-sensitive Staphylococcus aureus, which is sensitive to vancomycin, gentamicin, cefazolin, daptomycin, and linezolid. Based on this information, the most appropriate antibiotic regimen is to continue vancomycin for at least 4 weeks and monitor trough levels.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2873 is The additional infection control measure that you should recommend for this patient is \"D. Recommend that staff wear reusable gowns when caring for the patient at all times\".\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2874 is A, B, C, or D.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2875 is SELECT an answer.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2876 is A. Infection surveillance and use of infection rate data to drive prevention.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2877 is A. A tanker truck that has been repurposed from hauling vegetable oil for transporting water is an acceptable source of water for hemodialysis pretreatment systems.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2878 is The fundamental problem at this facility is a lack of individual accountability and a tendency to blame others for problems in the unit. This was discovered through interviews with numerous facility staff, including the medical director, and has been previously cited in the unit. The facility has poor infection control policies and a lack of an effective culture of safety.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2879 is A, B, C, or D.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2880 is A, B, C, or D.\n",
      "Answer: A. Implement no additional environmental measures at the dialysis facilities. This is the most appropriate management because the patient's partner has also developed similar symptoms, and it is likely that the bedbug bites are a common problem in the dialysis facility. Implementing environmental measures such as using permethrin cream may be helpful, but it is not necessary to dialyze the patient at the far end of the room or assign them to an isolation room as this may cause unnecessary inconvenience and cost.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2881 is \n",
      "A. Use extra care in the terminal cleaning of the dialysis station, with special attention to the dialysis chair after the patient has completed the dialysis treatment.\n",
      "B. Examine all patients in the facility for head lice because lice may survive for weeks on dialysis equipment and chairs.\n",
      "C. Institute daily hair washing with a shampoo/conditioner or conditioner before and after application of a topical pediculicide.\n",
      "D. Prescribe lindane shampoo for the affected patient.\n",
      "\n",
      "Answer: A. Use extra care in the terminal cleaning of the dialysis station, with special attention to the dialysis chair after the patient has completed the dialysis treatment. \n",
      "\n",
      "Justification: The medical director should immediately call the attending nephrologist and the dialysis unit's cleaning staff to take appropriate action. The affected patient should be isolated and appropriate preventative measures should be implemented to avoid the spread of the infestation. The terminal cleaning of the dialysis station should be done with special attention to the dialysis chair after the patient has completed the dialysis treatment to minimize the risk of transmission. The use of a topical pediculicide may also be appropriate, but this should be determined by the nephrologist and the dialysis unit's medical staff.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2882 is A. Review the patient’s baseline vital signs.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2951 is A, B, C, or D. (Note: The patient is already following a low-sodium diet, so option A is not relevant to her current diet.)\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2952 is A. and her child's risk of kidney disease is high.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2953 is A. Over the past decade, the total number of people with CKD in the United States has remained stable.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2954 is The most appropriate answer is C. Even mild elevations in blood lead levels among adults have been associated with an increased risk of CKD.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2955 is A, B, C, or D.\n",
      "\n",
      "Answer: A. approximately one out of two cases of CKD is attributed to diabetes.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2956 is A. A population-based approach to diabetes care based in the community and the primary clinical setting has been shown to be associated with the sharp decline in ESRD incidence among Native Americans over the past 16 years.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2957 is A. Tight control of BP and glucose are more effective in white than black adults with type 2 diabetes for prevention of CKD\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2958 is A or C. \n",
      "\n",
      "Answer: A. Incretin-based therapies increase the risk of hypoglycemia.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2959 is A, B, C, or D.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2960 is A. Daily but not occasional marijuana use is associated with CKD incidence and progression.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2961 is A. Yes, bicycle riding, swimming, and jogging are all effective ways to stay healthy.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2962 is A or B.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2963 is \n",
      "A. Cholecalciferol 1000 units daily\n",
      "B. A 2-gram sodium-restricted diet\n",
      "C. Paricalcitol 1 mg daily\n",
      "D. Lisinopril 5 mg daily\n",
      "\n",
      "Answer: C. Paricalcitol 1 mg daily may be the most appropriate management of the increased albuminuria. It is a renin-angiotensin system blocker that can help to reduce proteinuria and increase blood pressure. It may also help to improve kidney function in people with CKD. However, a 2-gram sodium-restricted diet is typically recommended for a person with stage G3a or G4 CKD to maintain healthy albuminuria levels. Cholecalciferol (1000 units daily) and lisinopril (5 mg daily) are typically not recommended for a person with this condition.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 2964 is \n",
      "Answer: A. The proton pump inhibitor should be stopped because it is a major risk factor for CKD progression.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2965 is A. An erythropoiesis-stimulating agent will not slow his CKD progression.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2966 is \n",
      "\n",
      "A. The patient's lifetime risk of ESRD may be increased by more than fourfold because of his child-hood history of kidney injury.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2967 is A. Tubulointerstitial nephritis with inﬁltrates predominantly of T lymphocytes\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2968 is Losartan. \n",
      "\n",
      "Explanation: Losartan is an ARB that can help to slow the progression of CKD by relaxing the blood vessels and improving blood flow. It can also help to lower proteinuria and albuminuria. Based on the information provided, Losartan is the most likely option to delay the progression of the patient's CKD.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2969 is A. Amputation has been reported with all SGLT-2 inhibitors.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2970 is A, B, C, or D.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2971 is A. It will not increase his risk of bleeding.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2972 is A. Furosemide\n",
      "\n",
      "Answer: A. Furosemide is the medication that is least likely to be directly contributing to the increased QTc interval. The other medications are known to cause interactions with QTc intervals, but they are not the primary cause of the increased QTc interval in this patient. Furosemide is a loop diuretic that does not cause any known interactions with QTc intervals and is therefore the most likely medication to be contributing to the increased QTc interval.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2973 is A. Increased pulmonary artery systolic pressureThere is no question in the given statement. Please provide a question for me to answer.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2974 is A, B, C, or D.\n",
      "Answer: A, B, and C. It is not associated with an increased risk of acute kidney injury, reduces the risk of incident CKD and ESRD, and does not have an impact on urinary protein excretion. Bariatric surgery can also have a positive impact on resolution or reduction of hypertension.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2975 is A, B, C, or D.\n",
      "Answer: C. Bariatric surgery is the best potential intervention to improve his cardio-vascular and kidney health. It is a safe and effective way to achieve significant weight loss, which is necessary for improving his blood pressure and kidney function. Diet and exercise can also help, but it may not be as effective as bariatric surgery in terms of achieving significant weight loss. Lorcaserin may cause side effects and may not be as effective as bariatric surgery in achieving significant weight loss. further BP reduction may not be effective in improving his kidney function and may increase the risk of hypotension and syncope.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2976 is A. The 1-year risk of infections and cardiac-related adverse events is increased with iron deﬁciency anemia.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2977 is A. Cardiac resynchronization therapy is MOST likely to improve his survival.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2978 is A. The current level of eGFR.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2979 is A.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 2980 is A. Statement A: \"Albuminuria and lower eGFR are associated with worse global cognitive function\" is incorrect. The statement is not supported by the available evidence. Statement B: \"Both higher UACR and lower eGFR are associated with abnormal white matter volume\" is also incorrect. While there may be a relationship between abnormal white matter volume and CKD, there is no direct relationship between albuminuria and cognitive function. Statement C: \"Both higher Uacr and lower eGFR are associated with higher grey matter volume\" is also incorrect. Grey matter volume may be affected by a variety of factors, including age, lifestyle factors, and other medical conditions. It is not clear how albuminuria, lower eGFR, and grey matter volume are related to one another. Finally, statement D: \"Increased albuminuria is not associated with poorer processing speed and working memory\" is generally accurate. While there may be some relationship between albuminuria and processing speed and working memory, the evidence is not conclusive and the relationship may vary depending on the age, lifestyle, and medical conditions of the individual.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5804 is \n",
      "A. Testing for anti-A antibody titers to assess suitability for non-A1 donor kidneys (B+ blood type)\n",
      "B. Consent for high KDPI kidney offers (B+ blood type)\n",
      "C. Desensitization with rituximab and IVIG (B+ blood type)\n",
      "D. Immunoadsorption therapy to remove lymphocytotoxic antibodies (B+ blood type)\n",
      "\n",
      "Answer: The best available treatment option to reduce her waiting time is Consent for high KDPI kidney offers (B+ blood type). This is because a high KDPI kidney would be a shorter wait for her, as it would increase her chances of receiving a kidney from a non-A1 blood type donor. Testing for anti-A antibodies to assess suitability for non-A1 donor kidneys and desensitization with rituximab and IVIG are not suitable options for her due to her age and the presence of IgA nephropathy. Immunoadsorption therapy to remove lymphocytotoxic antibodies is not recommended in the presence of IgA nephropathy as it can cause further damage to the kidneys.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5805 is A) A serious fall in the year before transplantation is associated with increased mortality after transplantation.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5806 is A. He should not be consented for KDPI .85 kidneys because of the increased risk associated with high KDPI kidneys transplanted to individuals with high EPTS scores. B. He should not be placed on the waiting list because he is not expected to have a survival beneﬁt from transplantation. C. He should be encouraged to consent for KDPI > 85 kidneys because of the increased survival associated with high KDPI kidneys compared with remaining on the waitlist for a KDPI 35-85 kidney. D. He should be considered only for KDPI > 85 kidneys, given his high EPTS. \n",
      "\n",
      "Answer: A. He should not be consented for KDPI .85 kidneys because of the increased risk associated with high KDPI kidneys transplanted to individuals with high EPTS scores. This is because high KDPI kidneys have been shown to increase the risk of post-transplant complications, including graft failure, Device-related complication (DRC), and death, especially in individuals with high EPTS scores. Therefore, it is recommended that individuals with high EPTS scores should not receive high KDPI kidneys.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5807 is A) There is no survival advantage in accepting the PHS-IR kidney versus accepting the next non-IR offer.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5808 is \n",
      "\n",
      "A. If untreated, HCV Ab1/NAT2 kidney donors carry a risk of viral transmission that is > 90%\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5809 is \n",
      "A. Age > 50 years\n",
      "B. BMI 25 kg/m2\n",
      "C. Relationship to the recipient\n",
      "D. None of the above\n",
      "\n",
      "Answer: D. None of the above increase the risk of ESRD after donation. The study found that the risk of ESRD after kidney donation is not increased by age, gender, relationship to the recipient, or body composition. Therefore, the best predictor of ESRD after kidney donation is the recipient's glomerular filtration rate (GFR).\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5810 is (A) Remote ischemic conditioning of the recipient (thigh occlusion) (B) Hypothermic machine perfusion (HMP) of the explanted kidney (C) Dopamine infusion of the donor before procurement (D) Complement inhibition of the recipient at the time of transplant. \n",
      "\n",
      "Answer: (B) Hypothermic machine perfusion (HMP) of the explanted kidney. HMP has been shown to reduce the risk of delayed graft function by increasing blood flow to the kidney and improving its condition for transplantation. It also delays the cold ischemia time, which can further increase the risk of delayed graft function.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5811 is \n",
      "\n",
      "A) Reduced incidence of delayed graft function \n",
      "B) Reduced incidence of acute rejection \n",
      "C) Improved graft survival \n",
      "D) Reduced mortality \n",
      "\n",
      "Answer: A) Reduced incidence of delayed graft function.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5812 is \n",
      "A) Lower C maximum (peak concentration) and lower AUC (area under the curve, total exposure)\n",
      "B) Similar C maximum but lower AUC\n",
      "C) Higher C maximum but lower AUC\n",
      "D) Lower C maximum but higher AUC\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5813 is A) Discontinue tacrolimus, start belatacept, B) Discontinue mycophenolate, start azathioprine, C) Discontinue tacrolimus, start everolimus, or D) Discontinue mycophenolate, start everolimus.\n",
      "\n",
      "Answer: Based on the patient's medical history and current condition, the most appropriate maintenance immunosuppression modiﬁcation for this patient is to continue tacrolimus and mycophenolate, but progressively lower the dose of mycophenolate to 250 mg twice daily. Tacrolimus should be continued at the current dosage, and the duration of exposure should be optimized to minimize the risk of developing tolerance. The patient should also be monitored closely for signs of rejection, and his BMI should be monitored to ensure that it does not reach 25 kg/m2.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5814 is \n",
      "\n",
      "Answer: The most likely option to result in transplantation within the next 6 to 12 months is \"1. Desensitization with plasma exchange, IVIG, and rituximab followed by living donor transplantation.\" This is because the patient has a strong positive crossmatch with her husband, who is her only potential living donor. The desensitization process would make her more compatible with her husband's blood type, and therefore increase the chances of success for the transplantation. The other options are less likely to result in transplantation within the given time frame. Continued waiting for a deceased-donor kidney is not a guarantee of receiving a transplant, and entrance into a paired exchange program or continued waiting for a deceased-donor kidney may result in longer wait times.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5815 is \n",
      "A) Decreased risk of antibody-mediated rejection\n",
      "B) Decreased risk of bleeding complications\n",
      "C) Decreased risk of infections\n",
      "D) Increased risk of uncensored graft loss\n",
      "\n",
      "Answer: The expected outcome at 1 year in this patient is decreased risk of antibody-mediated rejection.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5816 is [A] 1. Grade IA chronic active T cell–mediated rejection [B] 2. Acute mixed T cell–mediated and antibody-mediated rejection [C] 3. Acute T cell–mediated rejection [D] 4. Chronic active antibody-mediated rejection\n",
      "\n",
      "Answer: The histologic diagnosis is chronic active T cell-medicated rejection.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5817 is a) Plasmapheresis and IVIG, b) Plasmapheresis, IVIG, and rituximab, c) Plasmapheresis, IVIG, and bortezomib, or d) IVIG and rituximab.\n",
      "\n",
      "Answer: There is no single best treatment regimen for antibody-mediated rejection as the choice of treatment will depend on individual patient characteristics, such as age, medical history, and lifestyle. However, based on the available evidence, Plasmapheresis and IVIG is a good option for the treatment of antibody-mediated rejection in some patients. Plasmapheresis can help remove pathogenic antibodies from the blood, while IVIG can help block the production of these antibodies. The combination of these two treatments has been shown to be effective in several studies.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5818 is C\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5819 is \n",
      "Answer: The patient should be told that he has recurrent FSGS, which significantly reduces the rate of death-censored graft survival to about 10% at 5 years.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5820 is A. Pretransplantation skin cancer has no impact on the risk of graft failure.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5821 is \n",
      "\n",
      "Answer: The patient's concern is about the signiﬁcance of a positive EBV PCR result with a viral load of 4250 copies/ml, which is a risk factor for cancer other than posttransplantation lymphoproliferative disorder. The patient is considering antiviral therapy to mitigate this risk. Therefore, the answer is: \"Patients with EBV viremia during the ﬁrst 6 months after transplantation have equivalent allograft survival compared with EBV-negative patients.\"\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5822 is \n",
      "\n",
      "A) Younger age and female sex\n",
      "B) Use of two or more immunosuppressive agents\n",
      "C) Black race\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5823 is \n",
      "\n",
      "A) It will increase her risk of becoming diabetic. \n",
      "\n",
      "B) It will reduce her risk of becoming diabetic. \n",
      "\n",
      "C) It will increase her risk of rejection. \n",
      "\n",
      "D) It will reduce her risk of early graft failure and mortality. \n",
      "\n",
      "E) It will increase her risk of recurrent FSGS. \n",
      "\n",
      "Answer: A) It will increase her risk of becoming diabetic.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5824 is \n",
      "\n",
      "A) The presence of a history of cardiovascular disease on the patient's medical history. \n",
      "\n",
      "B) The patient's age and weight. \n",
      "\n",
      "C) The patient's family history of cardiovascular disease. \n",
      "\n",
      "D) The patient's lifestyle factors, such as diet and exercise routine. \n",
      "\n",
      "Answer: A) The patient does not have a history of cardiovascular disease on their medical history. Therefore, statement A is incorrect.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5825 is \n",
      "A) Statin therapy after transplantation is associated with improved survival after transplantation.\n",
      "B) Statin therapy after transplantation reduces the risk of major adverse cardiovascular events without affecting mortality.\n",
      "C) Statin therapy is ineffective after transplantation because of the impact of immunosuppression on lipid levels.\n",
      "D) There is no relationship between statin dose and outcomes after transplantation.\n",
      "\n",
      "Answer: A) Statin therapy after transplantation is associated with improved survival after transplantation.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5826 is The clinical parameter that is associated with the greatest risk of fracture after transplantation is a high PTH level. Therefore, the answer is \"3. The serum PTH level\".\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5827 is A. Cinacalcet is more effective in increasing serum calcium levels than subtotal parathyroidectomy.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5828 is \n",
      "\n",
      "Answer: 3. Denosumab is a safe and effective treatment for osteoporosis after transplantation.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5829 is \n",
      "\n",
      "A) Hepatitis C should be treated before trans-plantation to minimize the risk of liver failure after transplantation.\n",
      "B) Hepatitis C treatment should be deferred until after transplantation of a hepatitis C + graft to reduce waiting time.\n",
      "C) Hepatitis C should be treated before trans-plantation to abrogate the risk of coinfection with a different strain of virus that may pose the risk of drug resistance.\n",
      "D) Hepatitis C should be treated before trans-plantation to minimize the risk of rejection.\n",
      "E) Hepatitis C should be treated after trans-plantation to avoid the risk of anemia because of the requirement for ribavirin therapy.\n",
      "\n",
      "Answer: A) Hepatitis C should be treated before trans-plantation to minimize the risk of liver failure after transplantation.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5830 is \n",
      "A) HIV positive patients have a higher risk of graft loss than HIV2 recipients.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5831 is \n",
      "A. It is associated with a lower risk of BK virus allograft nephropathy after kidney transplantation compared with calcineurin inhibitor therapy. \n",
      "B. It is associated with a lower risk of CMV infection after kidney transplantation compared with calcineurin inhibitor therapy. \n",
      "C. It is associated with improved graft survival after transplantation compared with tacrolimus therapy. \n",
      "D. It is associated with a lower risk of acute rejection compared with tacrolimus-based immunotherapy. \n",
      "E. It has no impact on wound healing. \n",
      "\n",
      "Answer: A. It is associated with a lower risk of BK virus allograft nephropathy after kidney transplantation compared with calcineurin inhibitor therapy. \n",
      "\n",
      "Justification: The statement is the most correct because it is specifically mentioned in the question that the therapy for inhibition of mammalian target of rapamycin is associated with a lower risk of BK virus allograft nephropathy after kidney transplantation compared with calcineurin inhibitor therapy. The other options are not mentioned in the question.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5832 is \n",
      "A. Living donor kidney transplantation followed by a pancreas after kidney transplantation will likely provide the best long-term renal outcomes.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5833 is A) Kidney biopsy should be performed now to help assess his risk for recurrent glomerular disease.\n",
      "Answer: A) Kidney biopsy should be performed now to help assess his risk for recurrent glomerular disease.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5684 is \n",
      "\n",
      "A) Initiate amlodipine 5 mg daily so that you can assess if she needs additional therapy when she presents for her visit\n",
      "B) Recommend that she obtain kiosk-based BP measurements at her local supermarket until she is able to come into the clinic to be evaluated\n",
      "C) Recommend that she purchase a validated home BP monitor and provide her with guidance on appropriate measurement technique\n",
      "D) Initiate losartan-hydrochlorothiazide 25 to 12.5 mg daily so that you can assess if she needs additional therapy when she presents for her visit\n",
      "\n",
      "Answer: A) Initiate amlodipine 5 mg daily so that you can assess if she needs additional therapy when she presents for her visit.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5685 is \n",
      "\n",
      "A) Ignore the readings, given that his BPs are consistently well controlled in the oﬃce\n",
      "B) Suggest that he stop monitoring his BP at home because you suspect he is not able to use appropriate measurement technique\n",
      "C) Add spironolactone for improved BP control because of the presence of masked uncontrolled hypertension\n",
      "D) Recommend 24-hour ambulatory BP monitoring (ABPM) to conﬁrm the presence of masked uncontrolled hypertension\n",
      "\n",
      "Answer: C. Add spironolactone for improved BP control because of the presence of masked uncontrolled hypertension. The patient's home BP readings suggest that he may have masked uncontrolled hypertension, which can be confirmed with ABPM. ABPM can also help identify any errors in his measurement technique and provide a more accurate reading. Based on the patient's history and current medical conditions, it is important to optimize his blood pressure control to minimize the risk of complications such as heart failure, stroke, and kidney disease.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5686 is \n",
      "\n",
      "As an AI language model, I cannot make choices for the best approach to this patient's BP measurement based on the information provided. However, I can provide you with some possible reasons why the patient'sBP may be labile and some possible approaches that could be taken to evaluate this patient further.\n",
      "\n",
      "Possible reasons for labile BP include age, gender, weight, lifestyle factors such as diet and exercise, and medical conditions such as diabetes, hypertension, and heart disease. It is important to consider these factors when evaluating a patient's BP and making a diagnosis.\n",
      "\n",
      "Possible approaches to evaluate the patient further include:\n",
      "\n",
      "1. Reviewing the patient's medical history and current symptoms, including any recent illnesses, injuries, or surgeries.\n",
      "2. perform a physical examination, including blood pressure measurement, heart rate, and blood pressure cuff pressure.\n",
      "3. Ordering additional diagnostic tests such as a Stress Test or Ambulatory Blood Pressure Monitor, which can provide more detailed information about the patient's autonomic nervous system and blood pressure regulation.\n",
      "4. Consult with a hypertension expert or cardiologist to further assess the patient's condition.\n",
      "5. Encourage the patient to make lifestyle changes, such as diet modifications, exercise, and stress reduction techniques, to improve their blood pressure.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5687 is \n",
      "\n",
      "Answer: As an AI language model, I would suggest that the most helpful question to consider when evaluating a secondary component in the BP elevation would be \"What medications or drugs, prescription or otherwise, are you using?\" This question can help identify any underlying medical conditions that may be contributing to the high blood pressure. It is important to exclude any medications or drugs that may cause hypotension or affect blood pressure as these can artificially elevate blood pressure and make it difficult to diagnose the true cause of the elevation.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5688 is \n",
      "As an AI language model, I cannot determine which of the following items is most likely to identify nonhypertensive-related cardiovascular risk factors important for selecting therapy for her BP elevation. However, based on the information provided, the following items could potentially contribute to nonhypertensive-related cardiovascular risk factors: \n",
      "\n",
      "1. Low white blood cell count: A low white blood cell count can be an indication of anemia, which can be a risk factor for cardiovascular disease. Anemia can also contribute to increased cardiovascular risk in patients with high blood pressure.\n",
      "\n",
      "2. A urine dipstick registering ++ protein: A urine dipstick registering ++ protein can be an indication of kidney disease, which can be a risk factor for cardiovascular disease.\n",
      "\n",
      "3. An elevated C-reactive protein: An elevated C-reactive protein can be an indication of inflammation in the body, which can contribute to cardiovascular risk in patients with high blood pressure.\n",
      "\n",
      "Therefore, it is important to evaluate the patient's medical history and perform further testing and analysis to determine the most likely nonhypertensive-related cardiovascular risk factors important for selecting therapy for her BP elevation.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5689 is \n",
      "Answer: \n",
      "The most accurate statement summarizing the patient's current situation is: \"Now that you have had a heart attack, your body is showing us that it is vulnerable to things like an elevated BP, and we really need to work hard to get this under control soon.\"\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5690 is \n",
      "Answer: The most likely answer based on the given information is \"2. short-term BP variability as measured by ABPM is worrisome, but long-term BP variability using oﬃce or home readings has not been shown to be associated with the risk of cardiovascular events or mortality.\" This is because ABPM measures short-term variability in blood pressure, which is a risk factor for cardiovascular events, but long-term variability in blood pressure is not associated with the risk of cardiovascular events or mortality. However, it's also important to note that office and home blood pressure readings may still be useful in monitoring the patient's progress and identifying any changes in their blood pressure pattern over time.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5691 is \n",
      "To manage the patient's hypertension, the next best step is to start spironolactone with careful monitoring of potassium. It is important to explain the potential risks and benefits of spironolactone. It may be helpful to start with a lower loading dose and gradually increase the maintenance dose based on her response. It is also important to monitor her potassium levels carefully, as hyperkalemia is a common side eﬀect of spironolactone.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5692 is (A) Tighter BP control is associated with reduced progression of white matter changes, without changes in overall brain volume. (B) Intensive BP control is associated with reduced risk of mild cognitive impairment at 5 years follow-up. (C) Tighter BP control is associated with higher rates of falls, as compared with standard control, in patients with underlying cerebrovascular disease. (D) Intensive BP control is associated with reduced cerebral perfusion in those with small-vessel cerebrovascular disease. \n",
      "\n",
      "Answer: (A) Tighter BP control is associated with reduced progression of white matter changes, without changes in overall brain volume. This is supported by research studies that have shown that tighter BP control can reduce the progression of white matter changes in patients with hypertension. A previous study published in the New England Journal of Medicine found that patients with stage 3 hypertension who received a combination of amlodipine and losartan had a slower progression of white matter changes on MRI scans over a 5-year period compared to patients who received amlodipine or losartan alone. Additionally, a study published in the Journal of the American Medical Association found that intensive BP control (target systolicBP < 120 mmHg) was associated with reduced risk of mild cognitive impairment at 5-year follow-up in patients with diabetes and hypertension.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5693 is A\n",
      "The correct answer is: A\n",
      "The information provided in the question indicates that lifestyle changes and a low-salt diet are a good starting point for treating hyper-tension. However, after four months, the woman's blood pressure has improved and she is now on a low-salt diet. To continue her progress, she should start taking an antihypertensive medication. The information suggests that any of the four options listed are suitable choices for the first-line agent. Therefore, the correct answer is not determined by the information presented in the question.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5694 is A) Combination therapy is associated with reduced mortality at 3-year follow-up as compared with monotherapy.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5695 is \n",
      "\n",
      "Answer: 1.Intensive BP control that leads to acute kidney injury in patients without prior CKD is likely to progress to ESRD. \n",
      "\n",
      "Explanation: The SPRINT trial found that patients with essential hypertension who received tight BP control (target systolic BP < 120 mmHg) had a small but persistent decline in GFR compared with those who received standard BP control. This decline in GFR is a sign of acute kidney injury, which can progress to ESRD if not addressed. Therefore, intense BP control that leads to acute kidney injury is likely to progress to ESRD in patients without prior CKD.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5696 is \n",
      "\n",
      "Answer: The correct approach would be: \n",
      "\n",
      "1. He should be instructed on lifestyle modiﬁcation alone with follow-up in 3 months. \n",
      "\n",
      "This is because the patient is 60 years old and has a history of smoking one pack per day for 40 years. While the elevated BP is a concern, the patient's total cholesterol, HDL, and LDL levels are within normal range. Additionally, there are no other risk factors for cardiovascular disease and the patient's urinalysis is negative. Therefore, the patient is suitable for lifestyle modification therapy and should be followed up in 3 months. If the patient's condition improves, medication can be considered.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5697 is \n",
      "A 53-year-old African American man with uncontrolled hypertension and CKD stage 3 with estimated GFR 45 mL/min, a urine protein/creatinine ratio of 1 g/g, and a strong family history of hypertension and ESRD is referred for treatment of uncontrolled hypertension. His BP is 159/92 mmHg, with a heart rate of 55 beats/min. Medications include chlorthalidone 50 mg daily, losartan 100 mg daily, and amlodipine 10 mg daily.\n",
      "The best next action to adjust his regimen to control his BP is:\n",
      "A. Chlorthalidone should be discontinued because it is less eﬀective at this GFR.\n",
      "B. An ACE inhibitor should be added for additional anti-proteinuric eﬀect.\n",
      "C. A β-blocker is the most appropriate next agent.\n",
      "D. Spironolactone is the most appropriate next agent. \n",
      "\n",
      "Answer: C. A β-blocker is the most appropriate next agent.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5698 is A) 1. Around 25% of patients show nonadherence or suboptimal adherence to antihypertensive medications.B) Using electronic health record medication management tools plus nurse-led patient education improves medication adherence.C) Smartphone apps that provide reminder alerts, adherence reports, and peer support may lead to improved BP control.D) Smartphone apps that provide reminder alerts, adherence reports, and peer support may improve medication adherence.Answer: A) 1. Around 25% of patients show nonadherence or suboptimal adherence to antihypertensive medications.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5699 is \n",
      "\n",
      "A) 1. Number of hypertension-related deaths increased by about 50% between years 2007 and 2017\n",
      "B) 2. Number of hypertension-related DALYs reduced by about 15% between years 2007 and 2017\n",
      "C) Both overall number and age-standardized rates of deaths and disability related to hypertension continued to rise between years 2007 and 2017\n",
      "D) Number of deaths and disability related to hypertension continued to rise while age-standardized rates declined between years 2007 and 2017\n",
      "\n",
      "Answer: A) 1. Number of hypertension-related deaths increased by about 50% between years 2007 and 2017.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5700 is C\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5701 is (A) The number of people with hypertension will increase by only < 2% of the adult US population. (B) Hypertension prevalence will increase by almost ﬁvefold in older people (> 65 years). (C) Hypertension prevalence will increase by about 30%, and every newly diagnosed patient will receive recommendation for antihypertensive medication. (D) Recommendation for antihypertensive medication will in-crease by only < 2% of the adult US population.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5702 is \n",
      "A) Antihypertensives may be less eﬀective in the presence of periodontitis.\n",
      "B) Severe periodontitis is associated with a doubling of incidence of hypertension.\n",
      "C) Periodontitis does not predict BP control.\n",
      "D) Treating the patient’s periodontitis will not alter his BP control.\n",
      "\n",
      "Answer: A) Antihypertensives may be less eﬀective in the presence of periodontitis. B) Severe periodontitis is associated with a doubling of incidence of hypertension. C) Periodontitis does not predict BP control. D) Treating the patient’s periodontitis will not alter his BP control.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5703 is As an AI language model, I do not have access to the most recent study on the topic. However, based on the available studies, it is possible that low blood pressure in patients her age could be linked to dementia, but further research is needed to fully understand the relationship between the two. Therefore, the best answer would depend on the specific study and its findings.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5704 is \n",
      "\n",
      "A) Assure him that long working hours have no relationship with hypertension.\n",
      "B) Assure him that long working hours are associated with hypertension only if someone has a family history of hypertension.\n",
      "C) Assure him that long working hours are associated with hypertension only if someone leads a sedentary lifestyle.\n",
      "D) Assure him that long working hours are associated with both masked hypertension and sustained hypertension.\n",
      "\n",
      "Answer: D) Assure him that long working hours are associated with both masked hypertension and sustained hypertension.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5705 is a) 1. Across all economic regions, hypertension is more common among individuals of lower socioeconomic status. b) Hypertension generally correlates with the prevalence of obesity and physical inactivity. c) Individuals of lower socioeconomic class and education generally have lower risk of both hypertension and cardiovascular disease. d) Control of hypertension is higher among those of lower socioeconomic class.Answer: a) 1. Across all economic regions, hypertension is more common among individuals of lower socioeconomic status.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5706 is \n",
      "Answer: There is no reliable data linking alcohol intake and \"working too hard\" to hypertension.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5707 is \n",
      "\n",
      "A) Renal tubular α-adrenergic receptors \n",
      "\n",
      "B) Juxtaglomerular α -adrenergic receptors \n",
      "\n",
      "C) Preganglionic β-adrenergic receptors \n",
      "\n",
      "D) Vascular α -adrenergic receptors \n",
      "\n",
      "E) Cardiac β -adrenergic receptors \n",
      "\n",
      "Answer: A) Renal tubular α-adrenergic receptors\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5708 is \n",
      "The most likely mechanism by which this novel therapy is eliciting an antihypertensive eﬀect is:\n",
      "The most likely mechanism by which this novel therapy is eliciting an antihypertensive eﬀect is:\n",
      "The most likely mechanism by which this novel therapy is eliciting an antihypertensive eﬀect is:\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5709 is \n",
      "\n",
      "Answer: The component of the AHA’s DASH diet that would be beneficial in combating the gradual increase of BP in this patient is \"Decreased concentration of bicarbonate in the tubular ﬁltrate\". This is because a diet high in sodium and low in potassium can lead to an increase in blood pressure, and a decrease in bicarbonate levels in the tubular ﬁltrate can contribute to this increase in blood pressure. Therefore, a diet that includes more fruits, vegetables, whole grains, and lean protein sources, and fewer processed foods and high-sodium foods, may help to lower blood pressure and improve overall health.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5710 is \n",
      "Answer: It is most likely that the answer is \"2. EVs from this patient will cause direct vasoconstriction as compared with EVs from a normotensive individual.\" This is because recent studies have shown that EVs from normotensive patients can cause vasodilation, while EVs from hypotensive patients can cause vasoconstriction. As the patient's blood pressure has gradually increased over time, it is possible that the EVs in his circulation are contributing to this increase in pressure.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5711 is \n",
      "Answer: The physiologic mechanism resulting in reduced BP in this patient after regular use of CPAP is likely a combination of option 2 and option 3. Increased plasma angiotensin II concentrations and increased urinary aldosterone concentration may contribute to the reduced BP. Additionally, decreased activity of renal nerves and decreased urinary sodium excretion may also contribute to the reducedBP.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5712 is A. 1 and 2.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5713 is A, B, C, or D.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5714 is a) corticosteroids are not effective, b) corticosteroids are effective but should be tapered by 50% over the course of 2 weeks, c) corticosteroids are effective but should be given every 8 hours as an alternate-day treatment, or d) corticosteroids are not effective and rituximab should be used instead.\n",
      "The correct answer is b) corticosteroids are effective but should be tapered by 50% over the course of 2 weeks.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5715 is a) The variant of FSGS lesion seen on light microscopy is helpful in differentiating between primary and genetic forms of FSGS, b) Abnormalities in genes encoding glomerular basement membrane collagen are associated with primary FSGS, c) In secondary FSGS, glomerular hypertension causes podocyte injury, leading to podocyte detachment and loss, and d) The degree of foot process effacement seen on electron microscopy is used to differentiate between primary and genetic FSGS.\n",
      "Answer: a) The variant of FSGS lesion seen on light microscopy is helpful in differentiating between primary and genetic forms of FSGS.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5716 is A) Randomized controlled trials have demonstrated the eﬃcacy of rituximab in the treatment of FSGS.B) Up to 60% of patients will experience a relapse after initial treatment of FSGS with corticosteroids.C) In retrospective studies, up to 30% of adults with steroid-resistant FSGS had a potentially causative genetic mutation identified.D) Recent studies have shown beneﬁt for sodium-glucose transporter-2 (SGLT2) inhibitors in management of secondary FSGS.\n",
      "Answer: D) Recent studies have shown beneﬁt for sodium-glucose transporter-2 (SGLT2) inhibitors in management of secondary FSGS.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5717 is None of the above are correct with regard to PLA2R-negative MN.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5718 is \n",
      "The correct answer is: \n",
      "'2. Monitor serologies monthly and treat if PLA2R fails to decrease by > 25% in 3 months' \n",
      "\n",
      "Explanation: The patient presents with proteinuria and increased creatinine levels, which suggests that her kidneys are not functioning properly. A renal biopsy could lead to more information for the diagnosis of the underlying cause of the proteinuria, but in the meantime, monitoring her serologies monthly and treating her with rituximab and cyclosporine if her PLA2R levels do not decrease by > 25% in 3 months is a reasonable treatment plan. The MENTOR study found that patients treated with rituximab and cyclosporine had similar eGFR and rates of remission at 24-month follow-up, which supports this treatment plan.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5719 is \n",
      "Answer: 2. Costaining with IgG and C3 is seen in dense deposit disease.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5720 is \n",
      "Answer: 3. In patients with monoclonal gammopathy–associated C3 glomerulopathy, treatment with immunosuppression shows similar outcomes to clone-based therapy.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5721 is \n",
      "\n",
      "A) Renal cortical necrosis can be an underappreciated presentation of pregnancy-associated TMA.\n",
      "B) Pregnancy-associated TMA is rarely associated with abnormalities in genes encoding complement or complement regulatory proteins.\n",
      "C) All subtypes of complement-mediated TMA have high recurrence rates after transplantation.\n",
      "D) Eculizumab can be safely stopped in transplant recipients who have stable renal function at 6 months after transplantation.\n",
      "\n",
      "Answer: A) Renal cortical necrosis can be an underappreciated presentation of pregnancy-associated TMA.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5722 is A, B, C, or D.\n",
      "\n",
      "Answer: A. In a randomized controlled trial, immunosuppression comprising cyclophosphamide and steroids, followed by azathioprine and steroids, delayed progression of CKD.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5723 is \n",
      "\n",
      "A) The addition of a small molecule C5a inhibitor, avocan, to induction therapy was associated with higher rates of infectious complications as compared with standard treatment with corticosteroids and rituximide/cyclophosphamide.\n",
      "\n",
      "Answer: A) The addition of a small molecule C5a inhibitor, avocan, to induction therapy was associated with higher rates of infectious complications as compared with standard treatment with corticosteroids and rituximode/cyclophosphamide.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5724 is a) The rituximab dosing strategy based on repopulation of peripheral B cells and/or changes in ANCA titer led to fewer relapses and longer relapse-free survival than regular scheduled 6-monthly dosing of rituximab.\n",
      "Answer: b) The rituximab dosing strategy based on repopulation of peripheral B cells and/or changes in ANCA titer led to fewer relapses and longer relapse-free survival than regular scheduled 6-monthly dosing of rituximab.\n",
      "Explanation: The rituximab dosing strategy based on repopulation of peripheral B cells and/or changes in ANCA titer, as described in the question, has been shown to lead to fewer relapses and longer relapse-free survival than regular scheduled 6-monthly dosing of rituximab. This is supported by several studies, including a randomized controlled trial comparing it with maintenance therapy with azathioprine, which showed that the rituximab strategy led to better outcomes. Therefore, the answer is b) The rituximab dosing strategy based on repopulation of peripheral B cells and/or changes in ANCA titer led to fewer relapses and longer relapse-free survival than regular scheduled 6-monthly dosing of rituximab.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5725 is A) The time from diagnosis of SLE to the development of lupus nephritis is shorter in African Americans and other minority groups.B) The serologic evaluation of lupus nephritis is not useful in making a diagnosis.C) The histologic evaluation of lupus nephritis is not useful in making a diagnosis.D) The anti-PLA2R antibodies are never identified in patients with class V lupus nephritis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5726 is a. The LUNAR trial showed improved outcomes from the addition of rituximab to mycophenolate mofetil and steroids.\n",
      "\n",
      "Answer: b. The addition of rituximab to mycophenolate mofetil and steroids has shown promising results in the treatment of lupus nephritis. The LUNAR trial found that the addition of rituximab to mycophenolate mofetil and steroids resulted in improved outcomes for patients with lupus nephritis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5727 is \n",
      "Answer: \n",
      "\n",
      "The correct statement is: \"It is likely that his antiviral medications should be left unchanged because they have been effective in controlling HIV for over 20 years.\" \n",
      "\n",
      "Explanation: The patient's medical history and current symptoms suggest that he has developed kidney damage, which may be related to his HIV infection. However, it is not possible to determine the exact cause of his condition based on the information provided. Therefore, further evaluation by a kidney biopsy is recommended. \n",
      "\n",
      "As for the other options, they are incorrect:\n",
      "- \"His antiviral medications should be changed because they have been eﬀective in controlling HIV for over 20 years\" is incorrect because changing antiviral medications should only be done based on a thorough medical evaluation and after consulting with a healthcare provider.\n",
      "- \"He should avoid sports and other physical activities because of his kidney damage\" is incorrect because it is not possible to determine if sports and physical activities are safe or not based on the information provided. \n",
      "- \"He should consult a dermatologist because he has developed skin conditions\" is incorrect because the patient's medical history and current symptoms suggest that he has developed kidney damage, which may be related to his HIV infection. Therefore, further evaluation by a kidney biopsy is recommended.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5728 is \n",
      "\n",
      "Answer: The statement \"She should be treated with a DAA but not sofosbuvir because her eGFR is < 30 mL/min per 1.73 m2\" is accurate.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5729 is To diagnose a glomerular cause, perform a kidney biopsy. This is the highest priority \"next intervention\" as it is necessary to establish the underlying cause of the proteinuria and ensure that the patient does not have a glomerular disorder.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5730 is \n",
      "\n",
      "Answer: The statement \"He should do ﬁne with transplantation because the risks of transplantation are identical to those of HIV-negative patients, including the risk of rejection\" is true. Transplantation is a safe and effective treatment for patients with end-stage renal disease, including those with HIV. The guidelines for selecting patients for transplantation are based on factors such as the patient's medical history, lifestyle, and social situation, and the availability of a suitable donor. The decision to pursue transplantation should be made by the patient's healthcare provider with input from the patient and his family.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5731 is A. The patient is an inaccurate historian, and the diabetes was likely more severe and with accompanying retinopathy. (Option A is the most likely answer based on the information provided in the question. The patient's history suggests that her diabetes was more severe than previously thought, and the creatinine levels are consistent with this. The patient's history of a viral illness may also be related to her creatinine elevation. The other options are less likely because they do not fit the information provided in the question.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5732 is \n",
      "\n",
      "Answer: The statement \"Glomerular hyperﬁltration predicts cardiovascular mortality in type 2 diabetes\" is FALSE regarding hyperﬁltration. While hyperﬁltration is commonly observed in individuals with type 1 diabetes, there is no evidence to suggest that it is a risk factor for cardiovascular mortality in type 2 diabetes. In fact, a number of studies have shown that individuals with type 2 diabetes who develop glomerular hyperﬁltration are at increased risk for cardiovascular events, including heart attacks and strokes. Therefore, the statement that \"Glomerular hyperﬁltration predicts cardiovascular mortality in type 2 diabetes\" is not accurate.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5733 is \n",
      "A 48-year-old man is referred for management of diabetic nephropathy. He has hypertension, hyperlipidemia, and atherosclerotic cardiovascular disease. His HbA1C is 8.5%, microalbumin/creatinine ratio is 480 mg/g, and eGFR 48 mL/min per 1.73 m2. He is taking metformin, lisinopril, hydrochlorothiazide, and atorvastatin.\n",
      "\n",
      "Answer: \n",
      "A 48-year-old man is referred for management of diabetic nephropathy. He has hypertension, hyperlipidemia, and atherosclerotic cardiovascular disease. His HbA1C is 8.5%, microalbumin/creatinine ratio is 480 mg/g, and eGFR 48 mL/min per 1.73 m2. He is taking metformin, lisinopril, hydrochlorothiazide, and atorvastatin. \n",
      "\n",
      "Unknown: \n",
      "The following are NOT associated with SGLT2 inhibitors: \n",
      "1. Increased risk of genital fungal infections \n",
      "2. Decreased risk of progression to ESKD \n",
      "3. Increased cardiovascular mortality risk \n",
      "\n",
      "SGLT2 inhibitors are a class of diabetes medications that work by suppression of glucose reabsorption in the kidney. They are commonly used in patients with type 2 diabetes who have an elevated blood glucose level. SGLT2 inhibitors are generally well-tolerated and have been shown to reduce the risk of progression to ESKD and death. However, increased risk of genital fungal infections, decreased risk of progression to ESKD, and increased cardiovascular mortality risk are not associated with SGLT2 inhibitors.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5734 is \n",
      "As an AI language model, I cannot provide a specific answer without more context and information. However, based on the information provided, it seems that the best treatment option would be to continue the metformin and start an SGLT2 inhibitor. This is because the patient already has a history of hypertension, stage 3 CKD, and a recent diagnosis of diabetes, which makes her a good candidate for an SGLT2 inhibitor. Additionally, the eGFR of 40 mL/min per 1.73 m2 is within the recommended range for an SGLT2 inhibitor. Therefore, it would be best to consult with a healthcare provider to determine the specific treatment plan for the patient.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5735 is \n",
      "\n",
      "A. Light chain proximal tubulopathy\n",
      "B. Light chain deposition disease\n",
      "C. AL (light chain) amyloidosis\n",
      "D. Light chain cast nephropathy\n",
      "\n",
      "Answer: A. Light chain prostubulopathy. The patient's history and presentation suggest that he may have a monoclonal gammopathy of undetermined significance, which can lead to the development of kidney disease. The results of his bone marrow biopsy and urine studies are consistent with the diagnosis of light chain proximal tubulopathy. This diagnosis is characterized by the presence of increased numbers of abnormal light chain proteins in the urine, which can cause damage to the kidneys and other organs.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5736 is A. DNAJB9-positive ﬁbrillary glomerulonephritis is an underlying lymphoproliferative disorder.B. Congo red staining is required to rule out AL (light chain) amyloidosis.C. DNAJB9 positive ﬁbrillary glomerulonephritis is not an monoclonal gammopathy of renal signiﬁcance (MGRS)-associated lesion, and therefore no hematologic workup is recommended.D. The majority of patients with DNAJB9-positive ﬁbrillary glomerulonephritis have an underlying lymphoproliferative disorder.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5737 is \n",
      "\n",
      "Answer: The most likely diagnosis is 'Pauci-immune, necrotizing, and crescentic glomerulonephritis'. The patient's symptoms, physical examination, and laboratory findings are consistent with this diagnosis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5738 is \n",
      "As an AI language model, I cannot provide a specific answer based on the patient's medical history and factors. However, based on the information provided, it seems that the best management strategy would be to hold nivolumab and initiate glucocorticoids. It is possible that the patient may need temporary relief from the immune checkpoint inhibitor with the use of glucocorticoids, followed by a re-evaluation of the patient's condition after a few weeks or months. The decision to continue nivolumab or hold it should be made by the patient's healthcare provider, taking into account the patient's medical history, the nature of the immune checkpoint inhibitor, and the patient's symptoms.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5739 is \n",
      "\n",
      "A) Thrombotic microangiopathy\n",
      "B) Collapsing FSGS\n",
      "C) Membranous nephropathy\n",
      "D) AA amyloidosis\n",
      "\n",
      "Answer: A) Thrombotic microangiopathy\n",
      "\n",
      "Justification: Based on the information provided, the most likely finding at the time of the renal biopsy will be Thrombotic microangiopathy. This is because the patient is newly hypertensive with a BP of 160/92 mmHg, and her urine contains proteinuria. These symptoms are commonly associated with Thrombotic microangiopathy. Additionally, the increase in creatinine and albumin levels may also be indicative of this condition. However, further evaluation by a nephrologist is necessary to determine the exact diagnosis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5740 is \n",
      "\n",
      "A) Initiate zoledronate. \n",
      "B) Initiate denosumab. \n",
      "C) Rechallange patient with pamidronate. \n",
      "D) Antiresorptive therapy should be permanently discontinued. \n",
      "\n",
      "Answer: D) Antiresorptive therapy should be permanently discontinued. \n",
      "\n",
      "Justification: The patient's symptoms of nephrotic-range proteinuria are caused by Pamidronate-induced damage to the kidneys. Therefore, it is recommended to cancel the pamidronate and avoid any further medication that may cause kidney damage. Zoledronate and denosumab are both antiresorptive drugs that can cause kidney damage, and should not be initiated in this patient. Rechallanging the patient with pamidronate may also cause kidney damage and should be avoided. Therefore, the best step in the management of the patient's bone disease is to permanently discontinue any antiresorptive therapy.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5741 is [A. 1. Progression to end-stage renal disease, B. 2. Development of pulmonary hemorrhage, C. Increased risk of mortality, D. Drug-induced AAV]\n",
      "\n",
      "Answer: A. 1. Progression to end-stage renal disease is associated with double-positive MPO and PR3-ANCA.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5742 is \n",
      "\n",
      "A) Autosomal dominant\n",
      "B) Autosomal recessive\n",
      "C) X-linked recessive\n",
      "D) De novo somatic mutation\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5743 is (B) GLA mutation, α-galactosidase A deﬁciency, GB3 accumulation.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5744 is \n",
      "\n",
      "A) Serum parathyroid hormone (PTH) and ﬁbroblast growth factor-23 (FGF23) concentrations\n",
      "B) Serum protein electrophoresis and light chains\n",
      "C) Fractional excretion of phosphate\n",
      "D) Tubular maximal reabsorption of phosphate/GFR in a second morning urine after an overnight fast\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5745 is \n",
      "Answer: 3. When dietary phosphate is high, the passive paracellular route of phosphate absorption is less important in determining the serum phosphate concentration than the closely regulated transport-mediated transcellular pathway.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5746 is \n",
      "\n",
      "A. Her medications have no eﬀect on phosphate balance.\n",
      "B. Her phosphate concentration is maintained by intestinal absorption, internal shifts and renal excretion.\n",
      "C. A phosphate sensing molecule has been identiﬁed in humans and underlies post-transplantation hypophosphatemia.\n",
      "D. Her hypophosphatemia is most likely unrelated to her kidney disease or transplant status.\n",
      "\n",
      "Answer: B. Her phosphate concentration is maintained by intestinal absorption, internal shifts and renal excretion.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5747 is \n",
      "\n",
      "Based on the given information, the most likely diagnosis is Denosumab-induced hypocalcemia. This is because the patient's symptoms are consistent with the known side effects of denosumab, which include muscle cramps, paresthesia, and hypocalcemia. Additionally, the patient's medical history, specifically the diagnosis of adenocarcinoma of the prostate and bone metastatic disease, may also contribute to the development of denosumab-induced hypocalcemia. And, the patient's laboratory data at the time of the discharge also support this diagnosis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5748 is \n",
      "\n",
      "A) 1. Polycystin 2\n",
      "B) 2. Claudin\n",
      "C) 3. Klotho\n",
      "D) 4. FGF23\n",
      "\n",
      "Answer: A) 1. Polycystin 2, B) 2. Claudin, C) 3. Klotho, and D) 4. FGF23 are all proteins that regulate calcium excretion and have been associated with increased stone risk.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5749 is \n",
      "\n",
      "A) A loss of function mutation in the calcium-sensing receptor gene\n",
      "B) A gain of function mutation in the calcium-sensing receptor gene\n",
      "C) A loss of function mutation in the CLDN19 gene\n",
      "D) A loss of function mutation in the CLDN16 gene\n",
      "\n",
      "Answer: A loss of function mutation in the calcium-sensing receptor gene is most likely the explanation for the clinical condition. This is because the patient has a known genetic disorder that causes nephrocalcinosis, which is a condition that is typically associated with genetic mutations in the calcium-sensing receptor gene. A loss of function mutation in this gene would cause a decrease in the effectiveness of the calcium-sensing receptor, leading to the development of nephrocalcinosis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5750 is \n",
      "\n",
      "A 40 year-old man with a history of well-controlled HIV infection presented with irritability and polyuria after receiving a 2-month history of routine evaluation. He had no history of opportunistic infection, a viral load of undetectable, and a CD4+ T cell count of 600 (reference range, 410–1590 × 106/L). His medications were abacavir/lamivudine/dolutegravir. Laboratory workup showed creatinine of 2.5 mg/dl and albumin-corrected serum calcium of 15.1 mg/dl (confirmed twice). He denied use of illicit drugs, vitamin supplements, calcium, or diuretics. Computed tomography of the chest, abdomen, and pelvis showed nodular soft tissue densities in both buttocks. The patient confirmed a history of cosmetic injections with polymethylmethacrylate for HIV lipodystrophy 3 months before the onset of symptoms. Serum PTH was 5 pg/ml (reference range, 12–72 pg/ml). Based on the presentation, the most appropriate next step would be to measure the patient's 25-hydroxyvitamin D levels.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5751 is \n",
      "The most likely risk factor for his hypocalcemia is: \n",
      "\n",
      "A) High serum albumin \n",
      "\n",
      "The answer is A) High serum albumin.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5752 is a) Lanthanum carbonate alone and nicotinamide should be considered as a first-line therapy for reducing serum phosphorus in patients with stage 4 CKD.b) Lanthanum carbonate therapy can be expect to lower serum FGF23 concentrations by at least 30% in patients with stage 4 CKD.c) Lanthanum carbonate and nicotinamide should not be considered as a ﬁrst-line therapy for reducing serum phosphorus in patients with stage 4 CKD.d) Lanthanum carbonate alone can be used to lower se-rum PTH in patients with stage 4 CKD, but lanthanum carbonate therapy alone may not be eﬀective for reducing se-rum PTH in all patients.\n",
      "Answer: b) Lanthanum carbonate therapy can be expect to lower serum FGF23 concentrations by at least 30% in patients with stage 4 CKD.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5753 is \n",
      "A) Reduce calcium acetate to 1334 mg with meals\n",
      "B) Increase paricalcitol dose to 6 µg thrice weekly\n",
      "C) Change calcium acetate to sevelamer carbonate\n",
      "D) Increase cinacalcet dose to 60 mg daily\n",
      "\n",
      "Answer: A) Reduce calcium acetate to 1334 mg with meals. \n",
      "\n",
      "Based on the patient's current medication regimen and laboratory results, reducing the amount of calcium acetate taken with meals would be the most appropriate medication change at this time. The patient's current calcium acetate dosage of 2001 mg with meals may be contributing to his higher PTH levels, as well as causing hyperphosphatemia. Reducing the amount of calcium acetate taken with meals to 1334 mg would help to lower his PTH levels and also help to maintain his creatinine levels. While the other medication changes listed may also help to lower PTH levels, they may not be necessary at this time given the patient's current medication regimen.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5754 is \n",
      "\n",
      "A) Paricalcitol lowers PTH production by enhancing the binding of calcium to the calcium-sensing receptor\n",
      "B) Cinacalcet blocks the binding of PTH to its receptors in bone\n",
      "C) Cinacalcet stimulates the degradation of circulating PTH\n",
      "D) Phosphate increases PTH production by reducing binding of calcium to the calcium-sensing receptor. \n",
      "\n",
      "Answer: A) Paricalcitol lowers PTH production by enhancing the binding of calcium to the calcium-sensing receptor.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5755 is \n",
      "A) Increased risk of fracture, increased risk of vascular events, no increased risk of all-cause mortality\n",
      "B) Increased risk of precipitation, increased risk of cardiovascular events, no increased risk of all-cause mortality\n",
      "C) Increased risk of fracture, no increased risk of all-cause mortality\n",
      "D) Increased risk of rainfall, increased risk of cardiovascular events, increased risk of all-cause mortality\n",
      "\n",
      "Answer: A) Increased risk of fracture, increased risk of cardiovascular events, no increased risk of all-cause mortality.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5756 is The patient with a previous history of aluminum hydroxide treatment for severe hyperphosphatemia is most likely to have a diagnosis of a parathyroid carcinoma.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5757 is \n",
      "\n",
      "A) The bone formation rate does not change because bisphosphonates decrease the bone resorption rate.\n",
      "\n",
      "B) The bone formation rate decreases to levels that are average for normal people.\n",
      "\n",
      "C) The bone formation rate gradually decreases over approximately 6 months and then remains at a rate that is below normal.\n",
      "\n",
      "D) The bone formation rate increases because of stimulation of PTH.\n",
      "\n",
      "Answer: A) The bone formation rate does not change because bisphosphonates decrease the bone resorption rate.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5758 is The action of soluble klotho that raises the concern that supplementation could have a negative eﬀect on bone is the following: 'The action of soluble klotho decreases calcium reabsorption in the distal tubule, causing high urine calcium'.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5759 is \n",
      "\n",
      "A) A patient with high PTH and increased calcium and alkaline phosphatase\n",
      "B) A patient who has been treated with glucocorticoids, who has some metabolic acidosis and weight loss\n",
      "C) A patient who has evidence of skeletal lesions on magnetic resonance imaging\n",
      "D) A patient who received a bisphosphonate injection 3 weeks before the biopsy\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5760 is \n",
      "\n",
      "A. Increased phosphate concentration is necessary and suﬃcient for vascular calciﬁcation. \n",
      "\n",
      "The statement is accurate. In individuals with vascular calcification, there is a correlation between increased phosphate concentration and the development of calcification in the tunica media of the aorta. This is due to the fact that phosphate is an essential component of the extracellular matrix of blood vessels and plays a role in the formation of calcium phosphate deposits. Therefore, individuals with higher phosphate levels are more likely to develop vascular calcification.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5761 is \n",
      "A. The most accurate statement is: \"A low Kauppila score associates with a high cardiovascular risk.\" \n",
      "\n",
      "Explanation: The statement is accurate because the Kauppila scoring method is a commonly used method for assessing the likelihood of aortic calcification in thesetting of pancreatitis. Abdominal aortic calcification is associated with increased cardiovascular risk and mortality, but this association is quickly lost after transplantation. Therefore, a low Kauppila score would indicate a high cardiovascular risk, which is consistent with the literature.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5762 is \n",
      "A) Change sodium to 135 mEq/L\n",
      "B) Change potassium to 1 mEq/L\n",
      "C) Change magnesium to 2 mg/dl\n",
      "D) Increase dialysis time to target higher Kt/V\n",
      "\n",
      "Answer: Based on the given information, changing the sodium concentration to 135 mEq/L would improve the serum calciﬁcation propensity as measured by increased T50. This is because a higher sodium concentration would lead to increased fluid balance, which is essential for proper dialysis. The other changes would not be as effective in improving the serum calciﬁcation propensity as measured by increased T50. Changing the potassium concentration to 1 mEq/L would result in an increased risk of hyperkalemia and could negatively impact patient outcomes. Changing the magnesium concentration to 2 mg/dl could improve patient outcomes, but it may not specifically improve the serum calciﬁcation propensity as measured by increased T50. Increasing the dialysis time to target higher Kt/V would also improve patient outcomes, but it may not specifically improve the serum calciﬁcation propensity as measured by increased T50.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5763 is A) Magnesium supplement, B) Vitamin K supplement, C) Calcium-containing phosphate binder, or D) Calcimimetic agents.\n",
      "\n",
      "Answer: C) Calcium-containing phosphate binder. This is because the man's condition already includes high blood calcium levels, which can contribute to the development of vascular calcification. Therefore, a Calcium-containing phosphate binder may help to reduce the progression of vascular calcification. \n",
      "\n",
      "A) Magnesium supplement and B) Vitamin K supplement are not likely to prevent or delay progression of vascular calcification. Magnesium and Vitamin K are not directly involved in the development of vascular calcification. \n",
      "\n",
      "D) Calciumimetics agents are typically not recommended for individuals with ESRD or chronic pancreatitis as they can cause precipitation reactions and increase the risk of contrast reactions.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5764 is a) The statement that \"In her age group, the risk of fracture is higher for ESRD compared with non-ESRD patients\" is incorrect. b) The statement that \"The mortality risk for ESRD patients is higher after the fracture compared with mortality risk in nonESRD patients after fracture\" is incorrect. c) The statement that \"Factors that increase the fracture risk of ESRD patients include age and CKD with mineral and bone disorder but not osteoporosis\" is correct. d) The statement that \"She is more likely to have a prolonged hospitalization after the fracture\" is not supported by her medical history.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5765 is A. 1. The statement is most accurate.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5766 is \n",
      "A) Pamidronate\n",
      "B) Denosumab\n",
      "C) Teriparetide\n",
      "D) Romosozumab\n",
      "\n",
      "Answer: A) Pamidronate.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5767 is \n",
      "\n",
      "Answer: Teriparetide is best for her osteoporosis. It is a bone-Speciﬁc alkaline phosphatase is high, and her medical history includes diabetes, obesity, hypertension, and a 20-pack/year smoking history. Teriparetide is a once-monthly medication that works by increasing the amount of calcium in the blood, which helps to strengthen bones and teeth. It is also safe for patients with kidney disease and can be titrated based on the patient's individual needs. Alendronate and Denosumab are also options for bone loss prevention in patients with CKD, but they are not as effective as Teriparetide in improving bone density and reducing the risk of fractures. Abaloparatide is a new medication that is not yet widely used in the United States and is not recommended for patients with CKD.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5768 is \n",
      "A) The patient has a better than 10% chance of survival after one year.\n",
      "B) The patient's skin biopsy shows a location of the lesion in the perieccrine glands.\n",
      "C) The patient's creatinine level is < 100.\n",
      "D) The patient has a history of myocardial infarction.\n",
      "\n",
      "Answer: A) The patient has a better than 10% chance of survival after one year.\n",
      "\n",
      "Explanation: \n",
      "The presence of arteriolar calciﬁcation and thrombosis of subcutaneous adipose tissue suggests advanced lesion stage and worse prognosis. Therefore, the patient's condition is likely to progress and have a poor outcome. The fact that the patient has a history of chronic atrial ﬁbrillation and is receiving maintenance hemodialysis also contributes to her poor outlook. However, a 1-year mortality rate of < 10% is a relatively low estimate and could indicate a better than 10% chance of survival after one year. The location of skin lesions does not appear to inﬂuence prognosis, and the presence of ulcerated lesions has no impact on overall outcome. Therefore, the most accurate statement is A) The patient has a better than 10% chance of survival after one year.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5769 is \n",
      "\n",
      "Answer: The most appropriate treatment of mineral bone abnormalities in this patient is a combination of options 1 and 2. \n",
      "\n",
      "Explanation: \n",
      "\n",
      "Based on the patient's history and laboratory data, the patient is at risk for developing calcium-related abnormalities. The patient already receives long-term ambulatory peritoneal hemodialysis, which can help to maintain calcium levels in the blood. However, the bilateral skin lesions on her thighs are a result of calc ci*fic uremic arteriolopathy, which is a condition characterized by the narrowing or blockage of the arterioles that supply blood to the skin. \n",
      "\n",
      "Therefore, it is appropriate to add cinacalcet and urgent surgical parathyroidectomy to the patient's treatment regimen. Cinacalcet can help to lower calcium levels in the blood, while urgent surgical parathyroidectomy can help to improve the patient's skin symptoms and overall health. \n",
      "\n",
      "Adding aluminum hydroxide or sevelamer to the patient's treatment regimen may also be helpful, but further evaluation by a healthcare provider is necessary to determine the appropriate course of action.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5770 is \n",
      "To identify which of the following does not contribute to her risk of stone recurrence, we need to consider the patient's medical history, lifestyle, and physical appearance. Based on the information provided, the patient has a 10-year history of diabetes, hypertension, and hypercholesterolemia, and a steady increase in weight since her last pregnancy 30 years ago. She also tries to drink ﬂuids during the day but often leaves a bottle close to full at the end of the day. Her BMI is 33, with a waist circumference of 90 cm, and her BP at home is 140/82 mmHg.\n",
      "\n",
      "Therefore, based on the patient's medical history and lifestyle, the answer that does not contribute to her risk of stone recurrence is \"Insuﬃcient urine volume\". While a contributing factor to stone recurrence is a lack of water intake, this patient's water intake is likely adequate based on her attempt to drink ﬂuids during the day. The other factors, high BMI, diabetes, and physical inactivity, are all risk factors for stone recurrence and are likely to contribute to her overall health and risk of stone formation.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5771 is A) CT scan with intrvenous contrast material\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5772 is \n",
      "\n",
      "A) High calcium\n",
      "B) Low urine pH\n",
      "C) High uric acid\n",
      "D) High cystine\n",
      "\n",
      "Answer: D) High cystine. It is possible that the woman has a stones due to a genetic disorder, such as autosomal recessive polycystic kidney disease, but further testing and evaluation by her doctor is necessary to determine the exact cause.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5773 is an increase in dietary calcium and oxalate is not a true statement.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5774 is \n",
      "The best management strategy for her hyperkalemia is:\n",
      "A) Continue dialysate [K] 2 mEq/L, reinforce dietary restriction, check for recirculation, add if these measures do not yield a decrease in the serum [K], add a potassium-binding resin on non-dialysis days.\n",
      "B) Increase dialysis time to 4.5 hours, continue dialysate [K] 2mEq/L.\n",
      "C) Dietary restriction, change dialysate to [K] 1 mEq/L.\n",
      "D) Dietary restriction and continue current regimen.\n",
      "\n",
      "Answer: A) Continue dialysate [K] 2 mEq/L, reinforce dietary restriction, check for recirculation, add if these measures do not yield a decrease in the serum [K], add a potassium-binding resin on non-dialysis days.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5775 is \n",
      "The answer is: \n",
      "4. Have no effect on laboratory values or dialysis stability. Changing the dialysate [Ca] to 2.75 would not impact the laboratory values or dialysis stability.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5776 is \n",
      "The best approach to prevent episodes of pulmonary edema is to continue to monitor the patient's condition closely and adjust the treatment plan as needed. It is important to listen to the patient's symptoms and make sure they are being treated appropriately. If the patient continues to experience symptoms of pulmonary edema, it may be necessary to increase the ultrafiltrate rate or add a loop diuretic on non-dialysis days. It is important to limit the patient's UFR during dialysis to < 13 ml/kg per h to prevent overhydration and make sure the patient is not leaving above their dry weight.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5777 is \n",
      "\n",
      "A: The single best approach to preparing her for dialysis would be to refer her to interventional radiology/nephrology for a tunneled dialysis catheter so that it is ready to use when she needs it. This will ensure that she is prepared for dialysis in case of an emergency. While she may be a poor candidate for dialysis, it is still important to have a plan in place in case she needs dialysis. This approach also allows for the potential for her to be a good candidate for peritoneal dialysis in the future if her condition improves.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5778 is \n",
      "\n",
      "A. Wait until she becomes uremic and admit her for standard three-times-weekly dialysis. \n",
      "\n",
      "B. Refer her for transplantation evaluation and hope for the best. \n",
      "\n",
      "C. Refer her to palliative care to help with conservative therapy. \n",
      "\n",
      "D. Measure her creatinine clearance and discuss with her the possibility of starting dialysis 2 days per week. \n",
      "\n",
      "Answer: D. Measure her creatinine clearance and discuss with her the possibility of starting dialysis 2 days per week. \n",
      "\n",
      "The best single approach to renal replacement therapy for this patient would be to measure her creatinine clearance and discuss with her the possibility of starting dialysis 2 days per week. This approach is the best option because it allows for a more personalized decision-making process based on the patient's unique medical history, lifestyle, and personal preferences. By measuring her creatinine clearance, the healthcare provider can determine if the patient is suitable for dialysis, and if so, the provider can discuss the potential benefits and risks of starting dialysis. Additionally, this approach allows for the patient to be actively involved in the decision-making process and to make an informed decision based on her personal circumstances.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5779 is \n",
      "\n",
      "The most appropriate option for the management of the patient's APD would be to continue with the current APD regimen and reassess his condition after 2 weeks. This is based on the patient's good adapting to the APD regimen and the fact that his Kt/Vurea is within the normal range. Adding a day dwell of icodextrin or increasing the dwell treatment time could result in an increased risk of hypotension and other complications. Switching to HD would not be appropriate as the patient is euvolemic and has a good appetite, and the ISPD guideline recommends against the use of HD in such cases.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5780 is \n",
      "\n",
      "A) Straight single-cuff Tenchkoff catheter\n",
      "B) Straight double-cuff Tenchkoff catheter\n",
      "C) Coiled single-cuff Tenchkoff catheter\n",
      "D) Coiled double-cuff Tenchkoff catheter\n",
      "\n",
      "Answer: The best option for an access for the patient's peritoneal dialysis is not listed as the answer choices. It is important to consider the patient's medical history, lifestyle, and personal preferences when selecting an access method. It is recommended to consult with a healthcare provider or a CKD patient to determine the best option.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5781 is None of the above options are expected to improve her long-term outcome based on recent studies and KDIGO guidelines. \n",
      "\n",
      "Explanation: \n",
      "\n",
      "1. Increasing her statin dose to target a lower LDL is not expected to improve her long-term outcome as it is not supported by recent studies and KDIGO guidelines. In fact, recent studies have shown that higher LDL targets may increase the risk of adverse events.\n",
      "\n",
      "2. Reviewing the causes of her episodes of peritonitis to reduce risk of recurrence is not expected to improve her long-term outcome as it is not directly related to her diabetes, ischemic heart disease, and hypertension. It is possible that her peritonitis is related to an underlying infection or other medical condition.\n",
      "\n",
      "3. Escalating her antihypertensives to target BP at < 130/ 80 mmHg may improve her short-term response to her treatment, but it is not supported by recent studies and KDIGO guidelines. In fact, recent studies have shown that lower BP targets may increase the risk of adverse events.\n",
      "\n",
      "4. Stopping the angiotensin-converting enzyme inhibitor to improve her residual renal function (RRF) is not expected to improve her long-term outcome as it is not directly related to her diabetes, ischemic heart disease, and hypertension. It is possible that her angiotensin-converting enzyme inhibitor is related to an underlying medical condition.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5782 is \n",
      "\n",
      "A) Add oral loop diuretics\n",
      "B) Start with twice daily PD exchanges, then gradually step up\n",
      "C) Use low-glucose degradation product and neutral pH bio-compatible PD solutions\n",
      "D) Start him with automated PD\n",
      "\n",
      "Answer: \n",
      "Given the patient's advanced CKD and poor acceptance of disease trajectory, the best option to preserve his RRF would be to start with automated PD. This option is the best choice as it is the most effective way to manage the patient's fluid balance, reduce uremic symptoms, and avoid further complications. After a few weeks, if the patient shows improved compliance and stable fluid balance, the PD exchanges can be gradually increased. However, it is important to avoid over- or under-extraction, as this can lead to further kidney damage and further complications.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5783 is \n",
      "The answer is: \n",
      "The patient's 24-hour urine collection showed residual urine of 547 ml, indicating that he is still losing water through urination. Therefore, the answer is: \n",
      "'1. Change to three bags of 1.5% 2-L low-glucose degradation product neutral pH solution'. This will help to increase the amount of water the patient receives, which will improve his fluid balance. It is important to note that the patient's current CAPD regimen may need to be adjusted based on his age and medical history, and that ongoing monitoring is necessary to ensure his safety and well-being.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5784 is \n",
      "\n",
      "A) 1. More than 5%\n",
      "B) 2. More than 10%\n",
      "C) 3. More than 15%\n",
      "D) 4. More than 20%\n",
      "\n",
      "Answer: The level of culture-negative peritonitis that should be reviewed for a quality improvement project at a local center is 3. More than 15%. According to the ISPD 2016 guideline, when the frequency of culture-negative peritonitis is more than 15%, a review of sampling and culture methods should be carried out to ensure that the rate of peritonitis is not higher than what is expected.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5785 is \n",
      "\n",
      "Answer: Based on the information provided, the most suitable next choice of antibiotics may be option 2: \"Add intraperitoneal gentamicin\". This is because gentamicin is a good choice for gram-negative infections, and Enterococcus species is a common cause of CAPD peritonitis. The sensitivity results for the peritoneal ﬂuid culture are still awaited, but gentamicin is a good option in the meantime.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5786 is \n",
      "\n",
      "A) 1. Patients who start on “full-dose” PD have similar preservation of RRF as those who start with incremental PD. \n",
      "B) APD is associated with a lower risk of technique failure than CAPD.\n",
      "C) Biocompatible PD solutions have been associated with lower rates of PD peritonitis.\n",
      "D) Use of icodextrin-based PD solutions are associated with more rapid loss of RRF.\n",
      "\n",
      "Answer: \n",
      "A) Patients who start on “full-dose” PD have similar preservation of RRF as those who start with incremental PD.\n",
      "\n",
      "The patient in this scenario is at risk for decompensated heart failure, and her medical history suggests that she may be appropriate for PD. The options listed are all valid with regard to the initiation of PD. The patient may start on incremental PD, which can be adjusted as her condition improves. APD is associated with a lower risk of technique failure than CAPD, but the patient's medical history suggests that she may be appropriate for full-dose PD. Biocompatible PD solutions have been associated with lower rates of PD peritonitis, but the patient's medical history suggests that she may be appropriate for full-dose PD. The patient's energy has declined over the past month, and she wishes to discuss her options for starting dialysis, so the correct answer is A.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5787 is \n",
      "\n",
      "A) Embedded PD catheters are associated with higher rates of exit site infections.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5788 is a) Increased UF is not needed in this patient b) There is no need to change the patient's PD prescription c) The patient should continue with the current PD prescription d) The patient's UF should be increased.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5789 is A. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers has been associated with lower rates of cardiovascular mortality but faster loss of RRF.\n",
      "Explanation: The answer is correct. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are known to lower blood pressure and improve cardiovascular outcomes. However, they may also cause faster loss of RRF in some patients. Therefore, it is important to balance the benefits of these medications with the potential risks to RRF.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5790 is \n",
      "\n",
      "Answer: The correct answer is:\n",
      "\n",
      "1. Hyperlipidemia has been associated with increased mortality in PD patients.\n",
      "\n",
      "This patient has several risk factors for cardiovascular outcomes and mortality, including age, ESKD, and hyperlipidemia. Hyperlipidemia is a common risk factor for cardiovascular disease and can contribute to the development of heart attack.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5791 is \n",
      "Answer: The patient's creatinine levels after HD were higher than before HD, indicating that the patient may have lactic acidosis as a result of the presence of lactate as a buffer in the dialysate. Therefore, the answer is 4. Lactic acidosis related to organ ischemia or liver disease.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5792 is (A) Convert to nocturnal HD 7 hours 5 times per week at the same dialysate volume of 30 L (B) Dialyze for 4 hours ﬁve times per week (C) Convert to in-center HD 4 hours three times per week (D) Convert to PD.\n",
      "Answer: The best option to address the clinical issues described here is to convert the patient to nocturnal HD 7 hours 5 times per week at the same dialysate volume of 30 L. This will help to reduce the impact of hypotension and improve patient outcomes.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5793 is a) 1. BP control is likely to be slightly worse compared with three-times-weekly in-center HD, b) The Frequent Hemodialysis Network extended trial conclusively demonstrated that nocturnal HD results in lower mortality, c) He may not need to use phosphate binders with nocturnal HD, d) His left ventricular hypertrophy will likely worsen on intensive HD.\n",
      "\n",
      "Answer: b) The Frequent Hemodialysis Network extended trial conclusively demonstrated that nocturnal HD results in lower mortality.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5794 is \n",
      "\n",
      "Answer: The use of HHD in the United States is not mentioned in the question. Therefore, the answer is not available.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5795 is \n",
      "A) HHD has been associated with improved survival compared with both living and deceased donor transplantation.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5796 is A) Use of PD but not HHD, increased during the COVID-19 pandemic.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5797 is \n",
      "\n",
      "Answer: The most significant barrier to patients switching to home dialysis is the relative cost of therapies. According to recent data, the cost of home dialysis is significantly higher than traditional in-center dialysis. This may be a barrier for patients with limited financial resources, as well as those with health conditions that require them to be on a waiting list for a dialysis machine.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5798 is \n",
      "Answer: \n",
      "\n",
      "2. \"Prognosis varies; however, most experience tells us that on average patients may live about 7 days without dialysis. This may be slightly more or less depending on other medical conditions that someone has, and how much residual renal function one has.\"\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5799 is \n",
      "\n",
      "A) Eliquis\n",
      "B) Baclofen\n",
      "C) Gabapentin\n",
      "D) Losartan\n",
      "\n",
      "Answer: A) Eliquis. The patient has a medical history of ESKD on maintenance HD, diabetes with neuropathy, hypertension on losartan, and atrial ﬁbrillation on Eliquis, and is currently taking a low dose of gabapentin. She has had no recent falls or other symptoms that could indicate a cerebrovascular event. Therefore, the most likely causal agent of her altered mental status is Eliquis, which is a medication used to treat atrial ﬁbrillation and has been associated with cognitive function changes and even cases of cognitive enhancement.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5800 is \n",
      "A) Age > 65 years\n",
      "B) Number of hospitalizations in the past year\n",
      "C) Recent admission for a noncardiac cause\n",
      "D) Community dwelling\n",
      "\n",
      "Answer: B) Number of hospitalizations in the past year is the most predictive of multiple readmissions in patients receiving HD.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5801 is \n",
      "\n",
      "Answer: The patient is most likely to experience increased risk of hospitalizations or emergency department visits.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5802 is \n",
      "A. In the last 30 days of life, those who choose conservative management use fewer hospice services\n",
      "B. The family members and caregivers of those pursuing conservative management report lower quality of life\n",
      "C. In patients of all ages, those who choose dialysis live longer than those choosing conservative management\n",
      "D. In the last 30 days of life, those who choose conservative management use more hospice services\n",
      "\n",
      "Answer: D. In the last 30 days of life, those who choose conservative management use more hospice services.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5803 is \n",
      "\n",
      "Answer: There is no clear answer to this question as the information presented is incomplete. The question seems to be asking about the relationship between readmissions for patients on PD and patient characteristics, but the information provided does not establish any clear connections. Therefore, the answer cannot be determined.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5474 is \n",
      "\n",
      "A. Dehydration is the most likely cause of the patient's seizures. The patient completed a marathon and drank water frequently at the water stations during the race, so it is unlikely that dehydration is the cause of the seizures. However, it is possible that the patient may have developed dehydration as a result of the marathon. Therefore, further evaluation and treatment by a medical professional is necessary.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5475 is A, B, C, D, E\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5476 is A. Continue current treatment until his serum [Na+] reaches 135 mmol/L.\n",
      "Answer: A. Continue current treatment until his serum [Na+] reaches 135 mmol/L.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5477 is (A) Extracellular ﬂuid volume replacement by normal saline infusion leading to increased free water excretion (aquaresis) or (B) Increased water losses from sweating.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5478 is \n",
      "Answer: Aquaresis produced by tolvaptan. The patient's symptoms of lethargy and reduced diet-related quality of life suggest that the cause of hypernatremia is due to the syndrome of inappropriate antidiuretic hormone secretion. Tolvaptan is used to treat this syndrome by increasing the end result of the thirst mechanism in the brain to conserve water. The patient received 5% dextrose in water to correct his hypernatremia.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5479 is A) Hypernatremia is iatrogenic and requires extra water intake, B) Hypernatremia is secondary to lithium-induced partial nephrogenic diabetes insipidus, C) Hypernatremia is secondary to osmotic diuresis from hyperglycemia, or D) Hypernatremia is secondary to lithium-induced complete nephrogenic diabetes insipidus.\n",
      "Answer: B) Hypernatremia is secondary to lithium-induced partial nephrogenic diabetes insipidus.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5480 is \n",
      "Answer: 3. A change in the serum sodium concentration of 1 mmol/L/h is likely safe and should not cause neurologic sequelae. (Based on the information given, the patient's free water deﬁcit is 3.5 L, which is a small amount of water relative to her total body water content of 45%. The infusion of 2 liters of free water is unlikely to cause a significant change in the patient's sodium concentration.)\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5481 is \n",
      "\n",
      "Answer: 3. In the setting of sarcoidosis, nephrogenic diabetes insipidus due to hypercalcemia is the most likely cause of hypernatremia.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5482 is (A) The patient should be maintained on the same volume of 500 ml of double-strength Japanese seasoning soy sauce per hour. (B) The patient should be given 1000 ml of water per hour to correct the serum sodium concentration. (C) The patient should be given a low-sodium diet for the rest of her life. (D) The patient's condition is stable and no further treatment is needed.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5483 is \n",
      "\n",
      "Answer: Based on the patient's medical history and current condition, the optimal decision for renal replacement therapy is option 2. Continuous venovenous hemodiaﬁltration with isotonic bicarbonate replacement ﬂuid, while continuing hypertonic saline infusion to maintain permissive hypernatremia. This will help to manage the patient's electrolyte abnormalities and prevent further complications.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5484 is \n",
      "A) Magnesium deﬁciency\n",
      "B) Early (\"continuous\") vomiting\n",
      "C) Long-term laxative use\n",
      "D) Remote diuretic use\n",
      "\n",
      "Answer: A) Magnesium deﬁciency.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5485 is The most likely pathophysiologic explanation for this patient's severe hypokalemia is loss of potassium in the sweat glands from perspiration with extracellular ﬂuid volume depletion and secondary hyperaldosteronism.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5486 is (a) Plasma K+ ↓, Plasma HCO3- ↑, Urine pH ↔, Fractional excretion of [HCO3-] 15%\n",
      "\n",
      "Answer: Based on the given information, it is difficult to predict the expected trend and values for the Laboratory data in the next series of choices. However, the first choice is the most likely based on the patient's history of progressive fatigue and leg cramps, as well as the high levels of sodium and potassium in the initial laboratory data. The first choice suggests that the patient's hypokalemia may be related to an imbalance in the patient's acid-base balance. The third choice suggests that the patient may be experiencing a shift in their acid-base balance, which could be due to a variety of factors, including changes in diet or medication. The fourth choice is less likely based on the information provided, as it suggests a return to normal values for pH and fractional excretion of hydrogen ions, rather than a continued decline in sodium or potassium levels.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5487 is A) 1. Abuse of laxatives, B) 2. Surreptitious diuretic use, C) 3. Herbal medicine containing glycyrrhizic acid, D) 4. Remote vomiting, E) 5. OTC thyroid supplementation.\n",
      "\n",
      "Answer: A) 1. Abuse of laxatives. The patient's sister has a history of Hashimoto thyroiditis, which may be associated with hypothyroidism and an increased risk of constipation. Use of laxatives may be used to manage constipation. Therefore, it is likely that the patient is experiencing symptoms of hypokalmia due to the abuse of laxatives.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5488 is The most likely cause of hypokalemia and hypomagnesemia is a mutation in the SLC12A3 gene encoding NCC in the distal tubule. This is based on the fact that the patient has a stable creatinine of 0.7 mg/dl, which suggests that the patient is not experiencing dehydration. Additionally, the patient's medical history and current symptoms are consistent with changes in the distal tubule, such as muscle weakness and increased salt-craving. The patient's current urine K+/Cr ratio is also consistent with the diagnosis of hypokalemia. The patient's magnesium levels are within normal range, but the presence of high fractional excretion of magnesium in the spot urine studies suggests that magnesium dehydration may be contributing to the overall fluid balance.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5489 is \n",
      "\n",
      "A. Leave his regimen unchanged as recent studies have shown that low potassium confers higher cardiovascular risk and mortality than does high potassium.\n",
      "\n",
      "B. Avoid potassium-binding agents as they all have gastrointestinal side effects and are risky for long-term use.\n",
      "\n",
      "C. Initiate patiromer to allow continued treatment with renin-angiotensin system inhibitors.\n",
      "\n",
      "D. Add ﬂudrocortisone to reduce potassium in this patient. \n",
      "\n",
      "Answer: A. Leave his regimen unchanged as recent studies have shown that low potassium confers higher cardiovascular risk and mortality than does high potassium.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5490 is \n",
      "\n",
      "Answer: The most likely underlying cause of hyperkalemia in this patient is a loss of function mutation of the gene encoding the epithelial sodium channel, which could result in a sodium-deprived state leading to hyperkalemia. This could be confirmed by performing a sodium concentration measurement.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5491 is (A) Measuring potassium in serum is faster than measuring potassium in whole blood. (B) A deep learning algorithm using an electrocardiogram is able to exclude hyperkalemia with acceptable accuracy. (C) Serum potassium is usually lower than plasma potassium. (D) Measuring potassium in whole blood is not as accurate as measuring potassium in serum or plasma.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5492 is A. Sodium zirconium cyclosilicate should be chosen for this patient.B. Sodium zirconium cyclosilicate should not be chosen as it is effective in reducing potassium in non-dialysis CKD patients but not in dialysis patients.C. Sodium zirconium cyclosilicate also removes hydrogen ions and may increase serum bicarbonate.D. Sodium zirconium cyclosilicate has been shown to provide added beneﬁt to insulin and glucose in the treatment of acute severe hyperkalemia.\n",
      "\n",
      "Answer: A. Sodium zirconium cyclosilicate should be chosen for this patient. Sodium zirconium cyclosilicate is an evidence-based approach for the treatment of hyperkalemia in dialysis patients. It is also effective in reducing potassium in non-dialysis CKD patients, which is not the case for the 79-year-old woman in question. Therefore, the most likely evidence-based approach for this patient would be option A.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5493 is a) Metformin is the most likely culprit agent for acidosis in this case. b) The recent reduction in insulin dosing may be the precipitant for this clinical presentation. c) The patient’s near-normal blood glucose excludes ketoacidosis as a cause of this presentation. d) This patient should be given an intravenous infusion of isotonic bicarbonate.\n",
      "Answer: a) Metformin is the most likely culprit agent for acidosis in this case. b) The recent reduction in insulin dosing may be the precipitant for this clinical presentation. c) The patient’s near-normal blood glucose excludes ketoacidosis as a cause of this presentation. d) This patient should be given an intravenous infusion of isotonic bicarbonate. \n",
      "\n",
      "Explanation: \n",
      "\n",
      "1. Metformin is a medication used to treat type II diabetes. It is known to cause acidosis in some patients, especially those with kidney or liver disease. \n",
      "\n",
      "2. The recent reduction in insulin dosing may be the precipitant for this clinical presentation as it may have caused the patient's blood sugar levels to become too high, leading to an increased risk of ketoacidosis. \n",
      "\n",
      "3. The patient's near-normal blood glucose does not exclude ketoacidosis as a cause of this presentation as it is possible that the patient's body is using stored fat as a source of energy, leading to a rise in blood glucose levels. \n",
      "\n",
      "4. The patient should be given an intravenous infusion of isotonic bicarbonate to help correct the acidosis and maintain the patient's near-normal blood glucose levels.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5494 is \n",
      "A) Topiramate is associated with urine crystals and with crystalline stone formation.\n",
      "B) Valproate is highly protein bound and is not amenable to removal with hemodialysis.\n",
      "C) Concomitant use of antibiotics has been associated with increased risk of pyroglutamic acidosis from acetaminophen use.\n",
      "D) Linezolid causes a non-anion gap by blocking carbonic anhydrase.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5495 is A meta-analysis of treatment with NaHCO3 for metabolic acidosis did not show any increase in requirement for antihypertensive or diuretic agents.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5496 is A\n",
      "A switch to a diet of alkali-producing fruits and vegetables may delay progression to hypobicarbonatemic acidosis.\n",
      "B In observational studies, up to 40% of patients with CKD stage III have metabolic acidosis.\n",
      "C Decreases in urine citrate suggest H+ retention in patients with CKD and have been shown to trend closely with changes in serum [HCO3-].\n",
      "D Inhibitors of the renin angiotensin system have been shown to be protective against the development of acidosis.\n",
      "\n",
      "Answer: A switch to a diet of alkali-producing fruits and vegetables may delay progression to hypobicarbonatemic acidosis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5497 is \n",
      "As an AI language model, I cannot provide an answer to this question without additional context or information. Please provide more details or options to the question.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5498 is A) Glucocorticoid-remediable hyperaldosteronism.\n",
      "Explanation: The patient's mother and father have hypertension and diabetes, which are common features of glucocorticoid-remediable hyperaldosteronism. Additionally, the patient's physical examination, routine blood tests, and urine toxicology screen results are consistent with the diagnosis of this disorder. The patient's high levels of plasma renin activity and aldosterone concentration support the diagnosis of hyperaldosteronism. The other options are consistent with the patient's medical history and physical examination, but they do not explain the specific cause of the patient's hypokalemic metabolic alkalosis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5501 is \n",
      "Answer: \n",
      "Based on the patient's course, it is most likely that the metabolic alkalosis is generated by option 4, which is that it was generated by metabolism of retained lactate to bicarbonate and should spontaneously correct. The patient's initial laboratory values showed a low pH, high PCO2, and low [HCO3-]. The patient's symptoms developed over the course of a day, and the initial arterial blood gases showed a pH of 7.06, PCO2 of 18 mm Hg, and [HCO3-] of 5 mEq/L. The patient's pH and PCO2 values have stabilized, and the [HCO3-] level has increased, indicating that the patient's metabolic alkalosis is being generated by the metabolism of retained lactate to bicarbonate. Additionally, the patient's symptoms have been mild and have not required any additional therapy.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5502 is \n",
      "\n",
      "A 45-year-old woman presents with new onset of hypertension but is otherwise healthy. Physical examination results are is noteworthy for a BP of 160/105 mm Hg and are otherwise normal, with no evidence of volume depletion or edema. Initial lab results: Leukocyte count: 5,000/µl; Hemoglobin 13.9 g/dl; Platelets 230,000/µl; Serum Sodium 145 mEq/L; Potassium 2.5 mEq/L; Chloride 97 mEq/L; Total CO2 34 mEq/L; BUN 8 mg/dl; Creatinine 0.6 mg/dl; Random glucose 98 mg/dl.\n",
      "\n",
      "A random plasma renin is low, and a plasma aldosterone is high.\n",
      "\n",
      "Based on the physical and lab findings, the most likely diagnosis is Gitelman syndrome. Gitelman syndrome is a rare and idiopathic form of hypertension that is characterized by low renin values and high aldosterone levels. The other options are not consistent with the given findings. Renovascular hypertension is characterized by high blood pressure in a patient with narrowed or blocked arteries, which is not present in this patient. Primary hyperaldosteronism is a rare disorder where the body produces too much aldosterone, which can cause high blood pressure and other symptoms, but the patient's aldosterone levels are high, which suggests Gitelman syndrome. Liddle disease is a rare form of hypertension that is characterized by an increase in chloride concentration in the blood, which is not present in this patient. Therefore, Gitelman syndrome is the most likely diagnosis based on the given findings.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5503 is \n",
      "\n",
      "Answer: Based on the physical examination and laboratory values, the most likely diagnosis is Primary Hyperaldosteronism. This is supported by the low random plasma renin and aldosterone levels, as well as the normal cortisol levels.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5504 is A single measure that has been recently shown to decrease AKI-related length of stay is the use of cystatin C rather than serum creatinine.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5505 is A. Neutrophil gelatinase-associated lipocalin (NGAL) or B. Kidney injury molecule (KIM)-1.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5506 is \n",
      "A. Smoking status is a characteristic feature of patients who experienced AKI in recently published ASSESS-AKI.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5507 is A, B, C, or D.\n",
      "\n",
      "Answer: A. Oligoanuria on presentation to the hospital is the best predictor of CKD. Creatinine and urine protein 3 months after discharge are not always reliable predictors of CKD. Having had kidney replacement therapy (KRT) for 2 days is not a good predictor of CKD as it is a temporary intervention and does not reflect the underlying cause of CKD. Creatinine at the time of discharge is a poor predictor of CKD and does not accurately reflect the patient's overall condition.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5508 is \n",
      "\n",
      "A. Mortality is increased with severe (i.e., stage 3 AKI) but not stages 1 and 2.\n",
      "\n",
      "Answer: A. Mortality is increased with severe (i.e., stage 3 AKI) but not stages 1 and 2. This is supported by the available data which shows that the risk of mortality inAKI is increased in patients with more severe forms of AKI. However, it is also important to note that Mortality is not increased in stages 1 and 2 of AKI, as these stages do not have an increased risk of mortality.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5509 is \n",
      "A 24-year-old man presents to the emergency department with septic shock from Escherichia coli bacteremia related to urinary source. His vital signs are as follows: temperature 38 degree C, heart rate 119 beats/min, BP 82/43 mm Hg, respirations 19/min. Physical examination results are signiﬁcant for ill appearance, tachycardia, and cool peripheries. His laboratory results are as follows: creatinine 1.1 mg/dl, sodium 134 mmol/L, calcium 7.2 mg/dl, potassium 4.5 mmol/L, albumin 3 g/dl, chloride 98 mmol/L, arterial pH 7.29, bicarbonate 14 mEq/L, pCO2 30 mm Hg, BUN 22 mg/dl.\n",
      "Answer: It is not possible to determine the preferred resuscitative ﬂuid based on recent studies, as there are multiple options and the choice depends on individual patient factors and the specific situation. It is important to consult with a healthcare provider for the best decision.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5510 is A. Check urine sodium and risk-stratify for risk of contrast-induced-AKI. \n",
      "\n",
      "Answer: A. Check urine sodium and risk-stratify for risk of contrast-induced-AKI. \n",
      "\n",
      "Justification: AKI is a life-threatening condition that can occur after the use of contrast media in patients with pre-existing kidney injury. The risk of developing AKI is higher in patients with pre-existing kidney disease, high blood pressure, and diabetes. Therefore, it is important to risk-stratify patients before performing contrast-inducing procedures. In this case, the patient has diabetes, hypertension, and peripheral artery disease, which increases her risk of developing AKI. By checking her urine sodium levels and risk-stratifying her before the procedure, the cardiologist can take appropriate measures to reduce the risk of AKI. Giving D5 with 150-mEq sodium bicarbonate before cardiac catheterization may also help to counteract the contrast media and reduce the risk of AKI.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5511 is The strategy suggested by the PrevAKI randomized controlled trial to prevent AKI in this setting and be cost effective is: A. Work with Information Technology on developing E-alerts for surgeons alerting them to patients at high risk of AKI.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5512 is \n",
      "\n",
      "A. AKI after transcatheter aortic valve replacement is rare, occurring in <10% of patients. This statement is incorrect. AKI is a common complication of transcatheter aortic valve replacement and can occur in up to 25% of patients.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5513 is \n",
      "A. Using a serum creatinine criterion is more sensitive than urine output criterion in the diagnosis of AKI in cardio-genic shock.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5514 is A. The urinary test (TIMP-2)•(IGFBP7) can be applied in patients undergoing cardiopulmonary bypass as a screening tool to select those at high risk for AKI who might beneﬁt from an AKI bundle; this strategy has been demonstrated to reduce the prevalence of severe AKI.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5515 is A. Furosemide dose should not exceed 300 mg in 24 hours.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5516 is (A) Serum creatinine <1.5 mg/dl, (B) Treated bacterial sepsis, (C) Untreated spontaneous bacterial peritonitis with septic shock, (D) Fractional urinary sodium excretion <1%, or (E) No improvement in serum creatinine after ascitic drainage.\n",
      "\n",
      "Answer: (A) Serum creatinine <1.5 mg/dl. \n",
      "\n",
      "This answer is not specific to the given patient, but liver disease and ascites are known to cause changes in creatinine levels. A creatinine level of 1.4 mg/dl is consistent with the diagnosis of hepatorenal syndrome. The other answer choices are not specific to the given patient and do not exclude the diagnosis of hepatorenal syndrome.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5517 is \n",
      "The correct answer is A. Plasma angiotensin concentrations are increased. \n",
      "\n",
      "Explanation: The hepatorenal syndrome is a complex condition that involves a variety of factors, including abnormalities in blood flow, inflammation, and list of the five statements about the pathogenesis of the hepatorenal syndrome is not clearly defined. However, studies have suggested that abnormalities in blood flow, particularly reduced portal blood flow, may contribute to the development of the hepatorenal syndrome. Plasma angiotensin concentrations may be increased in this patient population, which can contribute to further damage to the liver and other organs. Plasma vasopressin concentrations may also be increased in some patients with the hepatorenal syndrome, which can contribute to portal hypotension and further complications.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5518 is A, B, C, D, E.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5519 is \n",
      "A. Continuous renal replacement therapy.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5520 is \n",
      "\n",
      "Answer: The most appropriate initial treatment for a patient with dialysis-dependent light chain crystalline cast nephropathy is peritoneal dialysis. Peritoneal dialysis is a suitable modality for the treatment of AKI complicated by light chain crystalline cast nephropathy. It is important to start with a low-protein diet and avoid taking any kind of medication that may cause proteinuria. The patient should also be monitored closely for any signs of AKI or other complications.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5521 is A, B, C, D, or E.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5522 is A. There are current indications to commence KRT immediately.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5523 is A. Continuous kidney replacement therapy (CKRT) (24 hours/day) or B. Intermittent hemodialysis (IHD) (4 hours x 3 days/week) or C. Prolonged intermittent kidney replacement therapy (PIKRT) (8 hours/day) or D. Peritoneal dialysis (commencing on short cycle times of 1–2 hours)\n",
      "\n",
      "Answer: Based on the most recent 2019 Kidney Disease Improving Global Outcomes “Controversies in AKI” Conference Report suggestions, the best option for KRT initiation for this man would be A. Continuous kidney replacement therapy (CKRT) (24 hours/day). This is because CKRT is recommended as the standard of care for AKI patients who require dialysis or kidney transplantation. IHD and PIKRT are not recommended as they are not as effective as CKRT in improving outcomes for AKI patients. Peritoneal dialysis is not recommended for AKI patients who require dialysis or kidney transplantation.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5524 is A,B,C, or D.\n",
      "\n",
      "Answer: The best anticoagulation strategy in this patient during KRT is not determined by the initial laboratory testing or the result of urinalysis. The best anticoagulation strategy depends on the individual patient's unique medical history, the specific type of KRT being performed, and the risk of the procedure. Therefore, the best answer cannot be determined.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5525 is \n",
      "A. Risk of AKI peaks within 24 hours after admission to the emergency department.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5526 is A, B, C, or D. \n",
      "\n",
      "Answer: A. Intermittent hemodialysis has been associated with worse renal outcome compared with continuous techniques.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5527 is A, B, C, or D.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5528 is A. AKI or B. Diabetes or C. Hypertension or D. Proteinuria\n",
      "\n",
      "Answer: A. AKI has the greatest effect on mortality. According to the information provided, the patient has stage 3 CKD, which is associated with high blood pressure and proteinuria. However, there is no information on the effect of AKI on mortality in this setting. Therefore, AKI is the most likely answer.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5529 is \n",
      "\n",
      "A. 10% to 15%\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5530 is \n",
      "A. Cisplatin nephrotoxicity: The patient has received three cycles of cisplatin 75 mg/m2, pemetrexed 500 mg/m2, and the checkpoint inhibitor nivolumab 10 mg followed by one cycle of nivolumab alone. The patient presented for her ﬁfth cycle of nivolumab when she was noted to have elevated serum creatinine. Cisplatin and cisplatin-based regimens have been shown to cause nephrotoxicity, which is a risk factor for AKI. Therefore, cisplatin nephrotoxicity is the most likely cause of AKI in this patient.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5531 is \n",
      "A. Kidney biopsy to rule out bevacizumab toxicity\n",
      "B. Stop denosumab\n",
      "C. Obtain cystatin C level, continue abemaciclib, and repeat laboratory studies in 1 week\n",
      "D. Stop abemaciclib\n",
      "\n",
      "Answer: Based on the information provided, the next step in the treatment of this patient may be a kidney biopsy to rule out bevacizumab toxicity.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5532 is A. Membranous nephropathy secondary to kidney GVHD.\n",
      "Explanation: The most likely cause of the patient's nephrotic syndrome is membranous nephropathy secondary to kidney GVHD. This is supported by the patient's age, medical history, and the presence of edema. Membranous nephropathy is a rare and idiopathic condition that can occur after kidney transplantation or as a postsurgical complication. It is characterized by the presence of immune complex deposits in the kidneys, which can cause damage to the kidneys and lead to proteinuria. The other options are less likely to explain the patient's symptoms. Transplantation-associated thrombotic microangiopathy is a condition that occurs after solid organ transplantation and is not mentioned in the patient's history or symptoms. Sinusoidal obstruction syndrome is a rare and life-threatening condition that occurs after solid organ transplantation and is not mentioned in the patient's history or symptoms. Sulfamethoxazole-trimethoprim is a medication used in the treatment of bacterial infections and is not related to the patient's symptoms.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5533 is \n",
      "\n",
      "A. Pigmented granular casts. \n",
      "\n",
      "Explanation: The patient has a history of non-Hodgkin B cell lymphoma and received CAR T therapy, which can cause immune system hyperactivity, leading to an increase in creatinine and muscle aches. On physical examination, he is mildly confused and agitated, with mild basilar rales. Therefore, it is most likely that the urine sediment will show pigmented granular casts.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5564 is \n",
      "\n",
      "A. Increase in the proportion of Blacks meeting criteria for a diagnosis of CKD\n",
      "B. Increase in the proportion of Blacks meeting GFR based eligibility for living kidney donation\n",
      "C. Increase in the proportion of Blacks eligible for specific medications (e.g., metformin, SGLT2 inhibitors)\n",
      "D. Decrease in the prevalence of CKD stages 4 and 5 among Blacks.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5565 is A. Lower eGFR predicts ESKD and mortality among individuals with CKD, but not in the general population.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5566 is A. Results differed signiﬁcantly in studies using total protein excretion rather than albumin excretion.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5567 is \n",
      "\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5568 is A. Atrasentan 0.75 mg/d or B. Dapagliﬂozin 10 mg/d.\n",
      "\n",
      "Answer: A. Atrasentan 0.75 mg/d is supported by current evidence as a novel Kidney Health Project that aims to slow the progression of CKD and delay the need for dialysis. It is a phase 2 study that involves a combination of atrasentan and an angiotensin-receptor blocker. The study is ongoing, but results have shown promising signs of reducing the risk of ESKD in participants with stage G3A3 IgA nephropathy.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5569 is A or B.\n",
      "\n",
      "Answer: A. Allopurinol has no effect on uric acid lowering and no effect on CKD progression.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5570 is A. Combining SGLT2i and GLP1RA improves glyce-mic control.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5571 is A. Fragmented and less sleep duration, B. Higher dietary animal protein intake, C. High urine NGAL levels, D. Use of allopurinol in patients with normal uric acid, E. Increased intake of fruits and vegetables.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5572 is A. History of CKD. \n",
      "\n",
      "Guidelines: The answer should be based on a multivariate analysis of the patient's medical history and other relevant factors.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5573 is A. Volume overload. \n",
      "\n",
      "The man has severe peripheral vascular disease and is status post right-sided below-the-knee amputation, which suggests that he has a high risk of experiencing a volume overload. Additionally, his age and medical history increase his risk of developing heart disease and further increasing his volume load. Therefore, the adverse event that he is MOST LIKELY to experience as a result of SGLT2 inhibitor use is a volume overload.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5574 is A. 5%–15% or B. 35%–55% or C. 65%–85% or D. 90%–100%\n",
      "\n",
      "Answer: A. 5%–15%\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5575 is A. < 10% or B. 20%–30% or C. 40%–50% or D. 60%–70%.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5576 is A. CKD G3aA3, B. CKD G3bA1, C. CKD G3bA2, or D. CKD G4A1.\n",
      "\n",
      "Answer: A. CKD G3aA3 is not considered very high risk for CKD progression.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5577 is A. Prevalence would increase among White adults and decrease among Black adults.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5578 is A. 4-variable kidney failure risk equation\n",
      "\n",
      "Answer: The 4-variable kidney failure risk equation would be appropriate to use in a population with GFR > 60 ml/min per 1.73 m2. This equation is designed to screen patients with normal GFR but at risk of developing kidney disease. The equation takes into account age, sex, race, and a Creatinine-based kidney function estimate (eGFR). The creatinine-based kidney function estimate is calculated by dividing the patient's creatinine by the patient's age and sex-specific creatinine. The creatinine-based kidney function estimate is then converted to a glomerular filtration rate (GFR) using the following formula: GFR = 173.16 x creatinine-based kidney function estimate (eGFR). The 4-variable kidney failure risk equation has been shown to accurately predict the risk of kidney failure in patients with normal GFR.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5579 is None of the above features were associated with risk of CKD progression in the Boston Kidney Biopsy Cohort.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5580 is \n",
      "\n",
      "A. Cationic ferritin-enhanced (CFE)-magnetic resonance imaging (MRI): glomerular number\n",
      "B. Point-of-care ultrasonography (POCUS): inﬂammation\n",
      "C. Diffusion-weighted MRI: ﬁbrosis\n",
      "D. Blood oxygenation level–dependent (BOLD) MRI: cortical tissue hypoxia\n",
      "\n",
      "Answer: D. Blood oxygenation level–dependent (BOLD) MRI: cortical tissue hypoxia is an incorrect pairing of imaging modality and detectable morphology or functional assessment. While BOLD MRI is a functional assessment of brain activity, it is not used for the evaluation of kidney disease. The other options are all imaging modalities used in the evaluation of kidney disease.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5581 is \n",
      "\n",
      "A. Sema 3B. \n",
      "\n",
      "Sema 3B is not an autoantigen in primary membranous nephropathy. It is a cell surface protein found on the platelet-endothelial cell adhesion protein (P-selectin) on the surface of platelets. It plays a role in the platelet-endothelial cell interaction and is not involved in the pathology of primary membranous nephropathy. Therefore, the correct answer is A. Sema 3B.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5582 is \n",
      "\n",
      "\n",
      "A. Congenital or cystic kidney disease.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5583 is A. COL4A\n",
      "\n",
      "Answer: A. COL4A is the most common genetic finding in populations with FSGS.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5584 is A, C, or D.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5585 is A. A study comparing new users of dihydropyridine calcium channel blockers (DHP-CCB) versus RAS inhibitors in subjects with CKD G4–5 not on dialysis, there was a signiﬁcantly lower risk of major adverse cardiovascular event and mortality in patients taking DHP-CCB.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5586 is A or B.\n",
      "\n",
      "Answer: A. SGLT2 inhibitors should not be initiated at GFR < 35 ml/min per 1.73 m2. This statement is supported by the DAPA-CKD trial, which found that SGLT2 inhibitors were not safe or effective in patients with GFR < 35 ml/min per 1.73 m2.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5587 is A. SGLT2 inhibitors have not been shown to be safe or effective in patients with glomerular disease such as IgA nephropathy.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5588 is A.HIF-PHIs lead to increase in ferritin and hepcidin.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5589 is A or C.\n",
      "\n",
      "Answer: A. Finerenone is less potent in blocking MR cofactor binding as compared to agents such as spironolactone.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5590 is A. The statement is true. A recent meta-analysis found that lower dietary potassium intake was associated with signiﬁcantly decreased odds of CKD.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5591 is A. Sodium Zirconium Cyclosilicate (ZS-9/SZC) is a non-absorbed highly selective inorganic cation, which binds K+ throughout the gastrointestinal tract in exchange for Ca2+.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5592 is A. In a study of CKD patients followed for > 6 months, treatment with veverimer was associated with improvements in objective measurements of physical function.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5593 is A. A 34-year-old woman with a history of diabetes and CKD G3 A2 comes to clinic for review. She is currently taking lisinopril 40 mg daily, chlorthalidone 50 mg daily, and amlodipine 10 mg daily. She checks her BP at home twice weekly and brings readings ranging from 126/84 to 142/88 mm Hg. Her clinic reading today is 138/90 mm Hg. You express concern that her BP is above goal and begin to discuss escalation of her medications. She is reluctant, saying “I had a coffee this morning, and I’m always racing to get here on time”\n",
      "\n",
      "Answer: A. The current guidelines state that BP readings taken in the home or in a clinical setting should be used to guide treatment.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5594 is \n",
      "\n",
      "A) Perform a kidney allograft biopsy\n",
      "B) Assess for donor-derived cell-free DNA\n",
      "C) Calculate eplet mismatch score\n",
      "D) Increase tacrolimus\n",
      "\n",
      "Answer: The most appropriate management choice is A) Perform a kidney allograft biopsy. The presence of a donor-specific antibodies with a high intensity suggests that the patient's immune system may be attacking the allograft. A kidney allograft biopsy would be necessary to determine the cause of the patient's increased creatinine levels and to rule out acute rejection.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5595 is \n",
      "\n",
      "Answer: There is no single most appropriate management for this patient based on the information provided. The management should depend on the specific context of the patient's symptoms and the results of the laboratory studies. Therefore, the best course of action would be to consult with the patient's transplantation team and make a decision based on their recommendations.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5596 is a) '1. Assess for non-HLA antibodies' b) '2. Assess for cytomegalovirus viremia' c) '3. Assess for C-reactive protein' d) '4. Assess for donor-derived cell-free DNA'\n",
      "A) The most appropriate option for the allograft protocol biopsy would be \"1. Assess for non-HLA antibodies\" because it is the most straightforward and safe option. The patient has a negative donor-speciﬁc antibody screen and no symptoms, so the risk of a rejection episode is low. The biopsy would only be necessary if there are any signs of rejection or other complications. Therefore, it is better to avoid the procedure and instead monitor the patient closely.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5597 is (A) 1. Assess for donor-speciﬁc antibodies, (B) 2. Assess for tacrolimus trough level, (C) 3. Assess for mycophenolate mofetil area under curve, or (D) 4. Assess for urinary chemokines.\n",
      "Answer: The most appropriate evaluation to determine the patient's response to treatment in combination with creatinine and proteinuria would be to assess for donor-speciﬁc antibodies. This would provide information on the presence and severity of humoral rejection, which is an important factor in the patient's response to treatment. Tacrolimus trough level and mycophenolate mofetil area under curve are not related to the patient's proteinuria and creatinine levels, and are not appropriate measures to evaluate treatment response. Urinary chemokines may be useful in evaluating the patient's immune status, but they are not directly related to the patient's proteinuria and creatinine levels and are not appropriate for this purpose.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5598 is The correct answer is '2. In an analysis by the Southeast Kidney Consortium, Black and non-Hispanic patients had similar rates of initiation of transplantation evaluation after transplantation referral as other groups'. This is because the analysis evaluated the referral rate for transplantation in Black and non-Hispanic patients and found that it was similar to other groups, which suggests that race or ethnicity may not be a factor that affects access to renal transplantation.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5599 is A. The Black race coefﬁcient from GFR estimating equations has been predicted to decrease the time to reach an eGFR of < 20 ml/min per 1.73 m2 by around 6 to 9 months.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5600 is A, B, C, or D.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5601 is Answer: There is interstitial inﬂammation involving > 25% of the sclerotic parenchyma and > 25% of the total cortical parenchyma with moderate tubulitis on the Banff classification scale. Therefore, the woman's rejection should be classified as a \"3. Grade 1A chronic active T cell-mediated rejection\" on the Banff classification scale.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5602 is \n",
      "The answer is: \n",
      "Based on long-term follow-up studies, statement 2 is TRUE. Studies of surveillance biopsies performed on transplants have shown that alloimmune injury is most commonly due to allograft failure.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5603 is \n",
      "A) It would be helpful to ﬁrst look at the matching at the DQ locus; if he is not matched at DQ, eplet matching may be of beneﬁt.\n",
      "I would choose this answer because it is the most accurate and comprehensive statement. While eplet matching may not have a role in this scenario, it is still important to determine if the patient is matched at the DQ locus. If he is not matched, eplet matching may be beneficial. Therefore, it is important to consider all aspects of the patient's situation and provide personalized guidance.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5604 is \n",
      "A) Patients were withdrawn from the initial pilot study with clazakizumab because of complications from diverticular disease.\n",
      "B) IL-6 inhibitors have been shown to improve long-term allograft survival in randomized controlled trials.\n",
      "C) Preliminary studies have shown that IL-6 inhibitors are associated with stabilization of eGFR.\n",
      "D) IL-6 receptor antagonists are associated with increased systemic IL-6, which can lead to rapid deterioration of allograft function after they are stopped.\n",
      "\n",
      "Answer: A) Patients were withdrawn from the initial pilot study with clazakizumab because of complications from diverticular disease. This statement is incorrect because clazakizumab is not an IL-6 antagonist, but rather an anti-IL-6 monoclonal antibody that has been used in a phase 2 study for the treatment of rejection. The study was stopped due to diverticular disease complications, but it is not believed that clazakizumab caused these complications.\n",
      "\n",
      "B) IL-6 inhibitors have been shown to improve long-term allograft survival in randomized controlled trials. This statement is generally correct. Randomized controlled trials have shown that IL-6 inhibitors can improve long-term allograft survival.\n",
      "\n",
      "C) Preliminary studies have shown that IL-6 inhibitors are associated with stabilization of eGFR. This statement is generally correct. Preliminary studies have shown that IL-6 inhibitors can improve eGFR by reducing inflammation and improving blood flow to the kidney.\n",
      "\n",
      "D) IL-6 receptor antagonists are associated with increased systemic IL-6, which can lead to rapid deterioration of allograft function after they are stopped. This statement is generally incorrect. While some studies have shown that IL-6 receptor antagonists can reduce systemic IL-6 levels, it is important to note that these antagonists are not as effective as IL-6 inhibitors in reducing inflammation and improving allograft function. In fact, some studies have shown that IL-6 receptor antagonists can actually lead to increased rates of acute T cell-mediated rejection.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5605 is A) Uncontrolled hypertension with concern for pulmonary hypertension, given her 30 pounds of weight gain.\n",
      "\n",
      "The most likely factor to affect this patient's long-term survival is uncontrolled hypertension with concern for pulmonary hypertension. This is because the patient has gained 30 pounds and there is a concern for increased blood pressure and possible pulmonary hypertension. The patient's medical history and current symptoms also suggest that she may be at risk for dehydration, which is a common complication of high blood pressure and can further exacerbate the effects of altitude changes. Therefore, the patient should be closely monitored for signs of dehydration and any complications of high blood pressure.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5606 is \n",
      "\n",
      "Answer: The most appropriate counseling for this patient is: \"Patient does require a second transplant but can-not be listed until his eGFR is < 15 ml/min or he requires dialysis.\" This is because the patient has a declining kidney function and a history of antibody-mediated rejection, which makes him a good candidate for a second transplant. However, he cannot be listed for a second transplant at this time due to his current eGFR of 18-20 ml/min. The patient's current medications are appropriate for his condition, and he does not describe uremic symptoms. The option of a short course of dialysis to prove his adherence to medical therapy could be considered if his eGFR continues to decline rapidly. The patient's girlfriend is also a potential living donor, and the decision to proceed with the living donation should be made by the patient and his transplantation nephrologist after appropriate evaluation.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5607 is \n",
      "\n",
      "A) Checkpoint inhibitors are not associated with immune-related manifestations of colitis, thyroiditis, and rash. \n",
      "\n",
      "B) A renal biopsy will distinguish acute interstitial nephritis caused by anti-PD-1 agent from transplant rejection. \n",
      "\n",
      "C) Acute rejection rates are roughly 40% to 50% and occur within 3 weeks of treatment initiation. \n",
      "\n",
      "D) His allograft dysfunction is most likely related to volume depletion and prerenal AKI. \n",
      "\n",
      "Answer: A) Checkpoint inhibitors are not associated with immune-related manifestations of colitis, thyroiditis, and rash.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5608 is \n",
      "A) A 24-hour ambulatory BP monitoring to decide whether or not she has hypertension.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5609 is C\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5610 is \n",
      "As an AI language model, I cannot make a subjective decision based on individual patient characteristics and medical history. However, based on the information provided, a 24-hour urine creatinine collection to further assess her GFR could be appropriate in this situation.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5611 is \n",
      "\n",
      "Answer: \n",
      "\n",
      "Based on the provided information, the next best step in her evaluation would be to perform a CT scan of her brain to rule out any intracranial abnormalities that may be contributing to her weight. This would help to determine if there is any structural damage to her brain that may be causing her obesity. Additionally, a CT scan of her abdomen may also be performed to rule out any abnormalities in her organs of unknown cause.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5612 is \n",
      "Answer: \n",
      "Based on the information provided, the best next step would be to perform a 24-hour urine stone proﬁle to determine if the presence of nephrolithiasis is due to increased risk of future ESKD after donation. If the stone proﬁle is normal, it would be safe to proceed with the kidney donation. However, if the stone proﬁle is abnormal, it may be recommended to perform a kidney stoneectomy to remove existing stones or to perform a kidney biopsy to determine the underlying cause of the stones. It is important to consider the potential risks and benefits of the donation process, and to ensure that the patient's health is prioritized.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5613 is A statement that best addresses the patient's situation and the available options.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5614 is \n",
      "\n",
      "A) Acceptable donor, proceed with transplantation\n",
      "B) Decline the offer because of donor’s history of ﬂu-like symptoms 4 weeks before his death\n",
      "C) Decline the offer because of high cPRA\n",
      "D) Decline the offer until COVID pandemic resolves\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5615 is \n",
      "\n",
      "A) Consideration of reduction in immunosuppression.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5616 is Oxygen requirement is not associated with increased risk of mortality in transplant recipients with COVID-19.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5617 is A) High-dose mycophenolate mofetil may impair the development of an antibody response to vaccination B) Her age is a risk factor for not mounting an anti-body response C) Being a transplantation patient decreases her response to vaccination D) After a third dose of mRNA vaccine, 25% to 70%of transplant recipients experience antispike SARS-CoV-2 IgG E) Her induction treatment with antithymocyte globulin does not decrease her response to vaccination.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5618 is \n",
      "The answer is 1. Failure to complete full dialysis treatments for nonmedical reasons.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5619 is \n",
      "\n",
      "Answer: There is no single correct answer for this question as it is a complex decision-making process based on individual patient characteristics, medical history, and personal preferences. The decision of whether or not to pursue kidney transplantation should be made after careful evaluation of the patient's medical history, age, and other factors. It is important to consider the patient's quality of life, the risk of the procedure, and the potential benefits of transplantation. It may also be helpful to involve the patient in the decision-making process and provide him with information about the risks and benefits of transplantation. Ultimately, the decision to pursue kidney transplantation should be made in collaboration with the patient, his family, and his healthcare providers.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5620 is \n",
      "\n",
      "Answer: The answer is '3. Treatment with stem cell transplantation'. The patient has been treated with stem cell transplantation and has achieved complete remission. Stem cell transplantation is a potentially curative treatment for patients with AL amyloidosis. It involves replacing the abnormal protein with healthy cells from a donor. In this case, the patient has received healthy cells from a donor, which has resulted in complete remission. The other options are not directly associated with the best kidney transplant survival in this patient.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5621 is \n",
      "\n",
      "Answer: Based on the patient's history and comorbidities, the best approach at this time would be to continue his dietary efforts and return for transplantation evaluation after his BMI is below 40. It is important to avoid starting any new treatments or operations that may increase his risk of developing complications related to his ESKD.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5622 is A) Kidneys from hepatitis C–positive donors have been shown to have lower graft survival.B) He is not a candidate for hepatitis C–positive donor kidney, given his hepatitis C–negative status.C) He is a candidate only for kidney from a donor with positive hepatitis C serology but negative hepatitis C NAT.D) Kidneys from hepatitis C–positive donors have not been shown to have lower graft survival.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5623 is \n",
      "\n",
      "The answer is: \n",
      "A study has shown that the best kidney survival is achieved with living donor kidney transplantation. The study found that the survival rate of patients who received living donor kidney transplantation was 83%, while the survival rate of patients who received deceased donor kidney transplantation was 60%. The study also found that patients who received deceased donor kidney transplantation followed by a pancreas after kidney transplantation had a lower survival rate compared to patients who received living donor kidney transplantation. Therefore, the best kidney survival option is living donor kidney transplantation.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5624 is \n",
      "\n",
      "A) 10%-20% - The answer is 10%-20%. \n",
      "\n",
      "B) 25%-35% - The answer is 25%-35%. \n",
      "\n",
      "C) 45%-55% - The answer is 45%-55%. \n",
      "\n",
      "D) 60%-70% - The answer is 60%-70%. \n",
      "\n",
      "Therefore, the prevalence of hypertension in the adult world population is either 10%-20%, 25%-35%, 45%-55%, or 60%-70%.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5625 is one of the following is TRUE with regard to current epidemiological trends in hypertension.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5626 is \n",
      "Answer: The US Preventive Services Task Force recommends the following approach to hypertension screening in the general population: \n",
      "1. Initial testing with ambulatory BP monitoring. \n",
      "\n",
      "It is important to note that the US Preventive Services Task Force does not recommend out-of-ofﬁce measurement or care ofﬁce measurement with return for repeated measurements if BP is elevated, as these methods may be less accurate and may lead to overestimation of blood pressure.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5627 is \n",
      "\n",
      "A. Hypertension treatment and control rates improved for all racial and ethnic groups.\n",
      "B. Black patients had lower control rates owing to lower intensity of treatment by their providers.\n",
      "C. Black patients had the lowest hypertension control rates.\n",
      "D. Differences in hypertension control were caused by economic disparities across racial and ethnic groups. \n",
      "\n",
      "Answer: A. Hypertension treatment and control rates improved for all racial and ethnic groups.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5628 is \n",
      "\n",
      "The statement is accurate regarding treatment of hypertension in patients aged 80 years and older in SPRINT. The trial did not include patients over 80 years old, so we cannot apply the results to this age group. However, it is important to note that the results of the SPRINT trial cannot be applied to all patients over 80 years old, as the study was not powered to detect differences in this age group. Additionally, further post-hoc analysis may be needed to determine if there is potential harm from intensive treatment of this subgroup.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5629 is A) The statement is accurate.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5630 is \n",
      "A) 2017 ACC/AHA blood pressure guideline\n",
      "B) 2018 ESC/ESH hypertension guideline\n",
      "C) 2021 WHO hypertension guideline\n",
      "D) 2022 ADA Standards of medical care in diabetes\n",
      "E) 2021 KDIGO hypertension guideline\n",
      "\n",
      "Answer: D) 2022 ADA Standards of medical care in diabetes.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5631 is \n",
      "\n",
      "Answer: The most likely mechanism for hypertension induced by vascular endothelial growth factor (VEGF) inhibitors is '1. Increased vascular resistance via impaired angiogenesis'. This is because VEGF inhibitors are known to cause a decrease in blood vessels, leading to reduced blood flow and an increased resistance to blood flow. This can cause hypertension by improving the resistance of blood vessels to blood flow.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5632 is none of the above.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5633 is \n",
      "\n",
      "A) Altered gut microbiota\n",
      "B) Impaired prorenin receptor binding in the collecting duct\n",
      "\n",
      "Answer: \n",
      "A) Altered gut microbiota is associated with a high-salt diet. The gut microbiota plays a crucial role in maintaining gut health and preventing diseases. Salt consumption can alter the composition of the gut microbiota, leading to an increased risk of developing hypertension. Impairs prorenin receptor binding in the collecting duct are not associated with a high-salt diet.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5634 is A or B.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5635 is \n",
      "\n",
      "A) Continue current medications\n",
      "B) Switch to losartan 100 mg daily\n",
      "C) Switch to amlodipine 10 mg daily\n",
      "D) Stop lisinopril because upregulation of ACE2 by lisinopril will exacerbate Covid-19 symptoms\n",
      "\n",
      "Answer: A) Continue current medications. It is currently unclear whether the patient's respiratory distress is caused by Covid-19 or other factors. Switching to a new medication without proper evaluation and monitoring may lead to worse outcomes. While the patient has been exposed to Covid-19, the medical team needs to consider the patient's individual health history, current medications, and other factors before making a decision. Additionally, the patient's family is not a medical professional and their concerns should be addressed by the medical team.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5636 is A) He should take all his BP medications at night because this will reduce the risk of CVD by 50%.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5637 is A, B, C, D, or E.\n",
      "\n",
      "Answer: A, B, C, D, E. \n",
      "\n",
      "Explanation: \n",
      "\n",
      "A, B, C, D, and E are all accurate regarding weight loss for the patient. \n",
      "\n",
      "A) Physical activity and exercise training reduce obesity, and a 2%–3% reduction in weight will lower BP, but reductions of at least 5%–10% are desired within 6 months to yield improvements in the major CVD risk factors. This statement is accurate as physical activity and exercise training can help the patient lose weight and lower blood pressure. \n",
      "\n",
      "B) Once weight loss is achieved it is usually easy to maintain. This statement is generally accurate, but it is not always easy for everyone to maintain weight loss. \n",
      "\n",
      "C) A 5%–10% reduction in weight is associated with 10 mm Hg reduction in systolic BP (SBP). This statement is generally accurate, but it is not always possible to achieve this level of weight loss. \n",
      "\n",
      "D) Weight loss in the ﬁrst 2 months of pharmacologic therapy is predictive of changes noted at 1 year. This statement is generally accurate, but it is not always possible to predict the time it will take for weight loss to occur with pharmacologic therapy. \n",
      "\n",
      "E) Medications including orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide, and semiglutide are ineffective for weight loss. This statement is generally accurate, although some individuals may experience weight loss with certain medications. However, it is not a comprehensive statement for all medications.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5638 is \n",
      "\n",
      "A) Younger age, macroalbuminuria, and preexisting CKD are associated with failure to achieve intensive SBP target.\n",
      "B) Baseline SBP >140 mm Hg, greater number of antihypertensive medications, and macroalbuminuria are associated with failure to achieve intensive SBP target.\n",
      "C) Macroalbuminuria and preexisting CKD are associated with failure to achieve intensive SBP target, but younger age and greater number of antihypertensive medications are not.\n",
      "D) Younger age, macroalbuminuria, and preexisting CKD are not associated with failure to achieve intensive SBP target.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5639 is \n",
      "A) The most effective approach is to use TM based on telemonitoring of BP and tracking of additional vital and nonvital signs with data exchange between patients and a case manager through the web, emails, text messaging, or video consultation, integrated with education on lifestyle, risk factors, and proper use of antihypertensive medications.\n",
      "B) TM is not accredited for the treatment of patients with hypertension.\n",
      "C) Use of TM for treatment of patients with hypertension should be limited to those with well-controlled hypertension.\n",
      "D) Use of TM for treatment of patients with hypertension should be limited to those on less than 3 medications. \n",
      "\n",
      "Answer: A) The most effective approach is to use TM based on telemonitoring of BP and tracking of additional vital and nonvital signs with data exchange between patients and a case manager through the web, emails, text messaging, or video consultation, integrated with education on lifestyle, risk factors, and proper use of antihypertensive medications.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5640 is A recent study of physician perspectives showed high level of implementation of home blood pressure monitoring in routine care.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5641 is \n",
      "\n",
      "Answer: The most appropriate next step in management would be to switch to triple combination therapy to improve BP control and compliance. This would include increasing the dose of amlodipine to 5 mg daily and continuing the current medications. Losartan and hydrochlorothiazide can be tapered if necessary to maintain the patient's blood pressure goals. Additionally, lifestyle modifications such as diet and exercise can also be implemented to further improve the patient's health.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5642 is \n",
      "\n",
      "A. 1. Resistant hypertension\n",
      "B. 2. Pseudoresistant hypertension\n",
      "C. 3. Refractory hypertension\n",
      "D. 4. Secondary hypertension\n",
      "\n",
      "Answer: A. 1. Resistant hypertension. This patient's condition is an example of resistant hypertension, which is characterized by persistent and untreated hypertension despite the use of maximal doses of antihypertensive medication.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5643 is \n",
      "A) Ask the patient to maintain a daily log of home blood pressure readings.\n",
      "B) Repeat the resting blood pressure 10 minutes later while the patient is left unattended.\n",
      "C) Calibrate the home blood pressure cuff against the office blood pressure cuff.\n",
      "D) Arrange for a 24-hour ambulatory blood pressure monitor.\n",
      "\n",
      "Answer: As an AI language model, I would choose A) Ask the patient to maintain a daily log of home blood pressure readings. This is because the patient's statement suggests that their home blood pressure readings are better than their ofﬁce blood pressure readings. Therefore, it is possible that the white-coat effect may be contributing to the discrepancy in blood pressure readings. By asking the patient to maintain a daily log of their blood pressure readings, the healthcare provider can better understand the relationship between the patient's home and ofﬁce blood pressure readings and identify any potential causes of white-coat syndrome.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5644 is \n",
      "This patient's symptoms are consistent with primary aldosteronism. The confirmatory testing via oral sodium loading conﬁrms the diagnosis. The CT scan of the adrenal gland shows a left adrenal nodule. However, given the patient's age and the fact that she does not have any symptoms related to hyperaldosteronism, it may be best to proceed with a lifelong spironolactone and monitor her closely for any symptoms. Therefore, the best next step in the treatment of this patient is to order an adrenal MRI.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5645 is \n",
      "\n",
      "Answer: \n",
      "Given the finding of a 75% stenosis of the right proximal renal artery, a more detailed evaluation of the patient's medical condition is necessary. A CT angiography can provide information about the degree of narrowing in the arteries, but it does not determine the cause of the narrowing. Renal artery angioplasty and stent placement may be necessary to improve blood flow to the patient's kidneys. However, it is important to consult with a cardiologist and/or a nephrologist to determine the most appropriate course of action.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5646 is \n",
      "\n",
      "The best next step to evaluate for pheochromocytoma/paraganglioma in this patient would be CT scan of the adrenal glands. This is because the elevated BP and symptoms such as headache, palpitations, and diaphoresis could be indicative of an adrenal tumor, which can be confirmed by a CT scan. MIBG scintigraphy and clonidine suppression testing are not directly related to an adrenal tumor and may not provide accurate results in this patient.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5647 is \n",
      "\n",
      "A. Loop diuretics are effectiveness at lowering BP and reducing ﬂuid overload in advanced CKD. \n",
      "\n",
      "B. Thiazide diuretics are effective in patients with eGFR < 30 ml/min per 1.73 m2. \n",
      "\n",
      "C. Potassium-sparing diuretics should be used only with caution. \n",
      "\n",
      "D. Close monitoring of serum electrolytes and kidney function should be performed after starting or adjusting the dose of diuretics. \n",
      "\n",
      "Answer: Loop diuretics are effectiveness at lowering BP and reducing ﬂuid overload in advanced CKD. Loop diuretics are effective at relaxing the blood vessels and promoting the excretion of salts and other waste products. By reducing ﬂuid overload, they can help to lower blood pressure and improve the patient's overall health. Loop diuretics are also safe and effective at treating mild to moderate high blood pressure. Loop diuretics are not effective in patients with eGFR < 30 ml/min per 1.73 m2. Therefore, the correct answer is B. Loop diuretics are effective at lowering BP and reducing ﬂuid overload in advanced CKD. Loop diuretics are also safe and effective at treating mild to moderate high blood pressure. Loop diuretics are not effective in patients with eGFR < 30 ml/min per 1.73 m2. Loop diuretics are not effective in patients with eGFR < 30 ml/min per 1.73 m2. Loop diuretics are effective at relaxing the blood vessels and promoting the excretion of salts and other waste products. Loop diuretics are effective at reducing ﬂuid overload, which can help to lower blood pressure. Loop diuretics are also safe and effective at treating mild to moderate high blood pressure. Loop diuretics are not effective in patients with eGFR < 30 ml/min per 1.73 m2. Loop diuretics are effective at relaxing the blood vessels and promoting the excretion of salts and other waste products. Loop diuretics are effective at reducing ﬂuid overload, which can help to lower blood pressure. Loop diuretics are also safe and effective at treating mild to moderate high blood pressure. Loop diuretics are not effective in patients with eGFR < 30 ml/min per 1.73 m2. Loop diuretics are effective at relaxing the blood vessels and promoting the excretion of salts and other waste products. Loop diuretics are effective at reducing ﬂuid overload, which can help to lower blood pressure. Loop diuretics are also safe and effective at treating mild to moderate high blood pressure. Loop diuretics are not effective in patients with eGFR < 30 ml/min per 1.73 m2. Loop diuretics are effective at relaxing the blood vessels and promoting the excretion of salts and other waste products. Loop diuretics are effective at reducing ﬂuid overload, which can help to lower blood pressure. Loop diuretics are also safe and effective at treating mild to moderate high blood pressure. Loop diuretics are not effective in patients with eGFR < 30 ml/min per 1.73 m2. Loop diuretics are effective at relaxing the blood vessels and promoting the excretion of salts and other waste products. Loop diuretics are effective at reducing ﬂuid overload, which can help to lower blood pressure. Loop diuretics are also safe and effective at treating mild to moderate high blood pressure. Loop diuretics are not effective in patients with eGFR < 30 ml/min per 1.73 m2. Loop diuretics are effective at relaxing the blood vessels and promoting the excretion of salts and other waste products. Loop diuretics are effective at reducing ﬂuid overload, which can help to lower blood pressure. Loop diuretics are also safe and effective at treating mild to moderate high blood pressure. Loop diuretics are not effective in patients with eGFR < 30 ml/min per 1.73 m2. Loop diuretics are effective at relaxing the blood vessels and promoting the excretion of salts and other waste products. Loop diuretics are effective at reducing ﬂuid overload, which can help to lower blood pressure. Loop diuretics are also safe and effective at treating mild to moderate high blood pressure. Loop diuretics are not effective in patients with eGFR < 30 ml/min per 1.73 m2. Loop diuretics are effective at relaxing the blood vessels and\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5648 is \n",
      "\n",
      "A) Doxazosin\n",
      "B) Hydralazine\n",
      "C) Labetalol\n",
      "D) Spironolactone\n",
      "\n",
      "Answer: A) Doxazosin\n",
      "\n",
      "Explanation: Doxazosin is a good option for adding on to the patient's current regimen as it can help to further lower blood pressure. Hydralazine and Spironolactone are also good options, but Doxazosin is a more effective and cost-effective option in this case. Labetalol is a less effective option and may cause side effects such as dizziness or nausea, so it is not recommended as a first choice.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5649 is A. Onset of hypertension after 20 weeks’ gestation.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5650 is \n",
      "A) Hypertensive disorders of pregnancy\n",
      "B) White-coat hypertension\n",
      "C) Gestational hypertension\n",
      "D) Essential hypertension\n",
      "\n",
      "Answer: A) Hypertensive disorders of pregnancy. This woman is likely experiencing gestational hypertension, which is a temporary condition that occurs during pregnancy. It is characterized by high blood pressure, but does not cause permanent damage to the fetus or mother.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5651 is a) Her risk of preeclampsia is high, primarily because of her history of preeclampsia and hypertension; type 2 DM and CKD also contribute to risk but to a lesser degree than hypertension and prior preeclampsia. b) CKD confers the highest risk of preeclampsia; all other factors play a lesser role including history of preeclampsia. c) She is not at high risk for preeclampsia because she is < 30 years of age. d) Type 2 DM, CKD, hypertension, and prior history of preeclampsia all contribute equally to risk of preeclampsia.\n",
      "Answer: a) Her risk of preeclampsia is high, primarily because of her history of preeclampsia and hypertension; type 2 DM and CKD also contribute to risk but to a lesser degree than hypertension and prior preeclampsia.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5652 is \n",
      "\n",
      "A. Continue losartan because her BP is well controlled. \n",
      "B. Stop the losartan and start labetalol. \n",
      "C. Continue losartan but add another agent to target BP < 140/90 mm Hg. \n",
      "D. Stop the losartan and add a calcium channel blocker. \n",
      "\n",
      "Answer: \n",
      "Based on the given information, the best approach to treating the woman's hypertension would be to continue losartan as it has been shown to be an effective medication for treating Hypertension. The woman's blood pressure is already well-controlled with losartan, and therefore, option A is the best choice.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5653 is C\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5654 is \n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is:\n",
      "The MOST likely explanation for the ﬁnding on the immunoﬂuorescence is\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5655 is \n",
      "A) Add an antihypertensive agent to tighten her BP control.\n",
      "B) Initiate a trial of prednisone therapy.\n",
      "C) Repeat her kidney biopsy.\n",
      "D) Send for genetic testing.\n",
      "\n",
      "Answer: A) Add an antihypertensive agent to tighten her BP control. \n",
      "\n",
      "The patient has proteinuria and her creatinine is slowly increasing over time. Additionally, her urinary protein levels are higher than last year. The patient has a history of hypertension and her renal US shows two kidneys about 11 cm each in size. Her body mass index is normal and she has no known family history of kidney disease. A kidney biopsy from 5 years ago was consistent with FSGS on the basis of light microscopy with negative immunoﬂuorescence and EM that showed segmental foot process effacement. She has never received immunosuppressive therapy. Based on this information, the next best step in management would be to add an antihypertensive agent to tighten her BP control. This will help to reduce her creatinine levels and may also help to slow the progression of her kidney disease. A kidney biopsy should be repeated only if there are changes in her symptoms or if there is a change in her medical history. Send for genetic testing only if there is a strong family history of kidney disease or if there are other symptoms that may be related to a genetic disorder.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5656 is N/A (There is no question provided to answer)\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5657 is \n",
      "\n",
      "Answer: It is not appropriate to add an ARB to help lower proteinuria as the current treatment already includes ARB medication. The patient's current treatment plan includes lisinopril, amlodipine, and metoprolol, which are all ARB medication. Therefore, adding another ARB medication would not be necessary. It's also not appropriate to initiate an SGLT2 inhibitor or make no changes as the patient's creatinine and albumin levels have improved, and proteinuria has decreased. only an SGLT2 inhibitor may be necessary for further improvements in proteinuria. It is appropriate to refer for genetic testing if there is a family history of FSGS or if the patient has any other medical conditions that may be related to proteinuria.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5658 is a) Holding immunosuppressive therapy, initiating an ACE-I, and monitoring PLA2R change are the ﬁrst steps in managing all patients with MN, b) Cyclophosphamide in combination with corticosteroids has been shown to be superior to rituximab on the basis of the RI-CYCLO trial, c) In the MENTOR study, patients treated with rituximab and cyclosporin had similar eGFR at 24-month follow-up, d) In the MENTOR study, those treated with rituximab had higher rates of remission at 24-month follow-up.\n",
      "\n",
      "Answer: b) Cyclophosphamide in combination with corticosteroids has been shown to be superior to rituximab on the basis of the RI-CYCLO trial. The MENTOR study found no significant difference in eGFR between patients treated with rituximab and those treated with cyclosporin, but the study was not powered to compare cyclophosphamide.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5659 is \n",
      "\n",
      "Answer: It is not possible to determine the next best step in managing this patient based on the information provided. The patient's creatinine, albumin, and proteinuria levels are within the normal range, and the patient's blood pressure is well-controlled. However, further testing and evaluation by the patient's healthcare provider are necessary to determine the appropriate course of treatment.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5660 is \n",
      "As there is no information provided in the question about the patient's medical history, it is impossible to determine which treatment option is most appropriate. However, based on the provided information, the most correct answer to the question would be \"1. In patients with contraindication to glucocorticoids, calcineurin inhibitors would be an appropriate ﬁrst line of therapy.\"\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5661 is \n",
      "\n",
      "A) Add dapagliﬂozin 10 mg/d\n",
      "B) No additional therapy is needed; the normal eGFR and proteinuria < 1 g suggest that he will not progress\n",
      "C) Add chlorthalidone 25 mg daily to target lower BP\n",
      "D) Add lisinopril 10 mg/d\n",
      "\n",
      "Answer: Based on the information provided, the next best course of treatment for the 67-year-old man with IgA nephropathy and microalbuminuria is to add dapagliﬂozin 10 mg/d. The normal eGFR and proteinuria < 1 g suggest that he will not progress, and adding dapagliﬂozin will help lower his blood pressure.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5662 is \n",
      "\n",
      "Answer: The statement that \"Glucocorticoids have not been shown to be effective in preventing decline in GFR in patients with IgA nephropathy\" is MOST accurate. Glucocorticoids are not recommended for the treatment of IgA nephropathy patients with high-grade proteinuria after a trial of nonimmunosuppressive therapy, as they have not been shown to be effective in preventing decline in GFR in these patients.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5663 is A) The tool is recommended by the 2021 KDIGO guidelines to inform whether or not the patient will respond to glucocorticoids.\n",
      "\n",
      "Answer: A) The tool is recommended by the 2021 KDIGO guidelines to inform whether or not the patient will respond to glucocorticoids. The International IgAN Prediction Tool is designed to predict the likelihood of a patient with IgA nephropathy responding to glucocorticoids. The tool takes into account proteinuria, age, and other patient characteristics, such as race and sex, to generate a risk score. The higher the risk score, the greater the likelihood that the patient will respond to glucocorticoids.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5664 is \n",
      "\n",
      "A) 1. Light microscopy can distinguish between C3GN and postinfectious GN. \n",
      "\n",
      "B) 2. Immunoﬂuorescence microscopy generally shows both IgG and C3 deposits in postinfectious GN but not C3GN. \n",
      "\n",
      "C) 3. Genetic screen would be of little utility in distinguishing postinfectious from C3GN. \n",
      "\n",
      "D) 4. Light microscopy can distinguish between C3GN and postinfectious GN. \n",
      "\n",
      "The answer is D) Light microscopy can distinguish between C3GN and postinfectious GN. This is because light microscopy is the standard method for diagnosing glomerular diseases, and it can identify the presence of both IgG and C3 deposits in postinfectious GN, but not in C3GN. On the other hand, immunoﬂuorescence microscopy can identify both IgG and C3 deposits in postinfectious GN, but not in C3GN. Therefore, the correct statement is D).\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5665 is a) None of the above are correct.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5666 is \n",
      "\n",
      "Answer: The variable that best predicts her risk of developing ESKD is \"Low C3.\" The presence of electron-dense intramembranous deposits on electron microscopy, a high chronicity score, and virtually no Ig deposition by immunofluorescence microscopy are all positive predictors of ESKD. However, a low C3 is a negative predictor of ESKD.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5667 is \n",
      "\n",
      "A. Indirect immunoﬂuorescence is the preferred screening test for detection of circulating ANCA.\n",
      "B. Positive testing for MPO-ANCA excludes a diagnosis of granulomatosis with polyangiitis.\n",
      "C. The demonstration of granulomatous inﬂammation on tissue biopsy is required to conﬁr a diagnosis of GPA.\n",
      "D. GN is more common in microscopic polyangiitis than in GPA.\n",
      "E. Serum-soluble CD163 is a sensitive and speciﬁc biomarker of GN in patients with both microscopic polyangiitis and GPA.\n",
      "\n",
      "Answer: A. Indirect immunoﬂuorescence is the preferred screening test for detection of circulating ANCA. statement is MOST correct. It is commonly used to identify ANCA-positive patients and to distinguish them from other types of vasculitis. MPO-ANCA testing is the second-choice test for diagnosis of ANCA-associated vasculitis. Granulomatous inﬂammation on tissue biopsy is required to conﬁr a diagnosis of GPA. GN is more common in microscopic polyangiitis than in GPA. Serum-soluble CD163 is not a useful biomarker for GN in patients with either microscopic polyangiitis or GPA.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5668 is a) Plasma exchange has no effect on renal outcomes in ANCA-associated GN.\n",
      "b) A reduced dose glucocorticoid regimen is equally effective as a standard dose regimen and associated with fewer infections in patients treated with cyclophosphamide.\n",
      "c) Avocopan is superior to glucocorticoids for achieving sustained disease remission at 6 months.\n",
      "d) A randomized, controlled trial has shown that daily oral cyclophosphamide and rituximab infusions are equally effective for the induction of remission.\n",
      "e) Treatment with mycophenolate mofetil is associated with fewer infections than with cyclophosphamide.\n",
      "\n",
      "Answer: b) A reduced dose glucocorticoid regimen is equally effective as a standard dose regimen and associated with fewer infections in patients treated with cyclophosphamide.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5669 is A.azathiopr\n",
      "B.rituximab\n",
      "C.prednisone\n",
      "D.azathiopr and prednisone\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5670 is a) The detection of circulating anti-GBM antibodies is essential for diagnosis, b) The detection of ANCA does not inﬂuence treatment or outcome, c) Antibodies to laminin-521 are found more frequently in patients with lung hemorrhage, d) Peroxidasin antibodies are found more frequently in patients with severe kidney disease, or e) Anti-GBM antibodies are detected in up to 5% of patients with SLE.\n",
      "The correct answer is: a) The detection of circulating anti-GBM antibodies is essential for diagnosis. The diffuse crescentic GN, with linear deposits of IgG and C3 on immunostaining, is a characteristic of anti-GBM disease. The presence of these antibodies in the blood can help diagnose the disease and determine the appropriate treatment plan. b) The detection of ANCA does not inﬂuence treatment or outcome. ANCAs (antibodies to myeloperoxidase and proteinase 3) are typically detected in patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), not in anti-GBM disease. c) Antibodies to laminin-521 are found more frequently in patients with lung hemorrhage. Laminin-521 is a protein found in the lung, and patients with lung hemorrhage may have increased levels of antibodies against laminin-521. d) Peroxidasin antibodies are found more frequently in patients with severe kidney disease. Peroxidasin is a protein found in the kidney, and patients with severe kidney disease may have increased levels of antibodies against peroxidasin. e) Anti-GBM antibodies are detected in up to 5% of patients with SLE. While anti-GBM antibodies can be detected in SLE patients, they are typically not found in the majority of patients with SLE.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5671 is a) The presence of lung hemorrhage is associated with poorer renal outcome, b) Treatment with daily oral cyclophosphamide is preferred to pulse intravenous dosing, c) Following treatment with plasma exchange, cyclo-phosphamide, and glucocorticoids, recovery from dialysis-dependent renal failure can be expected in approximately 30% of cases, d) A randomized, controlled trial has shown that imliﬁdase is superior to plasma exchange for the rapid removal of anti-GBM antibodies from circulation, e) Maintenance immunosuppression is not required. \n",
      "\n",
      "Answer: d) A randomized, controlled trial has shown that imliﬁdase is superior to plasma exchange for the rapid removal of anti-GBM antibodies from circulation.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5672 is A, B, C, or D.\n",
      "\n",
      "A) The time from diagnosis of SLE to the development of lupus nephritis is shorter in Blacks and other minority groups.\n",
      "B) Observational studies suggest that lupus nephritis is being diagnosed at a younger age.\n",
      "C) In patients with proliferative lupus nephritis who undergo rebiopsy, histologic ﬁndings correlate closely with clinical response to treatment.\n",
      "D) Anti-PLA2R antibodies are frequently identiﬁed in patients with class 5 lupus nephritis.\n",
      "\n",
      "Answer: A, B, C, and D are all correct. The time from diagnosis of SLE to the development of lupus nephritis is shorter in Blacks and other minority groups. Observational studies suggest that lupus nephritis is being diagnosed at a younger age. In patients with proliferative lupus nephritis who undergo rebiopsy, histologic ﬁndings correlate closely with clinical response to treatment. Anti-PLA2R antibodies are frequently identiﬁed in patients with class 5 lupus nephritis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5673 is \n",
      "\n",
      "A. Rituximab is an effective treatment for lupus nephritis\n",
      "B. Treatment with obinutuzumab, in addition to standard care, improves renal responses but is associated with a higher risk of infection\n",
      "C. Belimumab, in addition to standard therapy, has demonstrated efﬁcacy in the treatment of lupus nephritis and extrarenal manifestations of SLE\n",
      "D. Calcineurin inhibitors, such as voclosporin, are an effective alternative to mycophenolate mofetil for the treatment of proliferative lupus nephritis\n",
      "E. The addition of anifrolumab to standard therapy results in greater improvements in proteinuria in patients with high type 1 IFN gene signatures\n",
      "\n",
      "Based on the ﬁndings of recent prospective, randomized, controlled studies, statement A, C, and E are supported. Rituximab has been shown to be effective in the treatment of lupus nephritis, belimumab has demonstrated efficacy in the treatment of lupus nephritis and extrarenal manifestations of SLE, and anifrolumab has been shown to improve proteinuria in patients with high type 1 IFN gene signatures.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5674 is a) Remdesivir is the most likely cause of his AKI. b) A kidney biopsy would most likely show thrombotic microangiopathy. c) The mortality of stage 3 AKI in patients admitted to the intensive care unit with COVID-19 exceeds 50%. d) AKI most commonly occurs in the ﬁrst 5 days of COVID-19 illness.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5675 is a) COVID-19–associated collapsing glomerulopathy is not more common in patients with COVID-19 than controls, and there is no evidence to suggest that COVID-19–associated coll-apsing glomerulopathy occurs in patients with high-risk APOL1 genotypes. b) COVID-19–associated collapsing glomerulopathy has been described in patients with high-risk APOL1 genotypes. c) The pathogenesis of COVID-19–associated coll-apsing glomerulopathy involves direct viral infection of podocytes. d) Early antiviral therapy has not been shown to improve outcomes in COVID-19–associated coll-apsing glomerulopathy. e) COVID-19–associated coll-apsing glomerulopathy typically only occurs in patients with severe or critical COVID-19.\n",
      "Answer: The most correct statement is a) COVID-19–associated collapsing glomerulopathy is not more common in patients with COVID-19 than controls, and there is no evidence to suggest that COVID-19–associated coll-apsing glomerulopathy occurs in patients with high-risk APOL1 genotypes.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5676 is \n",
      "A. The statement \"He does not need to be screened for malignancy\" is MOST correct.\n",
      "B. The statement \"His antiviral medications should be changed\" is not necessarily correct, as the current antiretroviral regimen is already well-tolerated and effective.\n",
      "C. The statement \"His biopsy will most likely stain for THSD7 antibody\" is not necessarily correct, as the kidney biopsy may be negative for THSD7 antibody and it may be more difficult to predict the diagnosis.\n",
      "D. The statement \"Treatment of HIV alone is unlikely to lead to full or partial remission of kidney disease\" may be true to some extent, but it is not clear if antiviral medication can fully explain the kidney disease in this patient. Certainly, further research is needed to determine the cause of the kidney disease in this patient.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5677 is a) Her antiviral medications should be left un-changed because they have been effective in controlling HIV for over 20 years, b) Kidney biopsy is most likely to show immune com-plex GN that may or may not be related to HIV, c) Kidney biopsy will most likely show HIVAN, d) PLA2R levels can rule out MN, or e) Cessation of tenofovir disoproxil fumarate will lead to improvement in proteinuria and hypophosphatemia.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5678 is A. A direct-acting antiviral (DAA) regimen, such as sofosbuvir and velpatasvir, and rituximab should be started concurrently because she has an active GN.\n",
      "Answer: A. A direct-acting antiviral (DAA) regimen, such as sofosbuvir and velpatasiv, and rituximab should be started concurrently because she has an active GN.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5679 is \n",
      "\n",
      "Answer: The next best step in his management would be to exclude renal vein thrombosis with appropriate imaging. Based on the given information, the boy is known to be hepatitis B virus positive, and his poor compliance with antiviral therapy suggests that he may have developed resistance to the antiviral medication. Therefore, it is important to determine if he has developed renal vein thrombosis, which can be ruled out with appropriate imaging. A kidney biopsy may not provide a clear diagnosis in this situation, and the boy's poor compliance with antiviral therapy suggests that he may not be able to receive the necessary treatment for his MN.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5680 is A 61-year-old man with HIV infection who has stage 5 CKD (attributed to long-standing hypertension and diabetes) is referred for transplant evaluation. The most correct statement regarding transplantation is: The patient is a good candidate for transplantation because the risks of transplantation are identical to those of HIV-negative patients, including the risk of rejection.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5681 is A) Death does not occur as a result of kidney biopsy.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5682 is \n",
      "\n",
      "A. Start her on an SGLT2 inhibitor. \n",
      "B. Restart her on metformin. \n",
      "C. Start her on a GLP1 agonist. \n",
      "D. Restart her on an angiotensin receptor blocker. \n",
      "\n",
      "Answer: \n",
      "Given her history of AKI and the current state of her creatinine, it is recommended that she avoid any medication that can cause kidney damage. Therefore, the best medication change for her long-term cardiovascular and kidney health would be to avoid any medication that can cause kidney damage. This would include starting an SGLT2 inhibitor, which is a class of medications used to lower blood sugar levels. It is important to also monitor her creatinine levels and blood sugar levels closely, as any changes may indicate a need for medication changes.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5683 is \n",
      "\n",
      "Answer: Based on the current medical information, the best medication change to improve the overall medical prognosis for the 46-year-old man would be to add empagliﬂozin 25 mg daily. This medication has been shown to improve blood glucose control and reduce the risk of cardiovascular events in patients with type 2 diabetes mellitus. Additionally, it may also help to lower blood pressure, which could further improve his overall medical condition.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5834 is A, B, C, or D.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5835 is A. Measure fractional phosphate excretion.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5836 is \n",
      "A. In the general population, plasma phosphate levels at the upper end of the normal range have been associated with increased cardiovascular mortality. \n",
      "\n",
      "Explanation: The statement is accurate. Hyperphosphatemia has been linked to increased cardiovascular mortality in the general population. Therefore, the most correct answer is A.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5837 is A. Increased intestinal absorption of calcium.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5838 is (A) Gitelman syndrome.\n",
      "\n",
      "The answer is A) Gitelman syndrome.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5839 is \n",
      "A. Nephrocalcinosis\n",
      "B. Brain calcifications\n",
      "C. Nephrolithiasis\n",
      "D. Hypocalciuria\n",
      "\n",
      "Answer: A. Nephrocalcinosis.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5840 is A. A recent meta-analysis reported that the risk of hypocalcemia is doubled in patients treated with calcimimetics compared with controls.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5841 is A, B, C, or D.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5842 is A or B.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5843 is A. Tenapanor.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5844 is \n",
      "A. nearly 80% of phosphate removal by hemodialysis occurs within the first hour of treatment.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5846 is A. The patient likely has osteoporosis and should have a steroid minimization protocol after the transplant, along with antiresorptive medication.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5847 is A. Start an oral calcimimetic, because the patient has hypercalcemic hyperparathyroidism and high bone turnover.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5848 is A, B, C, or D. \n",
      "\n",
      "A) Advise denosumab\n",
      "B) Advise a bisphosphonate\n",
      "C) Advise vitamin D supplementation\n",
      "D) Schedule a bone biopsy before starting therapy\n",
      "\n",
      "Answer: A, B, and C are all correct answers. Denosumab is a monoclonalantibody that targets the RANKL protein, which is involved in the development of osteoporosis. Bisphosphonates are another type of osteoporosis medication that works by disrupting the bone-building process. Vitamin D supplementation is recommended to ensure adequate levels of vitamin D in the body, which plays a role in bone health. Scheduling a bone biopsy before starting therapy is recommended to rule out any underlying conditions that may contribute to bone loss, such as cancer or other illnesses.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5849 is \n",
      "\n",
      "Answer: A. The nephrologist should be worried about mineral and bone-related parameters, as CKD-MBD is associated with poor outcomes. Therefore, the answer is A.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5850 is \n",
      "\n",
      "A. The statement \"In her age group, the risk of fracture is the same for ESKD compared with non-ESKD patients\" is MOST correct. \n",
      "\n",
      "Explanation: The statement is MOST correct because there is no age-related increase in the risk of fracture for ESKD patients compared to non-ESKD patients. The risk of fractures is related to patient factors such as age, gender, lifestyle, and medical history, rather than ESKD status. Therefore, the statement is still accurate for this patient, despite her ESKD status. The other statements are not relevant to the patient's situation.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "THE COMPUTER ANSWER FOR ID: 5851 is A. There is little utility to screening by DXA because she likely has renal osteodystrophy, and DXA would not be sufficiently predictive of fracture risk.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5852 is A. Pamidronate or B. Denosumab\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5853 is (A. Alendronate)\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5854 is A. Hypercalcemia.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5855 is A) Glargine insulin, B) Lispro insulin, or C) Sevelamer.\n",
      "\n",
      "Answer: A) Glargine insulin, B) Lispro insulin, or C) Sevelamer. \n",
      "\n",
      "Explanation: \n",
      "A) Glargine insulin and Lispro insulin are both types of insulin that can cause an increase in blood sugar levels if they are not used as directed. Overuse or incorrect administration of these medications can lead to severe consequences, including weight gain, poor wound healing, and even cardiovascular disease.\n",
      "\n",
      "B) Sevelamer is a medication used in peritoneal dialysis to maintain proper fluid balance in the dialysis membrane. It does not cause an increase in blood sugar levels and is therefore not a risk factor for the presentation described.\n",
      "\n",
      "C) Warfarin is a medication used to prevent blood clots, but it is not used in the context of this presentation. It is not a risk factor for the development of an indurated area over right medial thigh.\n",
      "\n",
      "Therefore, the correct answer is A) Glargine insulin, B) Lispro insulin, or C) Sevelamer.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5856 is A. A void hypercalcemia.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5857 is A, B, C, or D. \n",
      "\n",
      "Answer: A. Teriparatide should be immediately started. \n",
      "\n",
      "Justification: Teriparatide is a medication that can help manage the symptoms of hyperparathyroidism, which is the condition that caused the calciphylaxis in this patient. It can also help prevent the progression of the disease. Therefore, it is recommended to start teriparatide immediately. The other options are not as relevant to the patient's condition and should be avoided.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5858 is \n",
      "A. Untreated pneumothorax \n",
      "B. Claustrophobia \n",
      "C. Sinus infection \n",
      "D. Diabetes mellitus \n",
      "\n",
      "Answer: D. Diabetes mellitus is an absolute contraindication for hyperbaric oxygen therapy. Hyperbaric oxygen therapy can cause hyperoxia, which can increase the risk of secondary infections, especially in patients with diabetes mellitus. Therefore, it is not recommended to use hyperbaric oxygen therapy in patients with diabetes mellitus.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5859 is \n",
      "A. Presence of circumferential calcium deposits in hypodermal vessels, B. Presence of noncircumferential calcium deposits in hypodermal vessels, or A combination of both. \n",
      "\n",
      "Answer: A combination of both features can help distinguish calciphylaxis from its mimics.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5860 is The best advice at this point would be to start him on expulsive medical therapy (tamsulosin) and get a follow-up with a urologist over the next week to evaluate further therapy.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5861 is A. Advise a low calcium intake in view of his hypercalciuria.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5862 is \n",
      "\n",
      "Answer: A. Any interventions done to control obesity will be of benefit to prevent new stone formation.\n",
      "----------------------------------------------------------------------------------------------\n",
      "THE COMPUTER ANSWER FOR ID: 5863 is A. 24-hour urine collection for measurement of stone risk factors and blood for genetic analyses.\n",
      "----------------------------------------------------------------------------------------------\n"
     ]
    }
   ],
   "source": [
    "import json\n",
    "idlist = []\n",
    "predictedanswer = []\n",
    "groundtruth = []\n",
    "with open(\"C:/Users/nirc/Downloads/completenephrologydata.json\") as file:\n",
    "    data = json.load(file)\n",
    "\n",
    "for item in data:\n",
    "    #item is the ID\n",
    "    context = \"Context: \" + data[item]['context']\n",
    "    question = \"Question: \" + data[item]['question']\n",
    "    choices = \"Choices: \" + str(data[item]['choices']) + \"Choose an answer: \"\n",
    "    answer = data[item]['answer']\n",
    "\n",
    "    idlist.append(item)\n",
    "    groundtruth.append(answer)\n",
    "\n",
    "    combined_string = context + \"\\n\" + question + \"\\n\" + str(choices)\n",
    "    computeranswer = generate_text(combined_string)\n",
    "    if(len(computeranswer) < 1):\n",
    "        computeranswer = \"C\"\n",
    "        \n",
    "\n",
    "    print(\"THE COMPUTER ANSWER FOR ID: \" + str(item) + \" is \" + computeranswer)\n",
    "    print(\"----------------------------------------------------------------------------------------------\")\n",
    "    predictedanswer.append(computeranswer)\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Data has been written to C:/Users/nirc/Downloads/orca_output.csv successfully.\n"
     ]
    }
   ],
   "source": [
    "import csv\n",
    "\n",
    "header = ['ID', 'Ground_Truth', 'Orca_Output']\n",
    "\n",
    "data = zip(idlist, groundtruth, predictedanswer)\n",
    "\n",
    "filename = 'C:/Users/nirc/Downloads/orca_output.csv'\n",
    "\n",
    "with open(filename, 'w', newline='', encoding='utf-8') as csvfile:\n",
    "    writer = csv.writer(csvfile)\n",
    "    writer.writerow(header)\n",
    "    writer.writerows(data)\n",
    "\n",
    "print(f\"Data has been written to {filename} successfully.\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "computeranswer = generate_text(\"Show me how to evaluate ramanujan sums: \")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      "Let's start with the definition of Ramanujan sum:\n",
      "\n",
      "A Ramanujan sum is a number that can be expressed as the sum of certain mathematical constants, such as 1, 1/2, 2, 3, 5, 7, 11, 13, 17, and so on.\n",
      "\n",
      "To evaluate a Ramanujan sum, we need to add up a list of these constants. The sum of all the even numbers from 1 to n is given by the formula 2^n - 1. Similarly, the sum of all the odd numbers from 1 to n is given by the formula 2^n + 1. \n",
      "\n",
      "To evaluate a Ramanujan sum, we can use these formulas in the following way:\n",
      "\n",
      "1. Find the smallest n such that the sum of the even numbers from 1 to n is greater than the sum of the odd numbers from 1 to n.\n",
      "2. Let m be the smallest odd number less than or equal to n. then the sum of the odd numbers from 1 to n is given by the formula 2^n + 1.\n",
      "3. The sum of the even numbers from 1 to n is given by the formula 2^n - 1.\n",
      "4. Add the sum of the even numbers to the sum of the odd numbers.\n",
      "\n",
      "For example, let's say we want to evaluate the Ramanujan sum 2+3+5. \n",
      "\n",
      "1. The smallest n such that the sum of the even numbers from 1 to n is greater than the sum of the odd numbers from 1 to n is n = 11.\n",
      "2. The smallest odd number less than or equal to 11 is 3.\n",
      "3. The sum of the even numbers from 1 to 11 is 2^11 - 1 = 92.\n",
      "4. The sum of the odd numbers from 1 to 11 is 2^11 + 1 = 100.\n",
      "5. The sum of the even and odd numbers is 92 + 100 = 182.\n",
      "\n",
      "So the Ramanujan sum 2+3+5 is 182.\n"
     ]
    }
   ],
   "source": [
    "print(computeranswer)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "accelerator": "GPU",
  "colab": {
   "provenance": []
  },
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 1
}
